var title_f36_41_37520="Typhlitis pneumatosis KUB";
var content_f36_41_37520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Typhlitis (neutropenic enterocolitis) on plain radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 304px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Supine film of the abdomen showing pneumatosis intestinalis of the right ascending colon (arrows) with slightly distended small bowel loops from typhlitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Katz, JA, et al. Typhlitis: An 18-year experience and postmortem review. Cancer 1990; 65:1041. Copyright &copy; 1990 John Wiley &amp;Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37520=[""].join("\n");
var outline_f36_41_37520=null;
var title_f36_41_37521="Patient information: Melasma (The Basics)";
var content_f36_41_37521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83982\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/53/36692\">",
"         Melasma on the cheek",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/30/6626\">",
"         Patient information: Eczema (atopic dermatitis) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?15/23/15730\">",
"         Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/60/33729\">",
"         Patient information: Sunburn prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/35/29238\">",
"         Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Melasma (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/melasma-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H25575148\">",
"      <span class=\"h1\">",
"       What is melasma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Melasma is a condition that causes brown patches on the skin. The patches are usually on the face.",
"     </p>",
"     <p>",
"      Melasma is common in women who are pregnant, but women who are not pregnant can also get it. Men can get it, too. Melasma is most common in people with darker skin and people who live in very sunny places.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25575163\">",
"      <span class=\"h1\">",
"       What are the symptoms of melasma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Brown patches on the skin are the main symptom of melasma (",
"      <a class=\"graphic graphic_picture graphicRef83855 \" href=\"mobipreview.htm?35/53/36692\">",
"       picture 1",
"      </a>",
"      ). The patches can be light or dark brown or sometimes gray or blue.",
"     </p>",
"     <p>",
"      It is most common for melasma to happen on the cheeks, forehead, upper lip, nose, and chin. Melasma can also happen on the jaw.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25575178\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you notice brown, gray, or blue patches on your skin, talk to your doctor or nurse. Some other conditions can also cause darker areas on the skin. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25575193\">",
"      <span class=\"h1\">",
"       Is there a test for melasma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. The doctor or nurse should be able to tell if you have it by learning about your symptoms and doing an exam. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25575208\">",
"      <span class=\"h1\">",
"       How is melasma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The doctor or nurse can prescribe a cream to lighten the dark patches. If the melasma is not gone after 2 or 3 months, the doctor or nurse can prescribe a different cream.",
"      <br/>",
"     </p>",
"     <p>",
"      If you have melasma, you should also:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Always wear sunscreen that protects against UVB and UVA rays (sample brand names: Neutrogena",
"        <sup>",
"         &reg;",
"        </sup>",
"        sunscreens with Helioplex",
"        <sup>",
"         &reg;",
"        </sup>",
"        , La Roche-Posay",
"        <sup>",
"         &reg;",
"        </sup>",
"        Anthelios SX). The sunscreen should have a sun protection factor (SPF) of at least 30. Put on more sunscreen every 2 hours.",
"       </li>",
"       <li>",
"        Wear a wide-brimmed hat to protect your face from the sun.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the creams do not make the melasma go away, the doctor might recommend a treatment called a &ldquo;chemical peel.&rdquo; In this treatment, a product such as glycolic acid is put on the skin. It makes the top layer of skin peel off. This can take off the melasma patches.",
"     </p>",
"     <p>",
"      Melasma caused by pregnancy usually goes away in about a year. But melasma can be a long lasting condition. The dark patches do not always go away completely, even with treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25575223\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/30/6626?source=see_link\">",
"       Patient information: Eczema (atopic dermatitis) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/23/15730?source=see_link\">",
"       Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=see_link\">",
"       Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/60/33729?source=see_link\">",
"       Patient information: Sunburn prevention (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/41/37521?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83982 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-A7177AF1CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37521=[""].join("\n");
var outline_f36_41_37521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25575148\">",
"      What is melasma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25575163\">",
"      What are the symptoms of melasma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25575178\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25575193\">",
"      Is there a test for melasma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25575208\">",
"      How is melasma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25575223\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83982\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/53/36692\">",
"      Melasma on the cheek",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/23/15730?source=related_link\">",
"      Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/30/6626?source=related_link\">",
"      Patient information: Eczema (atopic dermatitis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/60/33729?source=related_link\">",
"      Patient information: Sunburn prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=related_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_41_37522="Technetium Tc-99m pyrophosphate: Patient drug information";
var content_f36_41_37522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Technetium Tc-99m pyrophosphate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/35/33330?source=see_link\">",
"     see \"Technetium Tc-99m pyrophosphate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13210200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Technescan&trade; PYP&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13374392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with a special imaging test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13374391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560749",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to technetium Tc 99m pyrophosphate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13374395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13374397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13374394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13374399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17086 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-201.211.0.116-017BBC11AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37522=[""].join("\n");
var outline_f36_41_37522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210200\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374392\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374391\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374395\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374397\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374394\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374399\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/35/33330?source=related_link\">",
"      Technetium Tc-99m pyrophosphate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_41_37523="Triceps skin fold normals";
var content_f36_41_37523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67683%7EPEDS%2F78703%7EPEDS%2F72246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=18\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67683%7EPEDS%2F78703%7EPEDS%2F72246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=18\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Triceps skin fold - normal values",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\" rowspan=\"1\">",
"        Triceps",
"skinfold percentiles, mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        5",
"       </td>",
"       <td class=\"subtitle2\">",
"        10",
"       </td>",
"       <td class=\"subtitle2\">",
"        25",
"       </td>",
"       <td class=\"subtitle2\">",
"        50",
"       </td>",
"       <td class=\"subtitle2\">",
"        75",
"       </td>",
"       <td class=\"subtitle2\">",
"        90",
"       </td>",
"       <td class=\"subtitle2\">",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\" rowspan=\"1\">",
"        Males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 - 1.9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2 - 2.9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3 - 3.9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4 - 4.9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5 - 5.9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6 - 6.9",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7 - 7.9",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8 - 8.9",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9 - 9.9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10 - 10.9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11 - 11.9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12 - 12.9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        13 - 13.9",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14 - 14.9",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15 - 15.9",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        16 - 16.9",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        17 - 17.9",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        18 - 18.9",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19 - 24.9",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        25 - 34.9",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\" rowspan=\"1\">",
"        Females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 - 1.9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2 - 2.9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3 - 3.9",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4 - 4.9",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5 - 5.9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6 - 6.9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7 - 7.9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8 - 8.9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9 - 9.9",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10 - 10.9",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11 - 11.9",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12 - 12.9",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        13 - 13.9",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14 - 14.9",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15 - 15.9",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        16 - 16.9",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        17 - 17.9",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        18 - 18.9",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19 - 24.9",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        25 - 34.9",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        37",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Percentiles for triceps skinfold for whites of the United States Health and Nutrition Examination Survey 1 of 1971 to 1974.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Frisancho, Am J Clin Med 1981; 34:2540.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Percentiles of upper arm circumference and estimated upper arm muscle circumference for Caucasian boys in the US Health and Nutrition Examination Survey I of 1971-1974",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Age, years males",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Mid arm circumference (MAC) percentiles",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Mid arm muscle circumference (MAMC)&nbsp;percentiles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        5th",
"       </td>",
"       <td class=\"subtitle2\">",
"        50th",
"       </td>",
"       <td class=\"subtitle2\">",
"        90th",
"       </td>",
"       <td class=\"subtitle2\">",
"        95th",
"       </td>",
"       <td class=\"subtitle2\">",
"        5th",
"       </td>",
"       <td class=\"subtitle2\">",
"        50th",
"       </td>",
"       <td class=\"subtitle2\">",
"        90th",
"       </td>",
"       <td class=\"subtitle2\">",
"        95th",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-1.9",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        159",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        177",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-2.9",
"       </td>",
"       <td>",
"        141",
"       </td>",
"       <td>",
"        162",
"       </td>",
"       <td>",
"        178",
"       </td>",
"       <td>",
"        185",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        184",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3-3.9",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        189",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4-4.9",
"       </td>",
"       <td>",
"        149",
"       </td>",
"       <td>",
"        171",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        192",
"       </td>",
"       <td>",
"        149",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        191",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-5.9",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        175",
"       </td>",
"       <td>",
"        195",
"       </td>",
"       <td>",
"        204",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        175",
"       </td>",
"       <td>",
"        203",
"       </td>",
"       <td>",
"        211",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6-6.9",
"       </td>",
"       <td>",
"        155",
"       </td>",
"       <td>",
"        179",
"       </td>",
"       <td>",
"        209",
"       </td>",
"       <td>",
"        228",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        204",
"       </td>",
"       <td>",
"        201",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7-7.9",
"       </td>",
"       <td>",
"        162",
"       </td>",
"       <td>",
"        187",
"       </td>",
"       <td>",
"        223",
"       </td>",
"       <td>",
"        230",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        216",
"       </td>",
"       <td>",
"        231",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8-8.9",
"       </td>",
"       <td>",
"        162",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        220",
"       </td>",
"       <td>",
"        245",
"       </td>",
"       <td>",
"        168",
"       </td>",
"       <td>",
"        195",
"       </td>",
"       <td>",
"        247",
"       </td>",
"       <td>",
"        261",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9-9.9",
"       </td>",
"       <td>",
"        175",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        249",
"       </td>",
"       <td>",
"        257",
"       </td>",
"       <td>",
"        178",
"       </td>",
"       <td>",
"        211",
"       </td>",
"       <td>",
"        251",
"       </td>",
"       <td>",
"        260",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-10.9",
"       </td>",
"       <td>",
"        181",
"       </td>",
"       <td>",
"        210",
"       </td>",
"       <td>",
"        262",
"       </td>",
"       <td>",
"        274",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        210",
"       </td>",
"       <td>",
"        251",
"       </td>",
"       <td>",
"        265",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11-11.9",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        223",
"       </td>",
"       <td>",
"        261",
"       </td>",
"       <td>",
"        280",
"       </td>",
"       <td>",
"        185",
"       </td>",
"       <td>",
"        224",
"       </td>",
"       <td>",
"        276",
"       </td>",
"       <td>",
"        303",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12-12.9",
"       </td>",
"       <td>",
"        193",
"       </td>",
"       <td>",
"        232",
"       </td>",
"       <td>",
"        282",
"       </td>",
"       <td>",
"        303",
"       </td>",
"       <td>",
"        194",
"       </td>",
"       <td>",
"        237",
"       </td>",
"       <td>",
"        282",
"       </td>",
"       <td>",
"        294",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13-13.9",
"       </td>",
"       <td>",
"        194",
"       </td>",
"       <td>",
"        247",
"       </td>",
"       <td>",
"        286",
"       </td>",
"       <td>",
"        301",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        243",
"       </td>",
"       <td>",
"        301",
"       </td>",
"       <td>",
"        338",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14-14.9",
"       </td>",
"       <td>",
"        220",
"       </td>",
"       <td>",
"        253",
"       </td>",
"       <td>",
"        303",
"       </td>",
"       <td>",
"        322",
"       </td>",
"       <td>",
"        214",
"       </td>",
"       <td>",
"        252",
"       </td>",
"       <td>",
"        304",
"       </td>",
"       <td>",
"        322",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15-15.9",
"       </td>",
"       <td>",
"        222",
"       </td>",
"       <td>",
"        264",
"       </td>",
"       <td>",
"        311",
"       </td>",
"       <td>",
"        320",
"       </td>",
"       <td>",
"        208",
"       </td>",
"       <td>",
"        254",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        322",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16-16.9",
"       </td>",
"       <td>",
"        244",
"       </td>",
"       <td>",
"        278",
"       </td>",
"       <td>",
"        324",
"       </td>",
"       <td>",
"        343",
"       </td>",
"       <td>",
"        218",
"       </td>",
"       <td>",
"        258",
"       </td>",
"       <td>",
"        312",
"       </td>",
"       <td>",
"        325",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17-17.9",
"       </td>",
"       <td>",
"        246",
"       </td>",
"       <td>",
"        285",
"       </td>",
"       <td>",
"        336",
"       </td>",
"       <td>",
"        347",
"       </td>",
"       <td>",
"        220",
"       </td>",
"       <td>",
"        264",
"       </td>",
"       <td>",
"        324",
"       </td>",
"       <td>",
"        350",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18-18.9",
"       </td>",
"       <td>",
"        245",
"       </td>",
"       <td>",
"        297",
"       </td>",
"       <td>",
"        353",
"       </td>",
"       <td>",
"        379",
"       </td>",
"       <td>",
"        222",
"       </td>",
"       <td>",
"        258",
"       </td>",
"       <td>",
"        312",
"       </td>",
"       <td>",
"        325",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        19-24.9",
"       </td>",
"       <td>",
"        262",
"       </td>",
"       <td>",
"        308",
"       </td>",
"       <td>",
"        355",
"       </td>",
"       <td>",
"        372",
"       </td>",
"       <td>",
"        221",
"       </td>",
"       <td>",
"        265",
"       </td>",
"       <td>",
"        319",
"       </td>",
"       <td>",
"        345",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25-34.9",
"       </td>",
"       <td>",
"        271",
"       </td>",
"       <td>",
"        319",
"       </td>",
"       <td>",
"        363",
"       </td>",
"       <td>",
"        374",
"       </td>",
"       <td>",
"        241",
"       </td>",
"       <td>",
"        290",
"       </td>",
"       <td>",
"        356",
"       </td>",
"       <td>",
"        378",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35-44.9",
"       </td>",
"       <td>",
"        278",
"       </td>",
"       <td>",
"        326",
"       </td>",
"       <td>",
"        363",
"       </td>",
"       <td>",
"        374",
"       </td>",
"       <td>",
"        241",
"       </td>",
"       <td>",
"        290",
"       </td>",
"       <td>",
"        356",
"       </td>",
"       <td>",
"        378",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45-54.9",
"       </td>",
"       <td>",
"        267",
"       </td>",
"       <td>",
"        322",
"       </td>",
"       <td>",
"        362",
"       </td>",
"       <td>",
"        376",
"       </td>",
"       <td>",
"        242",
"       </td>",
"       <td>",
"        299",
"       </td>",
"       <td>",
"        362",
"       </td>",
"       <td>",
"        384",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        55-64.9",
"       </td>",
"       <td>",
"        258",
"       </td>",
"       <td>",
"        317",
"       </td>",
"       <td>",
"        355",
"       </td>",
"       <td>",
"        369",
"       </td>",
"       <td>",
"        243",
"       </td>",
"       <td>",
"        303",
"       </td>",
"       <td>",
"        367",
"       </td>",
"       <td>",
"        385",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65-74.9",
"       </td>",
"       <td>",
"        248",
"       </td>",
"       <td>",
"        307",
"       </td>",
"       <td>",
"        344",
"       </td>",
"       <td>",
"        355",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        299",
"       </td>",
"       <td>",
"        356",
"       </td>",
"       <td>",
"        373",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Frisancho AR. Am J Clin Nut 1981; 34:2540.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Percentiles of upper arm circumference and estimated upper arm muscle circumference for Caucasian girls in the US Health and Nutrition Examination Survey I of 1971-1974",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Age, years females",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Mid arm circumference (MAC) percentiles",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Mid arm muscle circumference (MAMC)&nbsp;percentiles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        5th",
"       </td>",
"       <td class=\"subtitle2\">",
"        50th",
"       </td>",
"       <td class=\"subtitle2\">",
"        90th",
"       </td>",
"       <td class=\"subtitle2\">",
"        95th",
"       </td>",
"       <td class=\"subtitle2\">",
"        5th",
"       </td>",
"       <td class=\"subtitle2\">",
"        50th",
"       </td>",
"       <td class=\"subtitle2\">",
"        90th",
"       </td>",
"       <td class=\"subtitle2\">",
"        95th",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-1.9",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        177",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        139",
"       </td>",
"       <td>",
"        143",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-2.9",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3-3.9",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        189",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        146",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4-4.9",
"       </td>",
"       <td>",
"        149",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        152",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-5.9",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        175",
"       </td>",
"       <td>",
"        203",
"       </td>",
"       <td>",
"        211",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        159",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6-6.9",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        204",
"       </td>",
"       <td>",
"        211",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        166",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7-7.9",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        216",
"       </td>",
"       <td>",
"        231",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        151",
"       </td>",
"       <td>",
"        171",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8-8.9",
"       </td>",
"       <td>",
"        168",
"       </td>",
"       <td>",
"        195",
"       </td>",
"       <td>",
"        247",
"       </td>",
"       <td>",
"        261",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9-9.9",
"       </td>",
"       <td>",
"        178",
"       </td>",
"       <td>",
"        211",
"       </td>",
"       <td>",
"        251",
"       </td>",
"       <td>",
"        260",
"       </td>",
"       <td>",
"        147",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        194",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-10.9",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        210",
"       </td>",
"       <td>",
"        251",
"       </td>",
"       <td>",
"        265",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        170",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11-11.9",
"       </td>",
"       <td>",
"        185",
"       </td>",
"       <td>",
"        224",
"       </td>",
"       <td>",
"        276",
"       </td>",
"       <td>",
"        303",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        181",
"       </td>",
"       <td>",
"        217",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12-12.9",
"       </td>",
"       <td>",
"        194",
"       </td>",
"       <td>",
"        236",
"       </td>",
"       <td>",
"        282",
"       </td>",
"       <td>",
"        294",
"       </td>",
"       <td>",
"        162",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        214",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13-13.9",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        243",
"       </td>",
"       <td>",
"        301",
"       </td>",
"       <td>",
"        338",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        198",
"       </td>",
"       <td>",
"        226",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14-14.9",
"       </td>",
"       <td>",
"        214",
"       </td>",
"       <td>",
"        252",
"       </td>",
"       <td>",
"        304",
"       </td>",
"       <td>",
"        322",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        201",
"       </td>",
"       <td>",
"        232",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15-15.9",
"       </td>",
"       <td>",
"        208",
"       </td>",
"       <td>",
"        254",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        322",
"       </td>",
"       <td>",
"        175",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        228",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16-16.9",
"       </td>",
"       <td>",
"        218",
"       </td>",
"       <td>",
"        258",
"       </td>",
"       <td>",
"        318",
"       </td>",
"       <td>",
"        334",
"       </td>",
"       <td>",
"        170",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        234",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17-17.9",
"       </td>",
"       <td>",
"        220",
"       </td>",
"       <td>",
"        264",
"       </td>",
"       <td>",
"        324",
"       </td>",
"       <td>",
"        350",
"       </td>",
"       <td>",
"        175",
"       </td>",
"       <td>",
"        205",
"       </td>",
"       <td>",
"        239",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18-18.9",
"       </td>",
"       <td>",
"        222",
"       </td>",
"       <td>",
"        258",
"       </td>",
"       <td>",
"        312",
"       </td>",
"       <td>",
"        325",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        237",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        19-24.9",
"       </td>",
"       <td>",
"        221",
"       </td>",
"       <td>",
"        265",
"       </td>",
"       <td>",
"        319",
"       </td>",
"       <td>",
"        345",
"       </td>",
"       <td>",
"        179",
"       </td>",
"       <td>",
"        207",
"       </td>",
"       <td>",
"        236",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25-34.9",
"       </td>",
"       <td>",
"        233",
"       </td>",
"       <td>",
"        277",
"       </td>",
"       <td>",
"        342",
"       </td>",
"       <td>",
"        368",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        212",
"       </td>",
"       <td>",
"        246",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35-44.9",
"       </td>",
"       <td>",
"        241",
"       </td>",
"       <td>",
"        290",
"       </td>",
"       <td>",
"        356",
"       </td>",
"       <td>",
"        378",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        218",
"       </td>",
"       <td>",
"        257",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45-54.9",
"       </td>",
"       <td>",
"        242",
"       </td>",
"       <td>",
"        299",
"       </td>",
"       <td>",
"        362",
"       </td>",
"       <td>",
"        384",
"       </td>",
"       <td>",
"        187",
"       </td>",
"       <td>",
"        220",
"       </td>",
"       <td>",
"        260",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        55-64.9",
"       </td>",
"       <td>",
"        243",
"       </td>",
"       <td>",
"        303",
"       </td>",
"       <td>",
"        367",
"       </td>",
"       <td>",
"        385",
"       </td>",
"       <td>",
"        187",
"       </td>",
"       <td>",
"        225",
"       </td>",
"       <td>",
"        266",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65-74.9",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        299",
"       </td>",
"       <td>",
"        356",
"       </td>",
"       <td>",
"        373",
"       </td>",
"       <td>",
"        185",
"       </td>",
"       <td>",
"        225",
"       </td>",
"       <td>",
"        264",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Frisancho AR. Am J Clin Nut 1981; 34:2540.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37523=[""].join("\n");
var outline_f36_41_37523=null;
var title_f36_41_37524="Aflibercept (ziv-aflibercept) (systemic): Patient drug information";
var content_f36_41_37524=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Aflibercept (ziv-aflibercept) (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/18/2342?source=see_link\">",
"     see \"Aflibercept (ziv-aflibercept) (systemic): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14933262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zaltrap&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F14855407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Holes in the GI (gastrointestinal) tract, wounds not fully healed, fistulas, and very bad bleeding have been reported. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F14855409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3870288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat colon cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F14855408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3870282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ziv-aflibercept or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F14855412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had blood clots, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698469",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your urine checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697735",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug and for 3 months after getting this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F14855413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698240",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or mouth sores.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697994",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A wound that does not heal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14855414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin wound that will not heal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14855411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F14855415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86262 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37524=[""].join("\n");
var outline_f36_41_37524=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933262\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14855407\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14855409\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14855408\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14855412\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14855413\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14855414\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14855411\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14855415\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/18/27939?source=related_link\">",
"      Aflibercept (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/44/25283?source=related_link\">",
"      Aflibercept (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/18/2342?source=related_link\">",
"      Aflibercept (ziv-aflibercept) (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_41_37525="Fludarabine: Patient drug information";
var content_f36_41_37525=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fludarabine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     see \"Fludarabine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/28/42438?source=see_link\">",
"     see \"Fludarabine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fludara&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fludara&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700694",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause anemia and low platelet counts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700892",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause some autoimmune diseases.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Higher doses of this drug may cause unsafe side effects. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700303",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with pentostatin. Very bad effects may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before a bone marrow transplant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702132",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fludarabine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust during care and for 6 months after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697016",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy during care and for 6 months after care ends. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698628",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chills.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11348 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37525=[""].join("\n");
var outline_f36_41_37525=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171868\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171869\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027524\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027526\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027525\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027530\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027531\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027533\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027528\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027535\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=related_link\">",
"      Fludarabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/28/42438?source=related_link\">",
"      Fludarabine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_41_37526="Medication positions";
var content_f36_41_37526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Positions for administering sinus medications",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 563px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIzAh0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorzj48eNtX8B+DrXU/D1rZ3V/PfxWixXSM6kOrngKynOVHeuJtPjtdaz498F6PoVnaNp2qxwjUZZo3LwzuCWiQhgAVAGcg9aAPfaK89T4saInjS08MX9rd2WpXUzwRB57SYeYvRWWGZ3jz23qv86h0n4v6HqniC30C207Wv7ee7ktJtPe3QS2oQAtLKd+0R4IwwJz2BoA9Ior57h+ImvNYeEHsvEF1efbvGH9k3ctzp0FuzwbgDEFUuMejghj7V0Pw8+I2o/wDCJ+JdW8SmXUlsvEV1YRsj2lqIYEVSu5pXiQgZPOS3PcdAD2OivKj8c/C3/CNWmtRW2q3EFxqn9keRbwxyypPt3dFchlIxgoWznjNWYfjJoQTV/wC09L13SJ9M07+1JLfUbVYZZIt20BU3k7i2BhsdRzjmgD0yiueu/FunWHgj/hKtTS5sdOFqt26TIDKisAQpVSfm5AwCeTXC+NfiNNN8KNS8S6aus+HLeNbeSHUDb2V67B5FXCxCcjPzAEOVIz3IxQB63RXl2q/GbRdIutetbjTdbuToCW7388MMOxVlC7XAMoJGWGQBn2IGa0Lr4s+H4NR1u0WDUZjpWkLrUsscSbJICqsAmWB3YccEAe9AHoNFeb23xe0W+vtKsdJ07VL/AFHUbCPUUtYzbxPHFJjaGMsqKWOR8qsxqbxJ8WNF0K91O3lsNVu/7Iihm1WS0jjdNPEpAUSEyAseckRh8AH0oA9Corg4vifpF94nk0HQbK/1m9iiimlNq0EaIsih15mljLfKdxChsDrXeUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBx3xR8E/wDCd6Lp+n/2h9g+yahDf+Z5Pm7/AC93yY3LjO7r+lYl98INFXxL4f1XQTHpKabqU+qXECRtJ9qllCg/MX+QDbwACBngCvTKKAPE9A+Bs2jXHhxY/EkMljoepyalAh03E0xcjKyyebhiMABgo78dMaujfCe/0zxvH4wHiuaXxBNcSNqEjWmIbq2YKFtxH5nyBAi4bJOQCQcCvV6KAPILD4MfZLLQ7f8At7f/AGZ4jPiDd9jx5uWB8nHmcdPvc/SoD8EAunxxR69G1zD4jk8QxGew8yAlwo8mSLzAXA2j5gw6nivZqKAPFbb4HSpbxLceJFlmXxMPEjuthtDNjmIDzDjJ/iyfpU/xk+G9z43+IPg25t7N/wCzYC6avc+aio1urrIkJXO5ssrdAQN2T7ex0UAZ+vWMmo6NdWUH2ENMnl4vbU3MBU9Q8QZdwIyMbh/SvHn+ANu3h3xXp0OsW9k+vC2UrZWDR21uIZFf5YWmYktt5JfjJ47V7jRQB5Fq3wZ/tC48dS/295f/AAk9vbW+Psefs3lBRn7/AM+dvT5cZ703VPg1JcXl/cWHiBbY6joCaDdiSx83cqqqiVP3i7T8i8Hd357j1+igDxrxF8ExrvhfSNCu7/RjDp1lDZJfNo7G9CpjcUl88KoODgFWAyevWp7/AOCdiPEV5qumT6VK15bRQTR67pCanteNAiyxkuhViBzncCeSOgHr1FAHkPjD4MxeKrmxN7eaPax2nkKtzY6OYL3ZGFAXzhNsH3eMR4UcACvXqKKACiisfxV4i0/wvo0uparLshT5UReXlfBIRR3JwfoAScAE0AXNX1Ox0bTp7/VbqG0s4Rukmlbaq/8A1z0A6k14h4t+NN9eSvb+ErdbS1B2/bbuPMrf7kZIVPbfkn+4K4Dxj4p1Txlq32vVJPLtoWLW9orERW68jJ9W6jd1JyBt/hyFjQDLKCF+XDD5R7EDqf8AYH484NZyn2O2lhuszbm8TeI7mUyyeI9ZeTOS0N7IqE/RFC/gBVi4+IPimayt7GbX7tI4y2HjHlyv02hpAu5sYPYZzzniubuEnncRsGLN0V+n1wOMD1HT1J4pkUMySKhuZGiGUUsThjnHOO2cgfUdRUXZ0OnHsdfpnj/xbpzbrbWp7mNTlo7gC5B9mJG8fQY/rXofhj4128vlxeJrE2xY7RdWgMkZPunLDnsCx9hXiYhVX+dWUx9dnDKPXA4IOOq4P61YmiIBkLeYjD/WKATj/aA4Yfy/WhTaJlh4S6WPr3TdQs9Us47vTrqG6tpPuywuGU/iKtV8leGdb1bw3e/bdDnMbHBlgJLwzr2OM/N+YYdiB1+jPAPjOx8Y6X59sPIvIsC4tWbLRn1BwMqcHBwOhBAIIGsZJnFVoyp+h1NFFFUYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBmeIdatNA0uS+vmbYpCpGgy8rnoijuT+QGScAE15heePPEN3IWie10+HqscMfmOPYu/B/BBVfx/qj6r4suYy2bbTj5ECZ4LEAyP9c5T22HHU1h0H1mU5PSlSVaurt7LyOig8f6/ZfPPNY3UA5YXEXlsfbepAH/fJrp9G+J+jXkONQjubK4XGQkL3ETf7kiKcj/eCn2rzNkVipZQSpyCR0NOt4rm9vBaadB58+AzljtjiX1dsHGewAJPpgEhNpK7OnGZPg+XnfuJdv6/I900jX9J1kuumahb3MiDLxI48xB/tIfmX8RWnXz34k8Ca7PZpLp2rWzXkQ3IqwGEhs5yr7mIPAGOAe/HFLpXiDXrB47eTVdSsdQCBpbW6l88++3zd+Vz/Epx71MakZbM8COWKtNxw80/XR/qfQdFeHHx740t5iySaTdxE/da2ZGUfQOAx99y/SrMfxL8RmZUKaMXI/1b28sTZ7kHzGDDr0/OrJlk2MX2PxR7RRXkSfFLVocfa9GtWA6sJmRW98gPtH1rRt/ifPLGH/saAg9Cl8WB/Hy6CHlWLX/Lt/gemUV51/ws0bMf2LP5n/Xddufr1x+H4VR1T4q3NlYTXKaAk3lKXKC+2kgf9s6CHlmLSbdNnqdFeXH4malJaq8OgWqSsmdr6gSAfTiLke+RVE+PvEN1GkkL6bDE4DAC1csAecZMmP0rdYao+hwXR6/RXjZ8XeIWJJ1QqT2SCIAfTKk/rUsPjfxJFgfaNPmXuZrUk/8AjrqP0/Kq+q1A5kev0V5ha/EbU48Ld6XZ3A7yRTtEfwQq3/oVbdj8RtGmIF7Df2DHp50G9T+MZYAe7YrOVGpHdBdHaUVV03UrHVLfz9NvLa8gzjzIJVkXP1Bq1WQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEdlRWZ2CqoySTgAV8rfEbxXL4x8QyXas40m2LJYxjg7BjdLj+8xxjuOOMrz7N8ctbfS/BjWVs+261SQWo9RGeXOPTGFPpvr58gjBMQX7rkEZ/55p93n6kH8azm+h2YWnf3mJKq21qkfyiRyGJAzjGPuj24AHrinon2eNZHTMpO2OPPQnt9epJ+tFyzPcBUxuU7EOOjEZJ/BfzzVnTbefUb2KO0iM9zN8sEYOPl7sT2Hcn0x34OR3kDKyfu1bdczfecD7o9fYDsPX8TTI4ox5alRscyREe3b9ExXrmn+A7WDQJradxJqU+He6x91h0VR2UdMd+vWvPr/wANapZfa4Lm1lCREyCdBlSC2QwPse351EZpiTTMmIbnEc2TNFyr9Cy+v+I/+tQf9FfcP+Pdj8w/uH1+nr6dfWkOZvkciO6TlSOh9x6j1H/1jTjI8sTBVAmQ/PEeQfbPoex/+uKsYwuttM+0/uvvSL/cz/EPbrn8/WrthqN54e1eDWtJfZc25y6n7sicblb2IHPfgEcquMxXChGXcVQEpxklOjIfcenXge9TRuYFaJBvULvix3TuB7jt9R70bCaUlZn1l4d1e21/RLPU7InyLlNwB6qejKfcEEH3FaNeI/s+a55V3qHh95N0Dr9rtfQY2hgPqrRkD1VzXt1dCd1c8ipDkk4hRRRTICiiigAooooAKKKKACiiigAooooAKKKKACiiq2pX9ppdjNe6jcw2tpCu6SaZwqoPUk0AWaK8g1v412e9o/DWmT346LdT5iib3UYyR9dtc43xk8UI26XT9Ijjz3ilPHfkPx9TxUuaRtGhOSvY+gqK8a0P42Qi4jh8SaabeKRtqXdoS6g+jIfmH4Fs9q9a0rUrLV7CG+0y6iurSYbklibcrf59KaaexE4Sh8SPnzXH+z+ML+VuIri8uoGY/wB8TuUHtkF/xwKsVL4jt4brVdZhlUNE95cAgHHPmtyCOQQecjkGsZLmbTgI9RYyQDhbvA/8iAdD/tDj/d6Uz9CwT5cPTvs4r8kXrqYW9rNMVLiNC+0dTgZwK9C8NaUuj6VHAdrXL/vLiQf8tJT94/TsPQADtXnV/J5dlLMAW8oebgc7tvzY/HFesIyuiujBlYZBByCPWuTFN6I8vO5S5oR6C1V1HT7TUrfyL63jnizkBxnafUHqD7jmrVQ3d1BZ27z3c0cEKctJIwVR+JrkPDOP1LwjdWytJo9x56D/AJdrtuR7LIBn8GBz/eFc7KQ0htNQtpLe4PJt7lQCcdx1DAeqkj3r1WCRZoY5U3bHUMNylTgjPIPI+hqDUtPtNTtWtr+BJ4Sc7WHQ9iD1BHYjkdq6IYiUdJanpYfNK1LSXvLz/wAzy3ZNbcxFp4v7jN84+hPX6H8+1IscNwDNauY5CcF0GDn0ZT1P1GR7Vo6lYSaRqrWMjvLCyebbSv8AeZc4ZSe7Kcc+jL1OapT25L+bAwjnxjOOGHow7/zH512xkpK6Po6NSNamqkNmItw0TBLtVQk4WRfuMf6H2PrwTVk9KrxSrOHhmTbIBh425BB7j1B/zg8UzbJZ/cDS2393q0f09R7dfTPApmydvQrxyjRmEczY01iBE2P9Qf7h/wBk9vQnHpWpZKyWcCuu1ljUEehxUEiQ3to6MRJBKpU7TwQfcUmkTvLbPFO26e3cxOe7Y5Vj7lSp/GvRwtZy9yXQ+Lz3Lo4ear0l7svwf/BL1FFFdp88FFFFAEYhVblbiMvDcqMLPC5jkA9A6kHHtmum0jxtrunFUuXi1W3HBE4EUo+jqMHHoVye7VztFZTpQn8SHex6vovjrRNTdIpJn0+7YgCC9AjLE9ArZKMfZWJrqa+fnVXQo6hlYYIIyDXofwmk8uyvrJNwhiZZI03EqgIIIUdFHyjgYHJPc1w1sNyLmT0KUrnfUUUVyFBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgP7Ql48vi/S7EkgW9iZY8HGGlkKE/gEFeb5UXv3tkUK8+gAH8juH/AHzXcfHGb/i5jNLkiDT4dv03S8D3JcVyfhvSZ9a1CKyi+9O2ZHHRY1OXb6biR/wIVhN6nqYfSmjU8LeDr3xDaXFzvW2jJCBpFPz5ILgY9jtz/sj8PV9A0Gw8P20hgVfNZR51w/BYD1PYDnir8EMOl6asUEbeTbxnCqMkgDP4k1DBA16Yri7eKRAA8cUZ3ID67v4j6HAHt3rjlNy9CmwaaS+kZLGfy4EHzToA25v7q5yOO5/DrnDJGnvFs/KmMLSQNLwAVLfJgEHqvzHjI/PBFrUnMenXTqdrLExBBxg4PemlUj1C1RcKBDIFUemUqSThta8GWmqy/wChYsL3G9raQEKD0JRgOnuM9R0zisOP4fa29wUmMC7VPl3KuOv91l7g+35DrXqeoPZsUjuLlIpUPmJiQK6nBGQO/fjBBo06SZ2mWQySRoRskkiMbH1BGBnHHIAHOOxNWqkkilJ7HgWsaffaXdmO9tXt59wPP3GboGVvQ52n6+1QIcw/ugSYsSxD1U5+X+Y9uK+ib2ztr+3aC8gjnhbqrrkV47470OPQNeia1TZZT/NEMk7c4Drz/tbW/wCBe1awqc2hSlcp/D69/s34haHLG2Ue4jRPQrKfKx/5FJ/75r6sr5L8LwO/i7w+kSF2i1S27dI/NRyfoMY/A19aV1U9jhxa99BRRRVnKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ+vaxY6DpNxqWq3CW9pAuWdj1PZR6sTgAdSSBXzV8Q/Fep+NLvdIhi0mFyYrHJGcdGYcZf8cDOB3LdT8etZkvPE9rpEZLWumQfa5Ix0edwQuR/spnH++fauB0HS5L/XbbTrW6WN5mchTyqIASTtyOhwMD26ZNZVJW0O7DUlbnkY8VpJLciKK2ZpXx5cYBYEnoAODntyDzwcZGeo0bwtrk+q2q3um3j2RdfObeYW2dTwcDpkYHI7HPT1vR/DOk6T5b2tpH56IqCZ/mbgYyM9Ce+MVs1yyrdjob7HA6j4DsLm2wNMSN02jFvtjDNuHzBVKZx1y5J4xgnmqHhnSfE3gXxDJdaJbXF9pcpR7mBpYlaXJO/IyASBtIIAPG3BGSfTaiuLeG4ULPEkgHI3KDj6VEasokOKejPNktdXlLzXWl3n2ieR55cKCN7sWbHPTJOPaoLtzaqft9vcWqHgvPCyxj2Lkbf1r0qw3RtPbuzP5TDyy5yxQjIye+DuGevy85PJtkAggjIPY1r9Zl1R61LN60Eo2Vl6/wCZ44LKa0wdLlURf8+0pJj/AOAnqn6j2pmg694u0qdLOOBJ9OjAWP7WyYRBxgMh3cepB+g7dV4l8P8A9kiS/wBKiJsPvT2qDPlD+/GPT1QfUc5BzNLtLvW2C6UFFv8AxXrjMS/7v98+w4GOSDwejnhON2d8quExNJTqO1un+X/AOjsfF8l3cCxXSZjqTqWRI5VaLH95n4Kr6kr7DccA7NnpZE6Xepyi8vlOUYriOHjGI1/h6n5jljnrjADtE0e00a2MVorF3O6WaQ5klb+8x7/QYAHAAAxWjXBJq/u7Hz1Tkc24KyCiisDXfE9rpzvbWq/bdQXgwI2Fjz08xudo5HHLY6A0lFydkEISm+WKuzH8Zyb5tK3grc+ZcYDDB8kHGfz8qsamEzz3U15fTedeTYDsBhVUdEQdlGTgc9SSSSTSkgAliAB1Jr0aUeSNmfXZfh5YeioT33I7iBZguSVdeUdeGU+3+HSkt3myUnQBl/jX7r/TuPp+pqVWV0DIwZWGQQcginVodltbldbfZP5kLbAxy6YyG9/Y+/fv2xWu3XT71b8nbA4EVyT0UZ+Vz6AEkH2bJ4WtGmSIksbRyKHRgVZSMgg9QaqE3CSkjnxeFhiaMqMuv5ksU8UpIilRyOu1gcVJWBZ3tksH2TU7hI7m0doQ8rlGI/hIc4yShUnB6mtDzYwMx6kuewZkYfj0J/OvZjNSV0fmlSm6c3CW60L9FVrK7W5Ei7ozJE21tjZB4yCPwP8AMVZqr3ICiiimAV3XwqB+2agc8BEBH4muFr0b4VwFbO/n7PIqD/gIJ/8AZq58U7U2UtzuqKKK8ksKKKKACiiigAooooAKKKKACiiigAooooA+ffjDo954g+Idpc6LC0kLQrp8s5KqgljaVyBk5JAPLAEArjkjFdZ4P8NQ+HbFgCJLuQDzZFGBgdEX2GT9evoBUlhkTxSTLLIq2mrTI0QPyhpFuJASO+VnhOf/AK9dXXn1ptux6NLSCRl6hZ32oRqgvDYJvDH7OMyMuDkbjwOvoenesiXwPYu4ma8vpLoEsJJ5jICT6r0/LH1rZfVVhmeK6s76IhiEZLdplkH94GMNj6Ng+1MfVzJ8lhY3txN6SQtAi+5aQDj/AHdx9jWabWxTSe5mTWkul2toJnWUxs2NgAV2DZVjH0+6MkryCM89tTX3UWkDGLzlMo+5GsjD5TyobjPv2Gap6xI8n2eOQQJftG6mGOUvu3YIQcocNtzu4+6R3q/rkbmyUxKNsTb228MqgH7vK4PQHkfKWFAGZL4dg1WCA3cyizeBPMtrTCwyMfvNkdQeAPYe9PHhHTo4ylpNqFoCAP3F3ImMAAcZwTwOTVi2nul0+2awgjl8tQtxbOWSQNgE4LH73OcN1yDuHUzLrUG395bajG4+8hspWwfTKqQfwJFF2FkXLdJ4iVllEyZJDsArD2OBg/XisfxvoX9v6FLbRgfaUPmQknHzYwRntkEj64PatmznNxCJGgmgyThZQAxHY4BOM+h59QKmpJ2dyjyD4caVqI8eeHWvrKWBLkGdJiVKOsalwRgnGc/dPPPsTX0rXlHw8hd9a0OHzJHhi0tL3k7grlTHgE9ARJwOn7v616vXo0neNzhrycpahRRRWhgFFFFABRRRQAUUUUAFFFFABRRVa/v7PTofO1C7t7WHO3fPIEXPpkmgCzRXC+IPFaXcjWemrfm148y6hs5mEmf4UZVxj1YH2HOSMZr+3AJa1vwO5/s+f/4igDyn4tSuPil4iwn73zIFQAAk4tlx9eCzfUYqt8O7CW/8T2Yt0DRwOJpXLEDCnOcjk8kYHTnLEk4qH4rSW8vjGK406aBmlskRGhcZMokIYMB32snXnjHeus+Bs0c0V2ViRdsUYUqcY5OQVPIPT1/Wuaromz0qMrwR397qxg1S4s0CF4bE3eCeT8xA/Dg/n+dywujcTXsThQ1tN5R2nrlFcH8nFVbvSLeXWRqkjlWFq9rKpYhXjJ3c89jnn3NTx3enRPK6XVsrSsJHPmj5jgLnr6KB+FcehRerNvNVVY7ZdORby4uk8yBVcBGTjMhbnCDcvIBPIwDWD4mvry01e4t4VS5gfTpJvs5lKySOHUY5woTb8uR82W6V594F8c61rusWiLo80NvJptuW1KCB5Y4VCyZCxrndliVzn70eSDjAtU21zEOok+U9aTTb55GmuNXmSZlCstrDGkeASRgOrnue/wCVSf2Qr/8AHze6hMfX7Q0X6R7RXMtaWlzJJBodnNJevCgW/lR43hbc26R5GAYtyDt/i4BwMkdu7qgBY9TgYGc1L0KWpnNoVhJxOk9wneO4uZZUP1VmIP4itJVCKFUBVAwAOABVXU9StNMt/Ovp1iQnaoOSznGcKo5Y8HgAmuSv/FeoXLldNt47SHp5tyN8jfRAcL7Ek+4FOMJT2Oihhqld2pxuduxCqSxAAGST2rnr7xfpkOVsmfUZR2tQGT8ZCQn4Zz7Vw2qxXmolWub97lgclbpd8Z9D5alVBHY4zWYbzUpnaPTntLkqSpkMDJEpHUbt5yev3QcEYOK6I4b+ZnqU8ocdaz+S/r9Dp9T1jVdUyks/2G2PWG0YhmH+1LgN/wB8hfqapQwxwRiOFFjQZO1Rgc1Sjh1MovnXlqGx83lW5HPtlz/Kn/Y5/wDoJXf/AHzF/wDEV0xgo6I9mhQp0FanC33X/MvUUeHtH1PUTe+VdRPDDMIxJcffzsViMIoBHzDn61tr4P1E4LaraD1UWTHH4+b/AEqXWhF2bMp5nh4Nxk9V5HMSRNbMZbZSUJJeEd/Ur7/z+vNWY3WSNXjIZGGQR3FdCPB97nnVbfH/AF5t/wDHKbD4LuIt+zU4cMxfH2U4BPXH7z1yfqTU/WIdzH+1sOnpf7jDoroP+ERuv+gnD/4CH/45Tl8GE4EmrXIHfy4kU/hkHH60vrEBvOMP5/ccjZDZrF8qnCvHFKR/tHepP5Io/Crn2S2/594f++BXRr4HtROJv7U1IyhSm79z0JBx/q/b+dWf+ESt/wDoI3/5xf8AxFdtLMqUIKLufI4+n7fETq09mcfLp1lNjzbO2fHTdEp/pUX9k2inMCPb+1vI0a/98qQD+Irsv+EPhxj+1NS+v7n/AON1G3g/b/qdWvCf+m0cTD/x1VrX+06D7/ccf1aocj9mvo/9TqG8Hr9ohD4+mzZ+uaXdqScGKzl/2vNaP9NrfzrpJ/C+qR5aC8srj/pm8Tw/+PBn/wDQax7lbiynjh1G2ktZJDiNmIZJD6Kw4z7HBx2ropYujVdoy1M5Upw1aKe3U3/5aWcXH/PNpP8A2Za9h+GB/wCKWRXdHnWVxKUUqCeo4JPbHevLK7/4VTnfqEBPBCOB6dQf6U8VG9MiO56DRRRXllhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHmnxGD2urW5iwolura6bHDMqyLFIfcKDESewb6Vq1N8RPDt5rdrHLpkdpJdxQXEAW5YoAJUHzKwViGBRRjjIJ5FU7K4S8s4LmHJjmjWRc+hGR/OuHERtK53UJXjYydS8WaHp0jx3OoRGVCQyRAyMD6EKDg/WuP1H4nkT403Tswjq1w+Gb2wucfXJ+lcFrGnz6VqdxZXSlZInIBP8S9mHsRz/8AqrS8FaF/b+uRwSAmziHm3B9V7L/wI8fQN6Vy3d7Hx9XPMfiMT9UoxUJXt3fzv/kesSzRXs+iXFsJEe9Kzsu44EYjLZZc7SclFz2yPQVvMAykMAQRgg96x9J2SXl/fzMiCNzaRJkAQxocc+hZvm912elatxPDbQtNcSxxRL955GCqPqTVs+1W2piX+tWGi6DPqFva/ukmMRijUIS6v5Zz2429fQfSsSx+JWlynF5b3Vsf7wAkXH4c/pWlqmnw6pLqumJIjQ6hbLdIw+YRyghQ/HY7YyB32N6mvFHR45HjlQpKjFHQ9VYHBB+hqZOx83nmZ4vL6kJUrcjXVdf+GPf9G8QaXrTSLpt2szoAzKVZGA9cMAcVY1q6Njo1/dqCWggklAH+ypP9K4D4QaW4N5qsgIjYfZ4v9rkFj9MhR9Q1dx4hjmuNOW1tVR5rmeGEI5IVlaRQwJAOBt3ZODxVR1aR6+X4mpiMLGvWVm1f5dPwNf4aW/kaYU3bmt4ILNyWBO+NMsDj/fH45rsqx/CulPpGkLbzCETvJJNKIeVBZiQoOBkAYXOBnbnArYr04LlikZzfNJsKKKKokKKKKACiiigAooooAKKKRs7TtIDY4JGRQBj69rJsnSzslSbU5l3JG33Y0zjzHx/DnoOrHgY5IwrTTo4ZzdXLvd6gww11Pgv9F7Iv+yuB+OTWL4YuLqe41GG6vLaTWIp2F43lFg5BIBjbfgxj7oH8O0qfmDVv7Lz/AJ72/wD34b/4ugCzRTYg4QCVlZ/VV2j8smo5muVf9xHC64/jcqQfwBzQBxPxN8MjxXog2Wk9tqVqfMt7gqrYPdG2EsVPsODg9jXkHhPVBoPiy3uL6KfTpEkK3kE6MDHnOeBgkHkjqM84ORX0jvvf+fe2/wC/7f8AxFUdY0DTPENsqa3psUrLwC33l/3XXBA/Ee4qJQUkbUqrhp0MTXb8Xa6FcadfA6fLfxpcPAwIZSrbVJ9C+xSP9rnjNX7Oa4bV2WQyPDJHINrDAQpKQP8AvpXH1CCsjT/AOhabNvtNM1ROgIS+KA4PGcSAtjtnNbR0WGQHy7K6jYHmSXUJVc/RlZiR7Eiuf6s+5r9YXYmGl2Y4EWEwR5YdvLwQQRsztwQTxj361m2/hnS9OsdsI+zGJ5JEuY8RyRBiWILADIGejZBwN2auDSNSA2jULkJ2Xz4zgemTBn8c596dFoUKSCSTTra5lU7le7upJ2U/7JdTt/DFJYaXVg8RHojnjqesoszWqz6tpiDf9ttYlR8egBBEowM7o1PPAFYtv4nu7wyS6VElvHuKGSdjIzYyMHDFiOflO9fXbgivUDc3C8PZSs3cxuhX8CSD+lcD4306001LrW9Os5onLeZfwJAR5nrIDjaX6Z5+YDjJAB2VCCN8DXpOsliPhf8AX3GLsd52uLmV57gjbvfA2r2VQOFX2AHqcnmpKq2t/a3W0QTKXKhth+VwD0JU8j8RVqtUktj7yiqaglStbyCmIixoqIoVFACqBgAelPopmgUh6UtU7uS3lu7XTri5htxdtiRpJQm2EffOSe4+UH+8wpN2VzOtVjRg6ktkd94Ht/J8N20rD57otcknqQ5JTPuE2j8K3qyxr2kKoWK/tpABjbA4kxj2XNJ/b1kDjZf/APgBP/8AEV5rjKTvY+FnUUm5Se5q0Vk/20pA2WGoMx6DygufxJAH41HPqkj4BtdTtmAP3I4nz+Rb+lHs59ifaQ7m1RWSdZJwI9Nv5G7gIifqzAUxtR1OXm20uONf+nq5CN+SK4/WmqU30E6sF1NmisRl1abIkv7eBD/z723zj23OzA/98006aZObq/1Cdux+0GHH4RbR+laLDTe5m8RFbG7RWD/Yumn/AFtnFMf70480/m2TSDTprU7tLvJbc/8APKUmaI/8BJyP+Asvvmm8M+jEsSuqN/oMngVzPiVoLqzl88RSQlPMYKxLNa/LukQ9AyNtcEZPyr0JGI7TxhCA9vrNr9hu45PKkV5o9h5xuBLA7SOQSBkdM1n6jHe66s8GmvcW6CctbalJHgJE6ASIFYhnBOcHAXBUgnYM5wpy5rGkqkeW5j6dK09hBI7o7MgJdPuv/tD2PUexrvfhZn+1bzrt8nn67h/9eubj8MXyRqo1K0AUADFm3/x2u6+G+ltp6XzXE8c87FQGSIxgLzxgse/9K+gq4iEqbinqebbU7WiiiuAoKKKKACiiigAooooAKKKKACiiigAooooAK870hPItpbPp9jnktgvcIjkJn6psP416JXFa1B9g8UzHBEOpRiZT/wBNkARxn3QRkD/Zc1hiI3jfsb4eVpWOX8a+FIvEUEckcggvoRhJSMhl/ut7eh7H6kGz4P8ADkPhzTmhVxNcyndNNtxuPYAdgP6k963qCOPSuA1WDoqu8Qo++1a5m6loGjaoXOp6Tp94XxvNxbJJux0zkHOKiPhnRmiWGXToJrdOEgmHmRRj/YRsqv4AVU1O11of6i+jdPVoCT+IVl/lVCP+3Z2VFMMRXo2Xkz+Hy7fzNWk7bnYqaep09hp9lp8bJp9nb2qNyVgiVAfwArkNf+HsOq63LfR37W0U5DSxLCGO7oSrZwM4zyDzk98V0+mW2oxhWv71JMD7kcW0H6kkn8jWlUs5MThKOJj7OtHmW5W06yg06xhs7RPLghUKi9fxJ7k9Se9T2Mf2nxTpMQ48gTXZP+6nlY/8jZ/4CadVvwVCZ7rU9TZfkdxaQn+8kRO5vbMjOv8AwAGtaEbzHWahCyOrooor0DhCiiigAooooAKKKKACiiigArzf4g+L4Y9Rl0FJ7u0jQKbyeG3lZ3DDPlRsinbkEbm6gHC8ncvpFeK+PP8Akc9V/wB+P/0SlAEc2t6I8cC2s17Zy24xBLBYzKYh6DKYK8DKkEHA44FWYviClr8t9aXF2O01layqT7tG4G38GbOPwrnKKAO8tfG+hXEauJ7mIHr51nNHt+u5AB/KrS+K/D5zu1nT4z6STqh/JiK85ooA9EbxboIzt1S3k/65EyZ+m3OfwqF/Gmhp1uLnrjiynP8AJK4GigDvl8Z6Gwz9puAMZ+azmH80qyninQH4/tnT1b+69wqN+RINecUUAem/8JDouM/2vp2D3+0p/jVabxboMYO3Vbacjqts3nsPwTJrzwEgEAnB6j1pKAOvv/iBptuP9FsdVvRnGYbfZ/6MKms2bxzdXWVjgfT4z/GIWnkI9gQqqfc7x7VhUUAaianoI06Gym0+e4t4hhVmtA4z64xgfQAAdgBVSRvDLH5bHUYh2WEzRKPoqsAPyqtRQXCpOnrBtehOP+EaH/Lrq/8A3+uP/i6cX8Nnraar+Ek//wAXVaigt4ms9XN/ex7HR+kc+txp2URhsfiyk/rWnperaJpcbrZ2l6rSEGSRomZ3x03MTk47enasmigKmIq1Vyzm2vNtnSf8JXYf88b3/vwaP+ErsP8Anje/9+DXN0UGJ0n/AAldh/zxvf8AvwaP+ErsP+eN7/34Nc3RQB0w8WaTjl7sH0+xTcf+OUv/AAlmkf8APS7/APAGf/4iuYooA6f/AISzSP8Anpd/+AM//wARR/wlmkf89Lv/AMAZ/wD4iuYooA6f/hLNI/56Xf8A4Az/APxFH/CWaR/z0u//AABn/wDiK5iigDpv+Eq0fdu33W4DGfsM+cf98Uv/AAlmkf8APS7/APAGf/4iuYooA6f/AISzSP8Anpd/+AM//wARW/4J8T6bd60tlBJcGWdCFD2kqAkDd95lAHAPU15zXRfD7/kb7D/tp/6LagD2aiiigAooooAKKKKACiiigAooooAKKKKACiiigArN8QaUmsaeYC/kzowlt5wuTDIM4YDv1II7gkd60qKGrhseew3MsV19g1SMWuogEiPPyTKOrxn+JeR7jIyBxVypPHNjbX+raXFdwpKgt7hlz1U7ocMp6qR2I5FYgtdSsAPsVyL2Bf8AlhdnEmPRZR6f7QJPdhXnVYKMrI9ClNyjdmvRWdaaxa3E620pa1vT/wAu1yNkh9dvZx7qSPetGsjQKKyZdajlYxaRH/aM4OD5TgRRn/bk5A+gy3tSHTLm9B/te7LxHra2wMUZHoxzub0PIUjqtO3cL9ie0mOv6jcaXpE5XyVBu7xORApLDah6NISrDuFwS3ICt39lawWNnBaWkYit4EEcaDoqgYArlPCqR2niKaGFFjjlskCIq4UCJyMDHTHm/qPSuyrvoRShdHDXbcrMKKKK2MQooooAKKKKACiiigAooooAK8Y+IihfG19t43QwufrgjP5KPyr2euM8R+CP7Z1ubUf7Q8nzI0j8vyN2Nuec7h6+lAHlVFekf8K3ixzqT5/64j/Gl/4VtD/0EpP+/I/xoA82or0n/hW0P/QSk/78j/Gj/hW0P/QSk/78j/GgDzaivSf+FbQ/9BKT/vyP8aP+FbQ/9BKT/vyP8aAPNqK9J/4VtD/0EpP+/I/xo/4VtD/0EpP+/I/xoA82or0n/hW0P/QSk/78j/Gj/hW0P/QSk/78j/GgDzaivTB8OLTHN/Pn/cFL/wAK4tP+f+f/AL4FAHmVFem/8K4tP+f+f/vgUf8ACuLT/n/n/wC+BQB5lRXpv/CuLT/n/n/74FH/AAri0/5/5/8AvgUAeZUV6b/wri0/5/5/++BR/wAK4tP+f+f/AL4FAHmVFem/8K4tP+f+f/vgUf8ACuLT/n/n/wC+BQB5lRXqI+HOn4Gby7z/AMB/wo/4Vzp3/P5d/wDjv+FAHl1Feo/8K507/n8u/wDx3/Cj/hXOnf8AP5d/+O/4UAeXUV6j/wAK507/AJ/Lv/x3/Cj/AIVzp3/P5d/+O/4UAeXUV6j/AMK507/n8u//AB3/AAo/4Vzp3/P5d/8Ajv8AhQB5dRXqP/CudO/5/Lv/AMd/wo/4Vzp3/P5d/wDjv+FAHl1dN8OQD4stcjorkf8AfJrrx8O9Jxzc32f99P8A4mr+ieDtP0fUEvLaa6aVAQBIykcjHZRQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByvis/8AE+0odzbXJ/8AHoap1qa5pl3d61FdoqtBBbmKMA/NudgXz7YSPH41Re1nQ/PDIP8AgJrhrp897HdQa5LXKl1bQXcJiuoY5oj1SRAyn8DVL+wNG/6BOn9c/wDHsn+FaZBHUEfWkAyeOtYXNhEVURURQqqMAAYAHpS1IsMrfdjc/RTUqWF0/SCT8Rj+dCi3sgckt2V9KfyfFmns5wktvPAPdyY3H/jsb12tcxFod017Y3JdYWtZvNGecgqyMMD1Vm/HBrp676CahZnBWac7oKKKK2MgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAqHUrQTeUZf3m7ZjaeucelOub63tZAk8m1iMgbSePwqzRQBXlvIIrdJ3fET42tg80Q3kE0Mk0cmY0zuODxgZqxRQBWtr+2uZNkMm58ZxtI/mKadStBMYjL+83bMbT1zj0q3RQBWub63tZAk8m1iMgbSePwpZbyCK3Sd3xE+NrYPNWKKAK8N5BNDJNHJmNM7jg8YGaS2v7a5k2QybnxnG0j+YqzRQBUOpWgmMRl/ebtmNp65x6U65vre1kCTybWIyBtJ4/CrNFAFeW8git0nd8RPja2DzRDeQTQyTRyZjTO44PGBmrFFAFa2v7a5k2QybnxnG0j+Ypp1K0ExiMv7zdsxtPXOPSrdFAFa5vre1kCTybWIyBtJ4/CllvIIrdJ3fET42tg81YooArw3kE0Mk0cmY0zuODxgZpLa/trmTZDJufGcbSP5irNFAFQ6laCYxGX95u2Y2nrnHpTrm+t7WQJPJtYjIG0nj8Ks0UAV5byCK3Sd3xE+NrYPNEN5BNDJNHJmNM7jg8YGasUUAVra/trmTZDJufGcbSP5imnUrQTGIy/vN2zG09c49Kt0UAVrm+t7WQJPJtYjIG0nj8KWW8git0nd8RPja2DzViigCvDeQTQyTRyZjTO44PGBmktr+2uZNkMm58ZxtI/mKs0UAVDqVoJjEZf3m7ZjaeucelOub63tZAk8m1iMgbSePwqzRQBXlvIIrdJ3fET42tg80Q3kE0Mk0cmY0zuODxgZqxRQBWtr+2uZNkMm58ZxtI/mKadStBMYjL+83bMbT1zj0q3RQBWub63tZAk8m1iMgbSePwpZbyCK3Sd3xE+NrYPNWKKAK8N5BNDJNHJmNM7jg8YGaS2v7a5k2QybnxnG0j+YqzRQBUOpWgmMRl/ebtmNp65x6U65vre1kCTybWIyBtJ4/CrNFAFeW8git0nd8RPja2DzRDeQTQyTRyZjTO44PGBmrFFAFa2v7a5k2QybnxnG0j+Ypp1K0ExiMv7zdsxtPXOPSrdFAFa5vre1kCTybWIyBtJ4/CllvIIrdJ3fET42tg81YooArw3kE0Mk0cmY0zuODxgZpLa/trmTZDJufGcbSP5irNFAFQ6laCYxGX95u2Y2nrnHpTrm+t7WQJPJtYjIG0nj8Ks0UAV5byCK3Sd3xE+NrYPNEN5BNDJNHJmNM7jg8YGasUUAVra/trmTZDJufGcbSP5imnUrQTGIy/vN2zG09c49Kt0UAVrm+t7WQJPJtYjIG0nj8KWW8git0nd8RPja2DzViigCvDeQTQyTRyZjTO44PGBmktr+2uZNkMm58ZxtI/mKs0UAVDqVoJjEZf3m7ZjaeucelOub63tZAk8m1iMgbSePwqzRQBXlvIIrdJ3fET42tg80Q3kE0Mk0cmY0zuODxgZqxRQBWtr+2uZNkMm58ZxtI/mKadStBMYjL+83bMbT1zj0q3RQBWub63tZAk8m1iMgbSePwqeKRZY1dDlWGQfanUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRTZpEhieWZ1jiRSzOxwFA6knsK5+XxfphJWxF1qDDobWElG+krYjP4NSbS3Gk3sdFRXJSeJNTmGbXSoYFbobq5+dfqiKwP4PVWS+1yfIl1SKAdjZ2oQ/j5hkB/ACs3XgupoqM30O3orgZLeabm61LU5X/vLdPD+kRVf0qB9H0+Xm5tIrlj1e5HnMf8AgT5Pc/nWbxMeiLWGl1Z3F3q2nWbbbu/tIGzjEsyrz+Jq4jrIivGwZGGVZTkEeorg7WztbQYtbaGEYxiNAvH4U7wVJJpmrtYOix294jyqicRpKhAJQc7Q6ndt7FGPJYkunXU3awp0HBXud3RRRXQYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHAfG6HxdN4MUeBRM96t1G11FbzLDNLbANvWOQ/dYnbyOcZxk8Hyy8+LT+GvC3iO40Ww1qz1/Tbi0hudJ8SXEt4kKyFsOjs/mHcCCctj7uBivf9e0LT9eghi1OKRxDJ5sTxTSQyRvgjcrowZTgnkGuF8bfCDSNd8H3+iaRM2lTX91FdXN9N5l5NMyHje8km9upAy3GeKAPKvjx4y1e98M/EHwfr0djLLpYsLmK7soniVkkljOxlZ3+YbhyDzg8Cut/wCFs6r4XbxXp+sWNlepoWj2t/aPaq8Jk8wRqEkDM3RpBlhjgE45wPQbj4X+ELrTtWsbrSWuItWkjlvnmu55Jp2QgpulLl8AjgbsVfPgXw22pahfyaVFLc6hZrYXRld3WWBQAEKElegHOM+9AHkl38X/ABjYaDq9/PocU9vFpMeoW2oHSLy1tlmZ0DQP5pG/hiQ6sAcDjri7afGHWtO1W7h1+y0+6th4WTxHCbKN4XBKjMTbncEZJG4YwB0Nd8fhd4SbTprCWwu5rKW3Nr5E2pXUiRxblbZGGkIjGUX7mOgHSr9v4D8NW+pxahHpaG6j00aQDJI7qbQf8sijMVI9yCT60AeXxfErXLlNF0/xLZ6TdWnivQLm/gSzjliNvthaQxyEyMXBTA3LsOc/WsfwP451C48OeEvCPhzT9K0tLrQrjU7l5I5p44og8qiOJWlDbiVPLO2M9DjFewaP8N/CujyO9jpjB2tmslMt1NN5UDZ3Rxb3PlqcnhMdaiPww8I/ZdKt49KeFNLieC0eC8nikjjckshkVwzKcnKsSOT60Act+zE8kXwD0KSGIzSKLtljBALkXEuBk9M1yX/C0bzxF4V8U6d4sisbHU10m+mbw7c6VdQu4jRzj7R5wDDABbCoeTgjGa9w8N+GdJ8NeHYtC0O2az0uIOI4kmkJXexZsOWLZyxOc5HbFZI+HHhhpbyW5srq9mu7R7CSa+1C5upBA4IZEeWRmQHJ+6QeaAPK9A+Ieu2Q8IeHPD9nollaT+EF1ZRLDPKInVXxGv70EphAOSTznJ6VpeDfjDrHiHXfhtavYafBb+JbW7lvMK5dHh80DyzuwATHnBDcHGe9ei2/w78LW17Y3cOl7bix07+ybd/tEp2WuCPLwWwfvH5jluetQw/DHwjBZ6Ha2+lNDHojSNp7RXc6SQeYxZxvD7mBJOQxI5xjFAHlNh8avFV14D0LXZNHtUhu7y5hvtQt7Ca5hskjICZhWQMS2epcDitbV/jDfS3+haX4XnstUmvtLl1M6jFo93NHNtd0WOO2jYyId6EMzMQv6V39n8M/DFjosek6fb6lZabGZCLe11e8hVt5+bdslG7P+1nHap5vh34Wkt9Lhi0v7J/ZaNHZSWVxLaywK2dyrJEyvg5JIzyST3oA811j4u+KNP07wzd6r4el8OWV7avJqN9e6VcXS2syu6+WYlaNlBCeZkk/K3AODXs/h+/i1TQtPv4LuC9jubdJVuIIzHHLlQdyqSSoPXaSSOhJrAuvh34dutNj0+aLUjYJEYTarq12sUilmZvMQSgSElmyXBJzyTXT2Fpb6fZW9nZQpBa28axRRIMKiKMAAegAoAnooqhq2sadpEQk1S+t7VT93zZApb6DqT9KAL9FcFdfFvwZbsB/arSjJyY7aQgf+O8/hmo2+MHgxow9tqctxkbsJbSLx/wNVH4daV0VyS7HoNFcLYfFfwfdkA6m1ux7TwOo/wC+sY/Wuu03VLDU4zJp17bXaDqYJVfH1weKLicWt0XKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKpaxqdpo+ny3t/L5cEeMnBJYk4CqByzE4AA5JOBV2vM/HEM2peOIrOUq8NvZpPDGxJRS7SK7sO5woGO4OMhS4aJy5FcqEeZ2JmuZ/Ebpc6phbXiS3sQwZAOqu+Cd7f+Ogj5c43HQrPsLyyLLBb3BmbJXzTllkcfeG/G0sO6g5HoAKmmibUNTsNLSR0FwzSTtG5R1gQAtgjkZYxpkcgOSMEA1wPmqS1O9ctOOhaorcHhXQdoH9j2O7/AJ6eSvmfXf8Aez75qCTwlYjm0uNQtX9UumkGPTbJuUfgK2eGfRmSxK6oyqKsy+Hb22jdl1qLyEBYvd2gZgB6lHRcf8Brm9OOt3dhb3D3dhEZkWTYbJ8rnnB/e9cfrWM6ThuawqKext1FFn/hIdAwf+Xt/wD0mmqGzjvkkY3lxbSpjgRW7RkH6l2/lViAbvEWhY5K3MjkD08iUZ+mSPzFFL40FT4GdzRRRXpHnBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVDeXMFlazXN3KkNvCpeSRzhVUckk1NXgvx28WS3mojw/YSH7PbkNPtP8ArJeMD6Lkf8COSPkpN2RdODnKyJPF3xfvb+8lsPCcf2a3Xhr2VMuR04U/d+h5/wB0ivMbyR7u4mmuZnupzzNc3LFwMfXqf5dz2KRw+Ui2sBwcbpXHB/8A1nHHoB9KewQt5fCW8Ay/oT1A/Dr+XvWDk2epClGC0RSliDZdw5+Uudx+YKOcn0JPQcY5IwRU0VmBbhQiGaIkMMAK/f8AkeD2/OiMM/nSvkGR412nsMg4x9Dg+4NXIuJ51PUkP+BGP/ZTSLSKwgEqiSLL9ishIZfUBuoP1z+FMt1eCZZLRpYpouQEIjlT3GPlP1/XirbIUuBJGMq/Eg/k39P/ANVPmhWUDJKuv3XHVT/ntRcfLc6rw18TvEWkFRPcf2tZqcMs+S4/H74P13f7te0eDPHGkeK4gLOXyrwLlraQjdgdSp6MPcdOMgV8ygF5SCRHdqOGA4dfXHce3UevIJfbySx3IubN2tr6Fgx2sRz2II/Rhz+RFWptHNUw0ZbaM+wKK85+FnxBHiRf7M1bEerxLw2AonA68DgOOpA4I+YcZA9GrVO558ouLswooopkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUV5j4y+L+l6FfzWOm2p1O4gO2ZxMIoUbuu/DcjvxjqM5BAteDfivpHiK1d5rO/spVIC7YHuIpuCf3ckakNgDkYB9u9LmRfJK17HoleRfFfxLomg+IxFrVy0KX6WVo3lRPIzL58hkX5QSPkY+/zcc4rsNR8SzXpFvoUc0YP+svLmBoxGPREcAs3oSNo6842ny6fwxoeueOLnVfFviBYpLKVUkW6EHlXa7flBygVXCnGVAfBx0AZs3KMny3Goyiuax3Woaql8tjO8EOmaNYkvGsjqHL7TGoIX5UUKzAAEkkjgYwd/wAG2EuyfVr2N47i7AEMTqQ0UA+6CDyGbJYjgjIU/dq1pmgaHFLFfWNpbyOPmhm3eaE4xlCSQuR3XGa26I03zc0twlNcvLHYKKKgvru3sLOa7vZ47e2hUvJLIwVUUdyTWpmYnjqYjRBZLy2oyraYzjKHLSc9v3ayY98Vl1iWfiOTxZ4lu7mO3MOk6cghtTIMPLI/Luw/hwqptXrhznBO0bdcOIleVux30qcqatJWYVzWseIrjRfFVo9nbQXTw2jmSKZyg/eOoUhgDg/unGcHrXS15je3H23W9UuxyrXBhT1Cx/uyPpuVz/wKlh43nfselgMLHFVeSa06nodn8TbYkLqGk3kJ7vbukyAfiVb8lNbdr478NXABOqxW4Pe7R7YfnIFrx+iu89Grw7Ql8EmvxPcYfEWiTFRDrGmyFjhQl0hyfbmny69o8MhSbVdPjcdVa5QH+deEuqupV1DKeoIyDSIiRrtjVVX0UYFBzf6tf9Pfw/4J7i/ifQEID65pak9M3cY/rWpbTw3UCT20sc0LjckkbBlYeoI4NfPtU5bu80YG5sLy+hswzSXFvb3Mka88mQKpAyMZPqCepxTSu7HPiuH50aTqU5czXS1vu1Z9JUV4RaeLNbsmD2+p320jIiuI/tKN6EnBbHsGFb9r8UL9AI5rLTLqU8ApdNbnPpsKuf1reWGqLzPneZHrFFeXxfFC8eQxSaBDHKBnBvyQw9QfK5H69OORV1PiVtObjRZiv/TvcK7fkwQfrUewqdguj0OiuNt/iLoj8XSahaE9BJbNJn8Yt4H41oweNfDcpAOs2UDHotzJ5DH8Hwahwkt0O50NFUrLVdOvyBY39pc56eTMr54z2PpV2pAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKmr3q6bpN7fSDKWsDzsM4yFUn+lfI3mvdajPeXT7pGZppHP8TEt834nef+Bd6+tPES2z+H9TW/ZlszayiZk6hNh3Ee+M18733ga6t9MK2rGW4MSiaIjkPsTcF9cA5A74P441ZJWudmEsrnLwnyrVppAdzAyuO446fgMD8KYYyIoYGxukO6THfu34E4H0NT3akR7WBBDqCD/vCobsE+cTniFtp+vX+QqDvEiz5dq2PvuXPtlWP9alf5LqNuzgofc9R/Jvzpbj5VjYfwuuPxOP5GluEMkJC43jDLnpkHI/WgYjyGOZQ4Hlvwrejeh+vb/64pZ0Z0BjOJFOVJ6Z9D7UDZc2/IOxxyOhH+BFNgdstFKcyp3/ALw9f8f/ANVIBDi6hDKSjqcgnqjD1/zzTCWlUSIuLiE4ZM9fVc+h4IP0+lOm/cSecP8AVtxIPT0b8O/t9Ke8ZE6SJjptf3Hb8j/M0wES5ktZrfU7GV4poSHEicMB1z9R1x9R3r6d8CeI08T+H4b3CpcofKuI16LIOuPYggj2PrXzFF+7neP+Fv3i/n8w/PB/Gu5+CWsvpXiwaY7f6NeqYcHgBlBaM/luT3J9quDs7HLiafNHm6o+haKKK2PNCiiigAooooAKKKKACiiigAooooAKKKKACvNPjR41XRNFn0XSZGfxBfRYREOPIiJw0jN/DxuC9yenQkehanew6bp13fXbbbe1ieaVvRVBJP5Cvk4X9zrFxcavfnN3qEhuH74B+6oPoFwB7CpnKyN8PS9pLXZGt8IfD+lX1/df25Gt5fW+2S3ilXbEqdMiM9WB7nI6YxivStW0+X/hLNMvkid44LaSKLaBiNi8ZYD3ZFYeny44JFeb+E9RttI8SWl5eBVhIaF5SufLDDg8c9QB9Ca9pgmiuIUmgkSSJxuV0YEMPUGuGpdSud0o20K+li4FqwuyxkE02C2M7PMbZ0/2dv8AWn3VsJbSWKHZG7fMrbeA+chiO/IBqxRWIjHsfDmmW1sImtIJiDnc8YPPqPQ+4+vWuz8FXRu/C2nSNI8rCMxGRySzFCUySep+Xr3rn7qYW9rNMRuEaFyB3wM1H4e1C90DRhpcWnG7eN3eKczqkbB2LneeWUhmI4VuMH1A6aFRJvmZz14NpcqOr8Ra7Y+H9PN3qMhAJ2xRJzJM+M7UXueCfQAEnABNeKeLvE1xrB+2a5KltYwsGhtFbKRnPBb+/J6ccfwjqTP4rXUv+EmFzrF4l013E7wIilVtVUqDGuTyDuQk4BJBJ7AcrfxpqeqfZJ1VrKJGR/VpWXgD0whY5/2h6V1xkpK6PoMpy+nCmsRLWb27I9O8D2rW/h23lkUrNdk3Thhhhv5UH3CbV/4DW9XOeE9eW9iSwvnRNTiXp0E6DjzFH5ZH8JPoQT0dedNPmdzzKymptVN+pU1e9Gm6VeXrLuFvC8u3+9tBOPxrzKyhNvZwws290QKzf3jjk/iea7Lx/Ps0i3tgcG6uo0z6BcyH8/Lx+NcrXVho6Nnu5JTtGVT5BRRRXSe4FFFFABRRRQBR0hvss0unNwkY8y356xH+H/gJ49gVrTZQylWAKnggjOaydThja4sZpY1ZUm8ttwz8rgrj/vrZ+VW332QMm9pLYffDnLIPUHqR6g/h0xXq4ao5Q16H57nGFWGxUox2eq+f/BJ4reGJt0UMaNjGVUA4pn2UoMQzzRj+7kMP/HgT+RqwOlFdFjyivtuhz5sLe3lkZ/HcaXddf88Yf+/p/wDianoosBSuI0uOLrTxMemSEYfqQf0pscMEfEelhMDA2pGP61fopOKe4yuJbrjyjexkdC1464+hVic1Kl7rEZDDUNSOO39rXDfoTin0VPs49gudn8Nde1O51p7LUbq8mgaEmJbjy22sMdGHzHjP3ia9NrxnwZL5PifT2z1k2f8AfQI/rXs1edioKE9C4sKKKK5hhRRRQAUUUUAFFFFABRRRQBzvjqQnR4rIHBv7hLc+jJy8in2aNHX8a5leLCG67K5uSP8AZbcT+St+lbfj/wA4f2Ubfb5pllWLfkqJfJcqTjtgNz7+9cHBpPi62mTytcgeFSFWGa3R4gg9SoV8kYHBI+nfixGsrHZh9I3NXWfCelarOJriEpLuDM0Z27yDnkdPx615z468NS6Ik00O+SwYEq/de+1v8816LDdXljEsc7RSyQlUeNDgeWIwTJ03DnPr6DJrQa7t5hNbXcfKjbKhQumD6nGMfXFZRk4nUpnhFyheB1X72Pl+vb9aUSqUjdc7ZMYPpkcV7FdeFdD1KBDBCkYUBVktmA4H5g/jXl/iTQn0LUJNPdy8TDzIJMYJQn+anj8j3FaxmpaGikmZH/HvP/0ylP8A3y//ANf+f1p9xGXCtGQsqcqT/I+xpRiVGjlAJxh1/wA9qWFXRSrtvAPyk9ce9WUPIBBBAIPBBqC2JjZoGydvKE91/wDrdPy9afOzoA6Dcq/eUDJI9R7+1MuCGiS4iwxT5wRzuXuPxH64oAW4+VopP7rgH3B4/mQfwqzoNy1r4n0656eTdRlsfxbXVwP++d1UJnKxzozbsoZY2/z6HH5irOngtrFqi8u12gVR1JKgD9SPzpomezPruiiiuk8UKKKKACiiigAooooAKKKKACiiigAooooA5X4pOyfD/WgpwJIfKb/ddgrfoTXzbagLbxqCDtUIcdMjg/yr6G+JXibw/YeHdasNYupBvtWikWGF5CjSDagJUEKxJGASOoPvXzlpNyt1ZJLtEcrAGVP7r9x+dZVDvwT3RYuEMkEiLjLKQM/Stzwh4rn8OwmN4muLAysGj3YMfzEZXtj24478c41NlTzInQnAYYNYtJ6M7WrnuWga1Z69YtdaezmNXMbh1KlWABIP5jpWlXiHhDVbXQvt8d5NcI9xL56NG7Kr4K4Q7cY6MPU+YMA443NK8XaPqGuwXt1M9tHBLuUz+Y7DcrRoFyPlU+YzMxx2GNo3Vg6bT0OduzsemXcJuI1j3bU3guMZ3KOcficZ9sip6KzPEWrR6NpxnZfMnc+XBDnHmSEHA9hwST2AJ7VCTeiGk5OyOQ8ZTfa/EUsUMm02lusW8AHY7ncwwe+0Rn8RXNeQlkx2Fj5QSUsxyWyz72PqcMTx6/StKBXVWaeTzbiRjJLJjG9zyTjsPQdgAO1NngEssb8YAZWBH3lI5H5gflXpQjyxSPscLhvY0Ywe6/UdPCk6qHDAqwdHVirI3Yqw5B9xW1pfii+scR6nGb63HAniAWZf95eA31XB/wBkmsaDd5YDjBBI65yAeD+IqSidOM9ysRg6WJXvrXv1Mj4o+Lkn1nSf7DuYpltoXklQ9y7ABHB+ZCAh7AjP4G/Y3KXtjb3UQIjnjWVQeoDAEfzrL8UaZaXtkXmgVrptsMUoJVlLHaOVwSATkj2rWtYI7W2ht4F2xRII0HXCgYFVGKjFRRlgsNLDN073RNTXG5SMkZGMjqKgka4jYsEWaP0X5WH5nB/T8akhmjmUmNs4OCCMEH0IPIpndfoU5l2sovOQDiO5T5Sp9Gx0z+R744Bl86S2OLvDRdpgMAf7w7fXp9OKtMAwIYAgjBB71TB+xEK5zaHgMf8Aln7H/Z/l9OgQ1y6l6iqfkSWxza4MXeEnAH+6e306fSrAmjMzRBh5gGdp4OPUeo96C0+5W1X/AI9o/wDr4g/9GpWnWVqq+aLW3yQZbhMEdtp8z/2SrvlTr9y5Lf8AXVAfy24r0cF8DPiuJJJ4qK/u/qx1pGYYBEeiEhf93Pyj8BgfhU1Qf6Uv/PGT8SmP50brn/nlD/39P/xNdh88T0VDuuf+eUP/AH9P/wATSbrn/njD/wB/T/8AE0XAnoqAG6bjbDH77i/6YH86Nt1/z2h/79H/AOKouBPRUHkynlrmQH/YVQPwyD/Oj7Ox+/PMw9Mhf1UA0XA3PCwJ8R6bgZ/fr/Ova68W8C2qjxVYbTITuJ+aRm6KT3PtXtNedjPiRcQooorjKCiiigAooooAKKKKACiiigDA8drGfCt+7nbLGoktyOvnhgYgPXL7RjvnHeuWuZrmzviYbS4u4Z13ERFB5bLgfxMBgjHA/un141PEdyNT16OzXJtdNIkkPZ7hl+VffYp3HPGXU9VqvNP5bqixvK5BbamOB6nJFcOIknKyO3Dxajcx9WSSRY7trd4sx4ZHjWSQMD8qDaSBu3EE8joPrX021NwAm1FQ43KDIQm0k4Ktx97jHPfHcnbeWSVCjWUhDcfvGTb+OCT+lFsWtzHDJCkauTtKyF8tyTnIByeTn6/jhc2seVfEy9uovEAtFmmSGKNXHzY3sernHfjHtt4rI0/xDMzwW+us2oaaG+dZiWkQd2R/vg47Z56d69j1vQNM1sJ/aVqsrJwrhmRgPTKkHHtXJ618NrSWENpE7wTj+GZtyMPrjIP51Ot7o+VxuWZjDEyxWGqX1va7Xytt+IzXfA2lQ2Zuraa9eRmVIIllTazOwVRu27gMkZOTgZPOKr2/w+tkt902r6nK4HMsUMYhB9lKlyPfcfqK9B0q1ay0uztXk8xoIUiL4xuKqBn9Kq2jPZo0at5ltDhMkNwM4JBIxx3GT07dK0U5H1abaTZ4rrNvNo2pT2N5h5YsN5kY+WSMjIkUHnHYjnBBHOMmjkW/7xCDbP8AM2OiZ/iHse/5+tb/AMQZIrjxBaRpLsli0+3jJ7Fsu2364ZTxz83vXNKl1buxRcg8lRgqffsQfoPzNdMdVc1i21cmuolFtGqcKuEH+6fl/kc/hXSfC3S21n4gWMbqNlq32ufHYIEK/wDj6gVyE9wtrayLIGjgZCAH48skcAHoR7dR9OnvXwD0E2nh+fXLiIrNqTkwbx8wgDEr9AxJb6Yq4K7McRU5YnqdFFFbnmBRRRQAUUUUAFFFFABRRRQAUUU2WRIo3kldUjQFmZjgKB1JPpQA6uN13xLJeSy2OgSgKjGO4vwNwQg4KRdmccgnop45IIFLWdbn8QEwWDyW2jHhphlJLsei90j688M3bC8tBFGkUaRxIqRoAqqowFA6ADsKAPLPjLF9l0rTLC1T9wXe6cFjl5FeP5mY5JJ8xyWOTnk5NecvffY5RexozRM/l3SEY8hz3GegJ6jPBIJ6mvpHUtPtNTtJLa/gjngcEFXHqMfhXBah8LbeeU+RqTrCRtImh3ybP7u9WUkfXPvmolFtnVRqxjGz0OKgvIpQOTGTjAcgE59s1Yrrl+FtvbxRrp+sXcJXqrqHj+oXII/EkVKnw7mwA+tseeStqB/7Maz9mzpWLh1OFuPK8yPeR5vOzPOPfHoPWq0emz6pfQWOnIJriRFVeeRGBncxxwCf5cZ6V6bafDfSY5N91c3tyD96NpAqN9cDcfxbiut07T7TTYPJsbeOGPqQo5Y+pPUn3NUqfcyqYtNWihqyazJ8xl0+3z/yzELzY/4HuXP/AHyK4TU7jVFvjc+KUWOZAY45IY2FqiZGSrZOCxAJ3EHgDGBz6PRTjSjF3SFhcdPDVFUsn6nm7S7rZpbUJOSu5AHwH9Of60lpcx3UPmRZ64ZWGGU9wR2NdrdeHtJupDJJYwrMTkyxAxOfqy4P61lP4H04XRuLW51C2kK7SUn37h2zvDbsds5xWh9BDiOm7c8GvSz/AMjGorUk8L36cwajbyKOiy25DH6sGx/47UJ0HWO0en/jcv8A/G6DvhneDlvK3yZmyRJK0ZdcmNt689Dgj+pqStBfDurSEB5bG3HdgXm/TCfzqxH4Unbi51VgP+naBYz/AOPl6CZ57g47Sb9E/wBbGPVee2WRhIjGOcDCyL1+h9R7H9OtdVH4TsMf6TNe3B9WuDH/AOi9tTL4X0odIrj8buY/+zUHLPiKhsoN/ccdDcEyeTOAk+MgZ4ceq/1HUfkTOQCCGAIPUGuluPCOjXC7ZYLkjORi8mBB9QQ/Bpj+E7XpDe38I9BIr/q6saAhxHQ+1F/h/mckhNkwR+bUnCMf+WZ/un29D+HpV2tqTwghUhdUvWB4KypEykemAg/nUC+ELqBAltqwKjtcW28j2BVl4+uaDaGfYS9tUvQ55T9o1pVBylpGWb2kfhfxChvwYVqUy20PVdNi8prE3kjEu81vMh3sepO8oR9OQAAAeKeIr3/oGXv/AHwP8a9ShOnCCVz5HH4l4vESq9Ht6dAooEV73029H/AB/jUi2mptyNKutvYl4hn8C+fzrV1qa6nHZkdFWk0jV5OVtrWJewmuCG/JVYfrVmPw1et/r9RhRT1ENudw+jMxH/jtZvFU11HZmZRW5H4Wt+k97fzr/dZ1T9UVT+tWE8NaSow9r56/3biV5l/JyRWbxseiDlOYlmjix5siJnpuYDNV/wC07DcV+3Wu4cEecvH613UGkabb58jT7OLPXZCq5/IVcRVRQqAKoGAAMAVDxr6IfKYvwylt7zxRGbeeKUxRPJ8jhsDG3PH+9+tev1w2lXP2W/hkJwucN9DXc1y1arqy5mNKwUUUVmMKKKKACiiigAooooAKyfFV/Npuhzz2u0XDNHDGzDIV5JFjViO4BYHHfGK1qiu7aG8tpbe6iSaCVSjxuMhgeoIpMEcPY2sdnbLDEWYDJZ3OWdicszHuxJJJ7k01/wDkJQkdTE+ffBTH8z+dZnjnwNBA1nqtnfXcctvNFDHulbzY1eQLhJM5Iy3IkEgxnpWolt+52yuWk3F96/Lgn09P6988151SDg9T0ac1NaFiq17/AMsNv+s81dn/ALN/47uo8q5Hyrcgp3LRgv8AgRgfp+dPitwj73kklkAwGfHA9gAB+OM1mWTUUUUDCsyeBYrK5fUJ1jtIzJK204AXcW3McZGOvHp3rTrOl0e2mnLytcOjP5hhadzGW9ducY/2enfGaaEcrc+CIda0976aSW21S8BmcOA6KT91GU/3V2pwR93NeZ6rpdxpF+9jqFvFFMoyCtuWWRf7yEdR+o7gV9D1U1PTbPVLbyL+3SePOQGHKn1BHIPuKuNRrcpOx826jbQtaSt5blQPvMoTP+yAAMknA54rb8KeJ9c8JT40q8f7MGw1u/zI/wAxGSDwCSDyMdsnnI6Dx7oOmaZGWs4mSZ7o2scZlZ/kEUbMw3E4P7xvwX655NEWSQKwyrCZSPUbxXSnpcaSmj6Y+H3jO18XaeXVRDexAGWHPGP7y55x7HkHg+/WV8q+BNal8PeJrG93nymkMc3+0M4fj3ALexWvqoHIyORW0JXR5+IpKnLTZhRRRVmAUUUUAFFFFABRRRQAV5H8SNb1GXxLNp22CTTLTYfs7swEshUNufH3gNwwp4yMnJ27fXK8V8ef8jnqv+/H/wCiUoAqf8JJqn/PtZf99t/hR/wkmqf8+1l/323+FZlFAGn/AMJJqn/PtZf99t/hR/wkmqf8+1l/323+FZlFAGn/AMJJqn/PtZf99t/hTl8UakBhtMs2PqLxlz+HlnH51lUUAa3/AAlOo/8AQKtP/A1v/jVH/CU6j/0CrT/wNb/41WTRQBrf8JTqP/QKtP8AwNb/AONUf8JTqP8A0CrT/wADW/8AjVZNFAGt/wAJTqP/AECrT/wNb/41R/wlOo/9Aq0/8DW/+NVk0UAa3/CU6j/0CrT/AMDW/wDjVKPFN/jnS7XP/X43/wAbrIooA2P+Epvv+gZbf+Bjf/G6P+Epvv8AoGW3/gY3/wAbrHooA2P+Epvv+gZbf+Bjf/G6P+Epvv8AoGW3/gY3/wAbrHooA2P+Epvv+gZbf+Bjf/G6P+Epvv8AoGW3/gY3/wAbrHooA2R4oved2m24+l2x/wDadL/wlF3/ANA2D/wKP/xusWigDa/4Si7/AOgbB/4FH/43R/wlF3/0DYP/AAKP/wAbrFooA2v+Eou/+gbB/wCBR/8AjdH/AAlF3/0DYP8AwKP/AMbrFooA2v8AhKLv/oGwf+BR/wDjdKviqcZEmlnPby5ww/UD+VYlFAG5/wAJXJ/0C5v+/qUf8JXJ/wBAub/v6lYdFAG5/wAJXJ/0C5v+/qUf8JXJ/wBAub/v6lYdFAG5/wAJXJ/0C5v+/qV6t4T1FtW8P2d48Lws4KlHIJ+Viucg45xmvDa9m+H3/IoWH/bT/wBGNQB0VFFFABRRRQAUUUUAFFFFABRRRQBx3xKmlt7PSJ4lLiO+BaMDJYeTKP064OOnHOAc3TNRh1CMtEJFZQNyvGyY/MDNdlrukwazZC3uGkjKOJI5I8bkbBGRkEdCRyO9cZojmXSbSR1QSNGC+wYUtjkj2J6e1ceJWtztw0o8nL1L1FFFcp0BRRRQAUUAggEHIPcUUAFFFFAHlXxB0a6Fzf61Esk1rDcfZygyRE5iibPtuLYz/jXEwJtmVM5MUeGP94scn8eM/jX0boCxNr99ZXUaSQX1osgjYAqxjYq+QfUSRj8KS4+GXhiWVnSykgLHLCKZgCfxJruhHmimjJYhQbjJHzlIpMNwFBLI+9B74Dfzr6x8NySS+HdLkmBEr2sTOCMEEoM1l6L4H8PaPOJ7PTkNwDkSysZCD6jPAPuBXS1rCLRhiKyqWSQUUUVZzBRRRQAUUUUAFFFFABXkvjLRdTu/FepT21hcywu0e11jJDYiQcH6givWqKAPDf8AhHdZ/wCgZd/9+zR/wjus/wDQMu/+/Zr3KigDw3/hHdZ/6Bl3/wB+zR/wjus/9Ay7/wC/Zr3KigDw3/hHdZ/6Bl3/AN+zR/wjus/9Ay7/AO/Zr3KigDw3/hHdZ/6Bl3/37NH/AAjus/8AQMu/+/Zr3KigDwj+w9W/6Bd//wCA7/4Uf2Hq3/QLv/8AwHf/AAr3eigDwj+w9W/6Bd//AOA7/wCFH9h6t/0C7/8A8B3/AMK93ooA8I/sPVv+gXf/APgO/wDhR/Yerf8AQLv/APwHf/Cvd6KAPCP7D1b/AKBd/wD+A7/4Uf2Hq3/QLv8A/wAB3/wr3eigDwj+w9W/6Bd//wCA7/4Uf2Hq3/QLv/8AwHf/AAr3eigDwj+w9W/6Bd//AOA7/wCFH9h6t/0C7/8A8B3/AMK93ooA8I/sPVv+gXf/APgO/wDhR/Yerf8AQLv/APwHf/Cvd6KAPCP7D1b/AKBd/wD+A7/4Uf2Hq3/QLv8A/wAB3/wr3eigDwj+w9W/6Bd//wCA7/4Uf2Hq3/QLv/8AwHf/AAr3eigDwj+w9W/6Bd//AOA7/wCFH9h6t/0C7/8A8B3/AMK93ooA8I/sPVv+gXf/APgO/wDhR/Yerf8AQLv/APwHf/Cvd6KAPCP7D1b/AKBd/wD+A7/4Uf2Hq3/QLv8A/wAB3/wr3eigDwj+w9W/6Bd//wCA7/4V6z4GgmtvC1lFcxSRSrv3JIpVh87HkGt6igAooooAKKKKACiiigAooooAKKKKACvNvD8gTT47CT5byxRbe4ib7yOoxn1wcZB7ggivSaoano2nam8b31pFLLGMRykYkj/3XHzL+BFZVaftFY1pVPZs5iitf/hEdJz0v/8AwY3H/wAcqRPCmiA5l0+O6I6G7Zrgj6eYWx+FYLDPub/WV2OZOo2vSKYTN/dh/eEfULnH1PFRtDPfcXQ8i2PWENl3/wB4jgD2Gc+uMin6dALFrzTgAFsrhoY1AwFjOHjUewjdF/Crlc8lyuxvF8yuIoCqAoAAGAB2paKdHG8jYjVmPoozUjG0VoQaTcynLKI19WP9K2LLTILbDEeZIP4m7fQVtCjKXkZTrRiY9ho0st9ZXzt5JtnLqCMlwUZSp9B8wP1UV01FFdsIKCsjjnNzd2FFFFWQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBQfSbJp55jDiWdw8jBj8xChQevooH4Uf2TZ/8APM/99Gr9FS4RerRSnJaJlWPT7SP7sCfjz/OrKqqjCgAegGKWimopbCcm92FFFFMQUUUUAFFFFAFM6dCZvN33W7dux9ql25zn7u7GPbGKfc2UVzIHka4BAx+7uJIx+SsBVmigCvLaRyW6Qs04RMYKzurfiwOT+JohtI4oZIlacq+cl53ZumOGJyPwNWKKAKttYxW8m+N7gnGP3lxJIPyZiKadOhM3m77rdu3Y+1S7c5z93djHtjFXKKAK1zZRXMgeRrgEDH7u4kjH5KwFLLaRyW6Qs04RMYKzurfiwOT+JqxRQBXhtI4oZIlacq+cl53ZumOGJyPwNNtrGK3k3xvcE4x+8uJJB+TMRVqigCmdOhM3m77rdu3Y+1S7c5z93djHtjFPubKK5kDyNcAgY/d3EkY/JWAqzRQBXltI5LdIWacImMFZ3VvxYHJ/E0Q2kcUMkStOVfOS87s3THDE5H4GrFFAFW2sYreTfG9wTjH7y4kkH5MxFNOnQmbzd91u3bsfapduc5+7uxj2xirlFAFa5sormQPI1wCBj93cSRj8lYClltI5LdIWacImMFZ3VvxYHJ/E1YooArw2kcUMkStOVfOS87s3THDE5H4Gm21jFbyb43uCcY/eXEkg/JmIq1RQBTOnQmbzd91u3bsfapduc5+7uxj2xin3NlFcyB5GuAQMfu7iSMfkrAVZooAry2kclukLNOETGCs7q34sDk/iaIbSOKGSJWnKvnJed2bpjhicj8DViigCrbWMVvJvje4Jxj95cSSD8mYimnToTN5u+63bt2PtUu3Oc/d3Yx7YxVyigCtc2UVzIHka4BAx+7uJIx+SsBSy2kclukLNOETGCs7q34sDk/iasUUAV4bSOKGSJWnKvnJed2bpjhicj8DTbaxit5N8b3BOMfvLiSQfkzEVaooApnToTN5u+63bt2PtUu3Oc/d3Yx7YxT7myiuZA8jXAIGP3dxJGPyVgKs0UAV5bSOS3SFmnCJjBWd1b8WByfxNENpHFDJErTlXzkvO7N0xwxOR+BqxRQBVtrGK3k3xvcE4x+8uJJB+TMRTTp0Jm83fdbt27H2qXbnOfu7sY9sYq5RQBWubKK5kDyNcAgY/d3EkY/JWApZbSOS3SFmnCJjBWd1b8WByfxNWKKAK8NpHFDJErTlXzkvO7N0xwxOR+BpttYxW8m+N7gnGP3lxJIPyZiKtUUAUzp0Jm83fdbt27H2qXbnOfu7sY9sYp9zZRXMgeRrgEDH7u4kjH5KwFWaKAK8tpHJbpCzThExgrO6t+LA5P4miG0jihkiVpyr5yXndm6Y4YnI/A1YooAq21jFbyb43uCcY/eXEkg/JmIpp06Ezebvut27dj7VLtznP3d2Me2MVcooArXNlFcyB5GuAQMfu7iSMfkrAUstpHJbpCzThExgrO6t+LA5P4mrFFAFeG0jihkiVpyr5yXndm6Y4YnI/A022sYreTfG9wTjH7y4kkH5MxFWqKAKZ06Ezebvut27dj7VLtznP3d2Me2MU+5sormQPI1wCBj93cSRj8lYCrNFAFeW0jkt0hZpwiYwVndW/Fgcn8TRDaRxQyRK05V85LzuzdMcMTkfgasUUAVbaxit5N8b3BOMfvLiSQfkzEU06dCZvN33W7dux9ql25zn7u7GPbGKuUUAVrmyiuZA8jXAIGP3dxJGPyVgKWW0jkt0hZpwiYwVndW/Fgcn8TViigCvDaRxQyRK05V85LzuzdMcMTkfgabbWMVvJvje4Jxj95cSSD8mYirVFAFM6dCZvN33W7dux9ql25zn7u7GPbGKfc2UVzIHka4BAx+7uJIx+SsBVmigCvLaRyW6Qs04RMYKzurfiwOT+JohtI4oZIlacq+cl53ZumOGJyPwNWKKAKttYxW8m+N7gnGP3lxJIPyZiKadOhM3m77rdu3Y+1S7c5z93djHtjFXKKAK1zZRXMgeRrgEDH7u4kjH5KwFTxII41RSxCjA3MWP4k8mnUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVm69rdhoVl9p1KYRqx2xoo3PK3Xaijkngn2AJOACa8x1zxnrGrlo7Zm0qyPASJgZ3H+044X6JyP75rSnSlU+FCbsejeIvE+k+HkQaldqs8nEVunzyyH2Uc49zwO5FcXf/ABG1GYkaXpkFtH2kvHMj/QxoQB+DmuB+zRReYkibo52y7sSWZj3ZjyT/ALROc0iXH2VzDdOWOMxvgkyD0wOrD2+vrjthhIr49SeY6mXxf4jmJZtSSAntb2yBR+Dhz+tMTxX4iQ5/tiVz6Pbw4/HCA/rXPfaHb/V20xB6E4UfkTkflQTdHgRwL/tby2PwwM/nW3sKfYV2dYnxF12xQPd2+nXy5CrGivbuxPA+bc4z/wABA+lb9r8SrMkLfaXfQc/NJFslQD14Ic/gteaR2580SzyeZIv3QBhV+g9fc5/DNWKh4SnLyHzM9isPGPh6+ZUh1a1SVvuwzt5Mh+iPhv0rdBDAEEEHkEV8/soZSrAFTwQRnNVBplgFZRY2oVuo8pef0rF4Lsx8x9GUV85DSdOBBFhaZHI/cr/hXpnwnuFjhvbBFVI1ImRVGAM8N/Ss6mFcI81wUrnoNFFFcpQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUV846Ron9s/Hz4mKfDHh3xAImsjt1mXYIcxdU/cS5Jxz93oOvbU0vxP41u/EnxFvLbXYzpPhO4mMOkDTomN0qxSFIvMGGUZUcjJPrQB71RXzpovxE8Vwt4Knl1r+1h4m0u+u7iD7NCosXiQsjRlFB2g/KQ5bO096qeB/iH4xvU+FtzqGvyXKeKJL+1vImtIFCGKQqkiFUBDAEdcr8o465APpaqerapp+j2bXmr31rYWikKZ7qZYkBJwAWYgcmvmj4c+IJPB3wXv8AUzrGsmSbXZLCC3tBaDZM0mc7pIW27h97dkDjAGayfiB4r8R6z8OfiJofimZJ59E1OwSNw0buBI5JRnjjjVsFOoRepoA+uaK4r4w+KU8H+BbrVGlv4pPMjhiax8rzd7MMAGVXQA8gkqeOnOK8R1v4n+O9G8O/Ea0u9RSPVtBlsPs9xiCd4hMw3ozCFEfA4z5Ywc9eDQB9R1SXVdObV20pb+0OqLF57WYmXzhHnG8pndtyQM4xXz/r3xO8WeF7vx1b/bRqo0/R7O/s2nt41aGSYxK3+rVQygyFsEE/KOTzm38OxdH9oxZL/VpdXupvB8U0l1IkSbi0sTfKI1VQvPHGcdSetAH0FRXiXxG8YeMJPiddeEvCv2y3kh0c3tqLWO0L3U5OFLm5IHlKeCEy/U9uOf0F9Y1n4+eErzWNSks9Tn8LiWdbN7eWPcszh4kba6lGKljglhuOGAAAAPoDSdW07WLd59Iv7S/gSQxPJazLKquOqkqSARkcVdr5F+G/iTXPCvhnRLvSNRZLS/8AGsmm3dk8MbRypIEy24rvDDHZgOnHXO7dfEnxpDpmraqmvMfsfjM6LHbPaQGJrY5+VsIGyMDBDA9c54wAfTtU9W1Ow0exe91e+tbCzjIDz3UqxRqScDLMQBkkCvnvXPif4s0Sz8d2S6gt1LpmuWun22oXFvHutoZt+WcIqo23YACV6tzngVV+J/jHXrLRPiboN1dwa5b6INPltr6+sLeXa0skW6ORPL8pj8xx8gIx68gA+kNQ1Kx03T5L/Uby2tLGMBnuJ5VjjUEgAlicDJI/Op4ZY5oUlhdZIpFDI6HIYHkEHuK+X/ip4n1jxJ4e+KNhd6j9i0zQYLGGHToooh9oMjKTJIxUtjIBAQqORnPf22/k8QRfCOB/BsME/iAabB9kScgKW2pn7xAyF3EZOM4zxQB1Wq6rp+kW63GrX9pYwM4jWS5mWJS56KCxAyewq5Xy54j8e3994Fv7TUn1WXxDpup6fHeW2vadYyxwGQtzEEhC5I5+Ybhxg9SbvjD4h+MrO4+K9zY6+8EXhe6sfsVuLSBkKSyFHRyU3EY5znOR160AfS1FfOuu/EvxTBq3xGWLUlt4dN0K0v8AT4xbxkQyyRxFmBZSWG524Ykc0/X/AB3410nTPD+v63Lq0XhCfRLS4nv9Ehs2m+0yIhdpVmRgBubgKFHzdeCKAPoeivnfXfH3jvWfE/i6z8IG4ifREtntIGSySGWJgHeW5a4ZZACvTy8AcZ973iTxz4t0DxdHdeK/7WsPCl49rHYTaGlnPFudcsspkR3YluPkI4BIzwaAPeqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiis/XdYsdD0573UphFCvygYy0jdlVRyzHHAFA0m3ZDta1W00bTZr7UJfLt4gMkDJYngKoHJJOAAOteOat4p1rWbp5pbu4sLfJ8m1tZTHsXtvdTlm9edo6AdzB4k1278RXy3eoKsFtAWa2tt2REMEb2PQyEHBPQAkDuWyftlt/wA/EP8A32KD67K8nhSj7XEq8n0fT/g/kNu7T7ZOk91dahPcIhjSWW9mdlUkHAJY8ZAOKj8m+hyYL7zf9m5iDfgCu0j6nNT/AGuDoJkY9gpyT+AqerjUlD4WerUy7CVlaVNfLT8ii2omJCuq23kRkYaZW3xD6tgFfqQB71aiuY44v38yLtO3ezABhjIOfcf1qSswaYLWZp9LZLaU8FCm6Nh6Y6r/AMBI55Oa6qeLe0zwcbw5b3sK/k/0f+f3mj9rjPRZv+/L/wCFBu4+flmPb/Uv/hUFrqIeZbe7iNtcsSFUtuWTv8jd+/BweOmOasW3LTuPuvJkH1wAP5g13RkpK8WfMVKU6UnCorNB58nP+izfmn/xVBnkH/LrN+af/FVPRVWMyD7VHn7s3/fl/wDCj7ZbfxTxqfRm2kfganooAg+2W2f+PiH/AL7Fdb8MbuJvE2yKWNy8DghWBOMg/wBK5mul+HgJ8U2+M8I+f++TWVZfu2NbnrdFFFeOaBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFK10rTrTULu/tbC0gvrvb9puI4VWSbaMLvYDLYHTPSlsdK0/T7m7uLCwtLae8fzLmSGFUad/wC85Ayx5PJq5RQBj6f4W8P6bPdT6doWlWk10CtxJBZxxtMDyQ5AywOe9Fv4Y0C2XT1t9D0uJdOZ3shHaRqLVnOWMeB8hJ5OMZrYooAw38IeGna+L+HtHY3/ADdk2UR+0c5/efL8/PPOeaji8FeFYbO4s4vDOiJaXBQzQrYRBJSn3Cy7cHbk4z07V0FFAFbUrCz1SylstTtLe8s5RiSC4jWSNxnOCpBB5ANY8XgjwpFaXNrF4Y0NLW5CCeFdPiCShDlNy7cNtPTPTtXQ0UAZv9gaP9pubj+ydP8AtFzCLaeX7Mm6WIDAjY4yy4GNp4qDR/Cvh7RLr7Toug6Tp1x5Zi820s44X2E5K5UA4yAcetbNFAGXrnh3RdfWJdd0fTtTWIkxi8tUmCE9cbgcVHc+GNAuWsGudD0uZrDH2MyWkbG2wQR5eR8mCB0x0rYooAxY/Cnh2O3igj0HSVgiuftkca2cYVJ/+eoGMB/9rr70reFfDzQyQtoOkmGW5+2uhs49rz/89SMcv/tdfetmigDM/wCEf0bGof8AEp0//iYkG9/0ZP8ASiOnmcfP1P3s1BF4T8ORaPNpMWgaQmlTMHks1soxC7Aggsm3aTkA8jtW1RQBh6n4R8N6tdG51Tw9o97cmMRGW5sopH2DouWUnHtV6/0jTdR0s6ZqGn2d1pxCqbWeBXiIUgqNhGMAgY44wKvUUAYcPhDw3Dpx0+Hw9o8dgZBMbZLKIRbx0bbtxkevWpZ/DGgXA1ET6Hpco1Eqb0PaRt9qKnKmXI+fB5G7OK16KAMW/wDCnh3UZll1DQdJupVh+zq89nG5EX9wEj7vt0qGTwT4VluobmTwzob3MKokcrWERdFQBUCnbkBQAAB0AGK6CigDH1jwt4f1u6judZ0LStQuIxhJbuzjldB1wCwJFRr4R8Npq41VfD2jrqgfzBeCyi84N/e37d2ffNblFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXnnxR8Wy6cI9F0dpf7QnXfPLD1gi9A3RXbtzkAEjnbkNaNGdeapw3Zo+K/Hdpo80llp0Y1DU04dFbbHCf8Apo+Dg/7IBPTOAc15Trd1Pq18NR129eWdQVTDmKKEHqqKDgA9ySScDJOBipDbyrGE3rBGOkcPJ98seuevQH3qaK2hifeqAydN7Hc3/fR5oPtsBlNLCpSavLu/0X9Mrj7JuBgtRI2cgpEAD7hjgfrV4U2R0jQvIyogGSzHAFQQX9pcSeXBdW8r4ztSQMfyBoPVVo6MtUUUUFBRRRQBBd28V1A0M67kb3wQexB7EdiOlJo8zyWflzkefAxhkOMZI6NjtlSrY7ZqxVPTBPJqGorZ2dzcfvVz5afLu8tc/MxC5xt4zXThanJKzeh85xJQjKhGr1Tt8maVFTppmry/6uxji9ftNwF/LYH/AKVOugaq/wB6Wxg9wXl/Hov5V3PE011PjbMo0VpDw1qGDnU7TP8A15N/8dp58N3n/QRt/wDwEP8A8cqfrdMOVmVXV/DSMv4jLD+CBmP5gf1rIPhu9wcajb5/69G/+OV2Xw30qTT7i+e5uY55WVQpSIx4GTnqzZ7VnVxMJQaQJM7qiiivOLCiiigAooooAKKKKACiiigAooooAKKytS8RaLpkhj1HVrC1l/55zXCKx+ik5NZknj3w4jY+3u/o0drM4P4qhFBcaU5/CmzqKK5D/hY3hn/n8u//AAXXP/xul/4WN4Z/5/Lv/wAF1z/8boNfqlf+R/czrqK5H/hY3hn/AJ/Lv/wXXP8A8bqB/iRon/LCPUJ+e1sY/wAfn20DWDxD2pv7mdrRXASfE+xHEejasW7FvIC/ifMJ/Soh8Tog3zaLebP9mWMn3wCQP1oNFluLf/Lt/ceiUVieGPEuneI7TzbGXZMpYSWsrL50WGK/Mqk4zjIPcEVt0HHKLi2nugooooEFFFFABRRRQAUUUUAFFFFABRRRQAUUVHczw2tvLcXMqQwRKXkkdgqooGSST0AFAEled+MvizoXh+eWzsw+rahGdrx2zKIom9JJT8oPsNzD0rzL4k/E++8SzTaZoDzWei52PKmUmu/xBBRD/dGGIzkqMgeeW8AjEaRZjVflVYgN3HZe2PU8L9etQ522OqlhnLWR6lN8ZfFEku+30/SIYif9XJDPIwHpuBXP12/hVyb426o9jBHbaJbR3+WE0kkjvFxjBVFG7nJ4YjGO+a8hnlyDsjQ5H3seYx9OT1+nTsCelRIkjSrHLbRCRAd23J5xkAc4zjPr0OB2qOdnQ6FPsezab8br6OVU1bRIJwT8zWkpjcD2jfJb8xXo3hb4heHfErJFZXvk3jHaLW6HlyFvQdmPspOK+XYxIwVRIGRuNsvzK3/1xz8vy/pTp7cE7JIxk8BWO4N3wrH/ANBbg49Oaam+pMsLF/DofZtFfOHgj4nav4ddINVebVdIB2kSH9/B9GY8/Rjg9iowD9A6Lqtlremw3+l3C3FpKMq65HsQQeQQeCDyDWikmcdSnKm7MvUUUUzMKKKKACiimyyJFG8krBI0BZmY4AA6k0Acr8QfE7aDYx29gVOq3eRCGGREo+9Iw7gZAA7kjtkjyGNNgYs8kkjHc8kjbnkY9WYnqTVnUNSk1vVLrVpwwa6I8pG4McI/1aY7cHJH95mqKg+7yjL1haSnJe/Lfy8gqG4mMSqEjkmlkYJHFGMvIx6KB/U8AZJIAJpbiZYIi77iBgBVBZmJ4AAHJJPAA6k12HhLQGsidQ1FQdRlXaqA5ECZztHbceNxHUgDoBWVWooI6MfjVhYWXxPb/MTw/wCFoLUJd6oiXWoH5gGG6O3/ANmMHv6t1PPQYUa+q6dHqMaxzxwTQ5AeKeMOrLnkjuG9D/8ArF+iuBybd2fJznKpJyk7tnmN5ZvpmqXWnu7SJHiSF25JibO0E9yCrLnqdoJ602ug8fW4WfS70Dne9s30Zd4J+hjx/wACNc/XoUZc0U2fWZbXdagnLdaf18gqKaURKMhmZiFRFGWdj0AHc0TzR28DyzMFjQbmPoKZouprbXD3S2bXepcpsdxHFaL/AHC2CTIf4toOMbeMZOhGZZhHBU77yey/U27Hwxc3SiTVLhrZGAP2a3I3D2eTn/x3GOzHrXT2Flb6fapbWUKwwrnCr6k5JJ7knJJPJNck2v60xyr6cmf4Tbu2PbPmDP1xTf7e1z/ntpv/AICP/wDHaD4fEYqtiXerJs7eiuI/t7XP+e2m/wDgI/8A8do/t7XP+e2m/wDgI/8A8doOc7eiuI/t7XP+e2m/+Aj/APx2j+2tYbl7q3B9I7fA/Vif1oA7etfwxJs1Pb/fQj+v9K8x/trWF5S6tyfSS3yP0YH9a1fCut6xJ4j0+OeWwMTzKrBLZ1bB4OCZDj8qAPZqKKKACiiigAooooAKKKKACkdlRWZ2CqoySTgAVR1vVrPRNNlvtRl8uCPjgFmYnoqqOST2ArxrxP4gvvFEhF6Db6aDlLANkH0MpH3274+6PcjdQd2CwFXGytDbq+iOv8S/E20tY5V0KOO7EakvezErbIB3HeT14wv+12rkLw+KvEcZm1Brg27ciO4mFrBt940yxHtICRxSeEtKGr3Y1C5XOn20n7hT0mlU/f8A91TwPVhnsCe/rlq13F2iejOFHCT5KKUmt29dfJbHlHkNpyRrJZpBbO2xZoGR4S5/hyp4P+8Bk8DNT16JfaZa30VxHcx7kuI/KlGcbh2P1HY9R+VebxpLBJPaXLFri2kaF2IwWx91sf7SlW/4FV0avPo9z3Msx8q96dTdElFFFbnrhRRRQAUUUUAZtuluJr83SIRFOJIyVyV3RpyvcEtnpzmuj0bxn4g0QBRN9vifmOxvGLygDr++ySO2S28DoKwIIUfXLhmGdkMTAdtxMgzj1wKty27+e08EmyRgFIYblIGce/c9DXp06calNcyPzfM48mLqJd2ew+F/GlhrkwtZFex1HnFvMR+8A6mNhw468cMOpArqK+dPMWV1huUMM4IeMhj94chkcYORjPYjGfevWPh74pk1dJNN1N1OqWybw4AH2iLON+Om4EgMBxkg8BgBy18P7P3o7HInc7OiiiuYYUUUUAFFFFABRRRQAUUUUAFfO/xq8avruqS6BpspGlWUuy4cHAuJ16qf9lMHPuCeoU1638U/ET+GvBt3dW7Fb2ci2tcdfMbPI91UMwHfbjvXzBBAFRIh93PlDHQgcufoSNv4VE5W0OrDUuZ8z6CrAsNoGYN5knCrnacHnB9OmWx2GB0FOiiUxNJMcQY54x5g7cf3fRf8akvtrSqCpbYvK5+8WOAv4kc+w9DTywlk3v8A6qJsAAZ3vnHA74PAHr7gViehYYV2ZneMCZziOP0JGOcd8dT2HTvmOOHIRWc5JcB8D74bIP5hj+JrvLDwJezaJLf3IKaiwDQWp/gTuD/tn9MY964x4pFEsRUpcwSsdjDBByTg/UHH4+1JST2BWYxY1uMsVCvnZMh5Df57H0pwG0/Z7j50fhGb+L2Pv/ntQTvxcQAl1+V0PBI9D7jt/wDXzSzyRyWu/BaI/eI4K+/1B/EYpjET9zLsk+ZX4WQ9T/sse/fB/r16DwR4qufBGsLMheXRp2C3VsOcdgyj+8O3rjb/AHSvMHDE+bg9ElIONwP3XH4/19BUwdTBLFdclBhzjqp6N7D/AANNOzuTOKmuVn17a3EV1bQ3FtIssEyCSORTkMpGQQfQipa8n+AWvvc6TdaBdvmfTzvgJPLRMTkfg3PsHQdq9YrdO+p5E4uLcWFFFFMkK5D4r332LwNfoAXe7KWgjXq4kYK4Hvs3nPbGa6+vNPjBclrrRLHGUBluj7MoVF/MSP8AlQdWBo+2xEKfdnn1rG0UCrId0hyzkdNxOTj29Pas/WtTks4bgWkQlmhha4kyCQiAHHA5JODgD0PI737u4S1gaWXOBgAKMlieAAO5J4rPt7eaXS71iqi8uTISCcgNyqjPsAo/Amg/QqjduWG9jr/h/wCHb+O3ttW8TbDqhUmK3RdqWwIweMnLkZGcnAOB3J7iqulX0Op6bb3tsT5U6BwG4K+oI7EHgjsRVqvLnJyd2fFVJyqS5pu7M/z5E18wOxMM1qHiX0ZHw5/HzI/yrQrn/F2oW2lHSrud9rpdqqqBksjAq5PoqqS5/wBwe1dBSa6kGD45i8zwzdP08lo5yfQJIrN/46DXG133iWIz+HNVhUZaS0lQD3KEV5sA+pzrZ2jssZUPPMvHloegH+23b0GT6A9eFejR7WWYqGHo1J1HorfqQy77i3ub9ADb2mRbKRkTXGcKSO6q2APVuf4QTatYEtreOGPO1BjJ6k9yfUnqTV7X4o7fQ0igRUijmt1VQOABMgAFVq6j5rF4qeKqurPr+C7BRRRQcwUUUUAFFFFABWt4U/5GXTP+vhP51k1reFP+Rl0z/r4T+dAHuVFFFABRRRQAUUUUAFU9X1K10jTbi/v5PKtoF3O2Mn0AAHJJJAAHJJAHNXK8k+KOrtqGvppUbf6JpwWSUf3p2GQD/uoQfTL+q0HVg8LLFVo0o9fyOd1vVLvxBqp1HUAyYG23tSwK2yHqOOC5/ib8BwBUGn2EutX/ANhgZkhQBrqZePLQ/wAKn++3b0HPoDz2oWc+upLDHN5Ucky2cAPKhmcRtIw/iKktgHj5c9xj1zw3odj4d0e303TIvLt4h1P3nbuzHuT/APq4rCtV5FZbn1OLxCwdNYahGytv/XfuX7aCK2t4oLeNYoYlCIiDAVQMAAemKkoqpaErd3kbcfOsij0UqB/6ErVwHgFuuC8Y2/2fxIkqjCXlvkgf34yASfch0H/AK72uU+IEf7rS5l4Zbkxk/wCy0bkj81X8q1ou00dmAnyYiD87ffoc1RTJZFijZ3OFUZJp9eifZBRRRQAUUUUAZtjOUur+4lTNs8uxZV52hAFO4dgG38/njrWuCCAQQQeQRVHQR/xJ7Vz96VPOb/ef5j+rGqGo3iWV9FZWBlNzL8zQRKGCqc/Ng8KTg8kheCcE4B9imuSCR+YYqr7atOp3bNi6ELRiO4wVc7QO5PXjHORjOe2M03Tr660+7hvbbMt7YOJYyMDz0IIK56fMu5fY846VVisZZ5jNqDq2cgQpyoX0J75wM8DPfIAAtTwyeb51u4WTbtKsPlcDoD3HU8j16GqkuZWZgfQVlcw3tnBdWriS3njWWNx0ZWGQfyNTVxvwnvHuPCS28ylZLKeS3IzkBc70A9gjqPw7dK7KvGkuVtGgUUUUgCiiigAooooAKKKKAPC/2iNRZ9a0bTUI228D3jI3R2Zgkf4gq3/fVeXJlLyGKPlY02knrjHP4/c/Ou6+Ocgl+JkYbAWDToFbnqN8z5PoAdtcLYW81/ceVAjNcXTiFFHUE8n6YXH4rWE9z08OrU0WNL0zUNXM8um20k5QhsoMhS+FU/guDj3PpXqXg3wRDpLxXmoYmu4wPKj6pBx1929+3buT0Hh/SrfQdIWBCi7Rvmk6BmxyT7YGPoK4bxd8QfOjFt4dkdAfv3TJgkeiA8j6kfT1HJOrfbY58dj6OCp89Z2/N+iOq8YeLbXw4IozEbm8lG5YFbbhf7zHnAyMD159DjO8carpunR2U9xpcd2t+pWRvuyCMAHjjkjIxyPr3ryK+ubi5kluLiWSe4YZLyMWJ44GT2r0f4uwCGz0VVYlYhJGM9TwnP6VkpdUfOwzytiKGIxFJWUOXl+/W5kax4OuQqahoLm9s5lDxyRjcSp6Bl7/AFHP06Vz0On6g926Q2U63QUu8BU/vAByVPr7dTjkdxJ4Z1268PagLi0+eJuJbcsQsg/ofQ4OPxNexeEvEkHiOzllhhkglhYLJG5BxnkEEdR+R46VrGs7HrZXnlHHrl2n2/VHg0hRDhRmMZXYRyox80ZH05A9sdMVNuxGHc7jD8shPO+M9/ywfwIr2/xD4Q0vW90k0Xk3R/5bxYDZzkZ7HkCvJdf0Z/D2tGxkbzI9oCPtwHjOSpxz0IZcVtGake0nc0fhVqDaR8RNMBYhJm+yyero42rn/gfk/wDfBr6gr5H8NLs8W+HCc701O1gPqR58bKT+Az+NfXFdNPY8/FK0woooqzmCvHvidKX8bOoOUjsYV+jF5Sf0K17DXjvxLjaPxvMf4JLKBwffdKpH/jo/Og9fI7fXI38/yOJVfteru7DMdlhUB/56suSfwUqAf9pqvQxiJCoOcszfmSf61Ws1eO+vw6ttkdZUbHBBQLj6gofwIq7QfcQXX1JdI1G70S4ke0Xz7OVt8toWxhu7xnsT3B4J5+Ukk9RH4y0or+/F7A/dGtJHI/FAy/rXJVmzXklxM1tpwDMp2yzn7kXqB/eb26DuR0OM6EZu552JyyhUlz6pvt1KMuq6h4n8bX819ayRaVFbPbxQykZVWZcZGchmCsSODjaOgBPrHhC8e98O2Uk77541MErf3nQlGb8SufxrgLS2jtYfLiz1yzMcsx7knua6nwBLtbVbUnJEqXA9g6bcfnGx/GoxEEoK3Q4swwaoYaNuj/M611V0ZXAKsMEHuK8w8CmEeGrSOKNo5o0UXCuxZvMKglix5OQQQfQjp0HqFeW2kclrpWmajbqWaO1jS5jUcyRheoHdlOSPXLDqRicL1PmcS3ZFvxL/AMe1qO5uUwPXGT/IE1UqxrsiSx6XJGweN7jcrKchgYpCCKr11nIFFFFABRRRQAUUUUAFa3hT/kZdM/6+E/nWTWt4U/5GXTP+vhP50Ae5UUUUAFFFFABRRRQAV85/bftiTalMTm6d7tv9kOS+PwBAHsK+hdQuVs7C5unICQxNIdxwMKCeT+FfOdnbldHgtmJBECxkkdPlx0oPpeHIXnUn1SX4/wDDEVhDMNEtBGwju0SOVWPIEow4J9RuGT616joOrQ6xp6XEI2SD5ZoWOWhfup/x7jBHBFeaaTL52mWzkbW8sBl/usOGX6ggj8KnVHiuhdWk8trdAbfOhOCR6MDkMOTwwIGeKxq0vaLzPYxuA+swjKD1S+9Hqtcrc+JrOPxvDpURV3WMRXThwPLd/miUjv8AdYdsF1xnJxjf29rgG0XtuV/vNbZf8wwH/jtcXoOjhF1G8ju7ia4u33R3MxDMWViwl4AGS5LA9wFrGGGevMeXDKazlaatv1/rqe71z/juPf4bmccGKWGXPoBIu4/987q1NGvl1LSbS9VdnnxK5T+4SOV+oOR+FVvFkP2jwtrEO3dvs5lAxnJ2HFc8XaSPNhJwkpdjzdP9NkWT/l1Q7k/6aHs30Hb16+lXaarBlDKQVIyCKZNNHAm+VtozgdyT6AdSfYV6h90tFdktRRzCSV0VWIXq+Plz6D1qAJLcsGmBjhByIgeW929vb8/SrlAJ3Ciis6Zpr+6a1tXMcEZxcTL97OPuIex9T2HTk5FQg5vliYYrFU8JTdWo9CDS7x5tLsbSwIacW8YllxlYPlHB9W9F/E4HW/HaQ2bW6RA7mlLO7HLSNsblj3P/AOrpVq1tobSBYbaNYol6Kox/k+9Mm+e8gTsoaQ/ltA/8eP5V7KVlqfmLtfQsUUVHcymGB5FRpGA+WNfvO3QKPcnAHuapuwj034Sow0C+mx+7nvnZD6hUSM/+PIw/Cu3rL8L6X/Y3h+w09mVpIYx5rr0eQ8u34sWP41qV4k5c0mzUKKKKkAooooAKKKKACiiigD5u+PkZT4m26xYka706FfKByxYSS54HOMBOO+SK6H4deFG0pBqOortu2QrEj/ejU8szejN6dh9SK0HknfxNEuyPyxq1y0jsP3jMftajn2RIwMj7pHPGK6quGtUbdj0aV1BIydVuLye2MWmWKXHmN5btcnZHtIOT/eI6dB3rg5Ph3ecSf6EqAkmCFpN2OwDOTn8cfWvS7a7t7p5kt54pXhYpIqMCUb0I7Gm39/a2EYkvJ0iDHCgn5nPoo6sfYZNYeVjOthaOIt7aKlbukzye48O2ejXWjy39tqrLPPtkQbSEZXA27gvIPUDglenNdh8UIdObQ4J9TF1+7mCxfZmVW3MDwSwIxx6Z4FUvideRPpWnO+oXtlayyMXSKBhI4A6kMVIx6HuQcHFaXxJ2p4Xy8l8uyVCJLYBipGeW5GR+I520WPMeHo0aeIpU4pKydtO39b2MKLwRHNBbf2bbNCk1ukjXOofPKjNn5TF9zKjrkdSOtdBY6PrmlWph0280kJw2xrHygWwMn92QBnHofr2q7puoLY6Dpb3sl1NG9uhe7kjxj5RzIMkr7k5Axye52YZY5okkhdZI3GVdDkEeoNF7HpYfD0qUV7OKj6WX5EdvNKxKXEBicE42ncpHqDj9DiuT+KGiNqWiC7tkJu7M7xgZJTjI/AhW+in1rr7e4huELW8scqhipKMGAI6jjuKkoTs7nSeH/DVodQ8faPHEY5GadZDHkEo0eWYn3wOv+zX1NXkfgWH7Rr/hjzoIDdWun+fHMowwhaMoynrn5jEew59q9cr0aTvG5w4iXNIKKKx/F2tDw94bvtUMXnNbp8kecb3JCqCewLEZNaGC1NivPfi9pbvZWmtQruFjujuQO0L4y/vtZVJz0Uue1eTx/EXxWL9rpdaLLI0UxjeBTEfmOECjBVD0ODuPHzdSep034z34t7qDUtJtb68WRUVLbdAmwqCQd3mEkkgADrznGBulTTOyjGrhqkasd0ZI6VXuGu1kH2aKCRCOfMlKEH8FOe1ddYeFdHu7Z7mOKeJJppZYfKuZEVYmkYxhUDbQNhXgDFWU8HaQDmRbyRvU3kq/orAVi8TFaH1SzunKN+Vp/I88ulneIvqV5FZ2v8SQuVJ9jKcHH0Cn3q9pttd3iLBoOlXVxFEQmYoCsScAgAkAdCCOce9d7a6HbWVyX06w0+2dRgXLR+ZK/HOTwfxLGtDTn1jTZLw2l3p5S5l85lltHJDbETAIlHGEHbvSWJTepyVs5q2/cxV/PX/Iw9G+H+r38itqzrpdp3RGWS4b2yMon1y30HWtPTtN0+w1jUxpFskFpH5druB3GZ03FnZjkscyFMkk/u66TTfENzcTGzvLJLe9dGNu8chkhlYDO3JAKtwTgjoDgnBxxvgeQzaO02+R0kcODJ94kxoWY+7PuY+7GivNOGnU8eeKr4mpes9unQ6GuIih+x31/ZHOIp2dM90kO8Y9gWZR/uV2c80VvEZJ5EijXqzsFA/E1yutMh8UyBA2/wCyRiQlcDAd9uD+L/l7GscO7TsZYhXjc5HVo5NPvtPtVTNjJdNJAw6RHypN0f05yv4jgAZtVtX1pDfWz29ym+JsEgEggg5BBHIIIBBHSuP02O/fT7WUX4dpIlZvPhDckA/wla7zhNaiqXkXp5a+UH/ZhAH6k/zo+z3n/P8Af+QRQBdoql9nvP8An+/8gij7Pef8/wB/5BFAF2iqX2e8/wCf7/yCKPs95/z/AH/kEUAXa1vCn/Iy6Z/18J/Ouc+z3n/P9/5BFbHg62mTxTpTyX08gFwmUKxhTz7Ln9aAPfaKKKACiiigDE8WeJbHwxYw3epMwjlmWEBcZ55LHPZVBJ+mOpFO8PeJtI8QtcLo92LhrcgSDYy4ySAeQMg4OCOuK+ZNY1bUbiO50rUt7NHfTSSB/vK8kgEgHoMhunfnvWn4M1PV9N8VWK6XdvAl3cRW7rkmNgzquWXOCRvcj6DpWfPrY6/q3uc19T6L8W2UmpeF9WsoZI4nuLWSINISFGVI+YjJA9SOa8MaO+htYri70y8hhkQOHCiUDIB52ElevVgBXpPxB8baDbwXXh46lENRuitrKihiIkcgOWcDapCEkAnOSOMVa6DA4FRWquDVjryzGVcLzOGz7nkNnHEsk1zaTLJbTfOUTDAv3ZSD37jueeDnLW1ixRC0sxhwM7ZY2RvyIBr0jVPDel6jK00tv5Vy3JngYxuT23Efe+jZFczqHh+K2kRbfV5LgCdElje3FxIgLAFgsQU/LnPToKIYiMtGfQQzmny+8rfj/kcqbptYjaKyE0do3yyXDIYyR3VAcHPbd0HYk9LonjQCC0jEhT5NqcImOxPQY9OvtXSWvhG0vryO3m8UsGlO1IptJltlcnoql3G4/wCzk59K7Cy+GGlw7RdX2o3MYGPJDpCmPbYoYf8AfVbJ32IlnuHhrq36f5/8E5v4dTSf2Xd2kzKXt7liuBj5XAkz9NzOPwrqmAZSGAIIwQe9ZxsdO0rxXdWeiWXkwC2RbmRQSPOBLKGY8s2yQEk9tvPYaVedWVps8KVVVZOcVZNnJeEPh9d3+iWUtzq0cEYTymjig3SBkJRvnZsA5U/wmumi+F+kJIZDfao8pGN7vETj0H7vA/CtXwRMY31TTX6QTfaIuc/u5stz/wBtBNx6YrqK9CD5opnPVzDFOVnUenZ2/I4g/DfTCD/p+pj33Rf/ABFebeJdHSx8S31jYanfmC1EaMZBCW8wrvP/ACz6bWT8c173dXEVrbTXFw4jhhQySOeiqBkn8q8BjmlujLd3IKz3Uj3Dq3VC7Ftv4Z2/hXXhaanLXZGf9oYqO1SX3syNTtHg064la+vJmVDsQsseX/hGUVTycd+9adjbR2dpFbxZ2oMZJyWPdie5JySe5NV9W+c2UGOJblMn02Zk/wDZMfjV+vRhCMX7qOariKtb+JJv1dwqta/vJribsW8tfouR/wChFv0qS7lMNu7qAX6ID0LE4A/MinQRCGFI1JIRQuT1PuavqYj62vAunDVvF1urjdbaeovJfQvkiJT/AMCDP9Yx61gXMwgiLbSzE4VB1Zj0FekfByweDw/eX07b5r67dt3oseI9o9FDI5H+9nvmubFT5YW7lR3O9oooryywooooAKKKKACiiigAooooA8w8bRx6XrbSRRkNd6naTuSflG8LDkemfLxj1PvWzVT4r2k5it7+CG8lWK2uE220Jl/e/JJEXUAnAaMkNxgkDPzc2kZXRWQgqwyCO4rgrxtI7qErxKt9p1hdsJb6ztZ2jHDzRKxUfUjiqVmul2sjy6Vp0RJHzy2kCgEf7wxu+gyfaptNtbae0hmmjWafGXeUb2Djhhz0wQeBgCrF/M8aJFBj7RMdkeeQvqx9gOffgd6x8jbzMDVrGWbxLo2pxanO1pI6xpZqT5bnY7b+uPugnkE8deldNPEs8EkTkhXUqSpwcEdjWPpcQuNSMi7jaacptLfccl3wPMc+uMBAeuQ/YituhkQgo3a6mJ4f06z8O6QYIL24uLbzcq0zhypOF2rtAGMjoB1JpWstAmmbzrLTxPIeRNbqrsT3wwBP1qJVktLu9tYgSY3+324HJYMT5qD1O7ec9vMX0rcVo7iAMpWSKRcjuGBFGw4QUYqMVohY0SNFSNVRFGAqjAA+lRX1ytnY3FzJ9yGNpG+gBP8ASq1vDDFqhW1iSNUixLsG0Ekjb04JADfTI9ah8VEHQbqJkd1udlqyohdsSuIzhQCSfm6AUJalN6Gh8MbJBbW11Kim6j022ty4JIXgsyj6/KfXpXeVz3ga0mttGkkuROstzcSTbZ1KuFztTIIBGUVTjAxnGOK6GvSpq0UjzqjvJsKyvFWjpr/h6/0x38v7RGVSTGdjjlWx3wwBx7Vq0VZB8iaxpWo6FM9lrVjLaSxnCOVyuAcja3R14HKkn1AORWO+rQ/bmit3BdJklYkMApUIwBIwRnHbnjj1H1P8T/E7+E/Cc97bKr38zrbWit0Mr5wT7ABmx3247183pGxR/PmlnmkYvLNIxLyueSxPXJNYySielRnKqtdj1vwZ4ssdW0KWWQRWclgmLiEHiNAPlYDqFIHA7YI7V0VheJexNIkVxEAcYniaM9M5wR7/ANDyMV4V4Z0iOfXVR7lYI44XmRyxXDKVwWI7AkfN1B2n+EZ9o8MuZNMEsm8TSOzSIzlthzjAJJyMAYPcc9646kUnoU9HY1qKKKzGZOp6jFZarZGaWaBUS4YyxoSYv3Eh8xeCGIxtwe7j1GeO+Hzf2P4M0bTL6dZtZgu2iVrhfndWuDuKE/eAQkblyOOtX/Etrqd1cQXE0gbSI5SWliOJLZA53SEE4faAGUr8wKAbWDkj2GTSbCXSU0x7WI2CIiJDj5UCY2Y9CpAII5BAIrspwU6drnJObhUvY81v7iWHT/EjwfJLETHAIlAYyGFGXGOSxd8D3xWbdytceIdQd4poTGkUCpNGyMyAFg+1gDgl2Gf9mvUrTw1otrPHPFpdn9pjbctw8QeXd6+Y2WJ981g/EnSt9nHrdsv7+xUicD/lpb9W+pT749gwH3qunRUHdmdSs5qxx1clo3/IIsf+uCf+gius6jIrk9G/5BFj/wBcE/8AQRW5iW6KKKACiiigAooooAK1vCn/ACMumf8AXwn86ya1vCn/ACMumf8AXwn86APcqKKKACiiigDhPHnw4sPE80l7a3D6bqrKA08aBklxwDIncgADIIOAAcgAV4l418Na94QvtNRtQ0t79pVnga3kfzIghyJWjZNpAYDALcnjkAkfTurX0Wl6Ve6hc58i0heeTH91FLH9BXyjLqVxrd/c6vqBDXl2+4tnOBgfKvoBjaB6KM+tZzstTrw3PN8t9CreR4jmleSRpJCWldipMjMcszk4ySTzz34xXvMGu6e2n2V1LeW8S3cSyxKzgFwQD8oPJ69K8RruvAtvBDpFhNbsz3dw6qzAKzpkcgBs/IjGRcryNoHABrlqK6uzsqK1rHfWd9bX6yrCxbbgOkkbIwBHGVYA4Pr0NWIo0ijWOJFRFGAqjAA+lV9Nt3trREmffLzuYsWPJJA3HkgZwM1arnIM7xA6LpcwYgcBic/MgDDLr3yv3hjuBWt8UvHtp8PNBttV1CzuLqCa7jtT5WAI92TuY9gAp+pwO9YHioWhs7YXcBlJuY9jJAZZIsMGeRAASGVFZgRzkDGTgF1jZH4l3z6hq8AbwtHujtrZzkXHOGLD8OT/AMAHG8v24b4WcmJ+JGf4E8Q2+v6VBehJ47y/8y6mEqnG/K7gr9HVQyBSCfl2e1dRTrjwZY6F4dtLXwfpsNt/Z8jSxWqNjzlf/WJuY9TwRk43ImSAKqwPf3bFbLSL9sDl50Fuqt6HeQx+qqwrKrRlzaa3NKVWPLroW/D4Z/GAMY+WKwcTEdi8ieXn1+5Lj059a7Osjw3o40q0LTFZNQnw91MCSGb+6ueiLkhR+PUknXrrpx5IpM5akuaTZxvxVvxbeGRZK2JNSmW2xn/lngtJn2KKy/8AAhXmNdL8Sr4Xvi1bdSDHp0Hln2kkw7A/8BERH+8a5E3kbcQBrg/9MuR/310H516+Ejywv3MZbkU/z61ap1WOGSQj0YlVU/kXq9WbpzSTalqE0qqhTy7cKrbvurvznA/56Y/CtKuhCK0/z3lvH2XdKffHAH/j2f8AgNWar2/z3NzJ2BWMehAGf5sR+FWKaEQ3RKxb0iEs44iTuznhVHuScfjXu3h/Tl0jQ7DT1bf9mhSIvj77Act+Jyfxrwy3nt4fEOhm7uGghW8SZyqlgBH8+WwCdvyhfTLLXtMHivw9OAYtd0tjjOPtceR9RnIrzsY25JFxNqoL+8gsLOW6vJBFBEMsx5/AAckk8ADkk4FR3+o2tjpkmoTyj7Kib96fNuB6bcfeJyAAOpIxXJXUN1rjCbV5JYoNyvDYxSFViIIKs7KfncEA/wB0EDAJG48ZRuWniWzmuYoLiO5snmIEJuY9qyE9AGBIDHsrEMfSrWq63Y6XLHDcyO1xICyQQxtLIw9dqgkDPG44Ge9cXql79lsJ7PUIVu5nAjgRgALrcQoB9DlhuOMAfNgDgUdF03VbCa4hl1oXGoyBZGluoBIJVCheMENhTxyxx8pPLHIB3dp4l024uEt3kltZ3YKiXULRB2PRVZhtYn0BJrZrgbG8j1QXmnalbwrdwgLcWxYSIyN91hkDKnB6gHII+u14Pmmhe70iaWSdbNY5IJZGLP5TlgqMx5YqUYZPJXbkk5JAOkooooAKKKKAAjIweledaCnk6VBbc5tN1oxPcxMYyfxKk16LXC3cP2HxLqVseI7krew+mGAV1HuHUsf+ugrnxMbxudGHlaVirKr2dy08SM8Ev+uRBllP98AdeOCPYY75daJJLcPdToUyNkSNjKr1JPoSccegXvmrlI2dp2gFuwJxXCdhjXuhyzLcLZ6zqWnJM+8rbeSdjE5YrvjbGTyfcnpmm3Oj6hd2n2WfXbuOMAATWsccUzY/vNgj/vlV/pUeoazf2x2/2XKW9UdGB+hZl/lVX/hJbh8eTZXEjD7y+Tsx+LlQfwJq0pFqk2bOm6ULOXzZbu6vZxGIlluSpZV64G1VHJxk4ycDJ4ohNxZiWCO1eaMMTCysoUKedpycjByOAeMYycik029vbsI0untbxn7xlkAP4AZz+daVS/MlqxXsoGghPmMGmkYvIw6Fj6ewGAPYCnxR/afEGj2+AwEzXEi/7CI2G/CRovzFS1Y8Jx/ate1C86x2ka2aH0dsSSfUY8n8Qa0ox5poyrPlgzrqKKK9E88KKKiu7mC0tpLi6mjhgjXc8kjBVUepJ6UAeQ/tCuxn8MRZPll7hyvbcFQA/huP515VXqHxmv7fXtJsLzTba8kXTpzJJO0Plp5LIQ/DkNwdhyFxhTXlyOrorowZWGQRyCKwqLU9PBtclhklvE8gkKASr92RfldeMZDDkcE9D3rS8MeLrzw7KIrdWvLJnLS2zuhkOfvOrk7i3GfmJzjHy9RRqrei3YETnnAIUtjP4Hg1Fk9GdEopn0Hpl/a6pYw3lhMs9tKMo6/XBGDyCDkEHkEYNRT3zCaGNLeZ4JwNt1GyGNc9M85+hwRyOa8l+H/jCy8NCaz1GWX+zrhjMtw6sTHJhQVJxyCBnjnIPXPHbXi2cVmuu6VrUlvpSMJZLZFV4pSHzsUN9xmb5eMHJ6A1zuFnYweh2Ph3RRrHk3t6MaXC4NnajOJSh+WVz3GRlV6YwxySAvb1z/hPUdLTRtM0621XT7meC2ihKwXKPkqoHGDXQV6EIqKsjzZScndhSEBgQQCDwQaWiqJPHNR07+wtYuNJGfIQCa0J7wMThf8AgBBX1wFJ+9XH6N/yCLH/AK4J/wCgivfte0Gw12KJb+Jy8RJiljco8ecZww7HAyDkHAyDiuSi+FemxRJFFrGspGihVUNAcADHeKgDzmirPxR0SfwhDpzWWovOblpA3nRLxtC4xjHrXlUHi/WZII3MtsCyg/6n2+tYzrwg+VmsaM5q6PTKK4TQfEGrajr+k2Es8Kx3l7BbOyw8qskioSOeuGr3/wD4VjF/0Grv/v1H/hV06kaivEmdNwdmed0V6QPhdYd9a1n87f8A+NUv/Cr7D/oNa1+dv/8AGqsg82rW8Kf8jLpn/Xwn867Nfhfp4YE6zrLD0Jg5/wDIVXdM+H9hp+oW95HqOpSPA4kCSNFtJHY4jBx+NAHZUUUUAFFFFAHK/FIMfh/rWzoIcv8A7m4bv/Hc18w2Lj7PbDusmD7ZUkfzFfUXjLVdNFjeaLcpNeXF5bPE9rbAFxG4KlmJIVAecbiM4OM4r5cvbW7026ksr+IxXaYDjGQTnKsvqM5IHccdVIGdRHbhJJXRo0zzJ7TMllcXVuxcSMLe4kiDMOhZU4Y8DqDRBKs0YZSM9wDnBxnH60+sTvaUj1j4d+Im1/RSt22dStG8q4yApfjKyBeOGHsBkMBwK6a4mW3heWQSFVGSI0Z2/BVBJ/AV8/W99PYX/n6bNcQ3irt3wuOFODgqxwRwOoIr1rwx4ij8VaHCbW/ittXRQ08SKCUYcHKNzsJ/nwc81hOFtehhJcuhsxak1+6W+lRO95LIY0WeNowuACzsCAwVQR2GSQO4NdxoOlpo+mpapK8z7mkklfrI7HLNjoOTwB0GBXlWnRao3ia6kl1RT9mjMRks4TB88nlkocs2SFjQnt8w6ciugEuoqQ0es6gjDodyN+jKR+ldVCCjG/c4K83KVux6LRXAQ6xrtnyl3DqK9THdxiNm9g8YAX8Uaur0HW7bWYJDCskNxEQJraYASRE9M4JBBwcMCQcHng43MTUoornNW8VwWt7JZWFtLf3UR2y7CEihbAIDue+DnChiO4GRkA8ia7Oo3FzqDHJvJnuAe+1jlAfou1fwqOaaOBN0rBV6D3PoB3PsKq6QrLpMFu5Mc8EYgkGOUdQARg+9TCGG2DzkFnVSS7Es2OuBnoPYcV7ULKKsZkGiHfYmbnE0skgJ6lS52/8AjuKv1T0ZDHpFij/eWCNT9Qoq5Vx2ERwMrxK6LtVvmHvnv+PWllkSGNpJGCovU1Xt5o4NOt2lYKPLUAdSTjoB3PsKWKN55RNcLtVf9XGedv8AtH3/AJUrgZ8EWpS38900NtEX/dwtK5Zo4xz9wAck8n5h0A7Zq4LS7fmXUZFb0giRV/Jgx/Wr1FHKMSGbUodNt9Pj1e7FnBL50cRigIV9xYHmPsxyAeAcY6Cicz3Oftd7fTgjBV7l9jfVAQp/KloqfZQvewXKR0uzWRZYLeK3uUO6OeFAkkbeqsBwf/1HI4r0PQ5pNX8P215dyeZLDMLe5KDY8E/ADoR/CwZTt5IEmCSM1xNdN4IvrW10bxNFdXUEUEoXb5jgBpTGylRnq2ETjrXNi4Ll5kOLL09rLBG17B5lxqFhO7OwUF7iJtrMnAGTs2YHHzRr2re8L3VvL4iupIpVZbywt5bdg2RKivKWK+uPNTP+8KrXW+zuHu0Uvbso89B1XH8YHfjqOuAMdMHFvrOK1uYCkrRWM8wltLqI82Vy3QqemyQkjB4yxU5D4HnFnqNFZXhzU31OwY3KLHe27+Tcon3RIADlf9kgqw74YZ5zWrQAUUUUAFYPizS5r22hu7BQ2oWZLxJkDzlI+eIk9N2AR0AZVJ4BreopNJqzGnZ3RwNjdxXsHmwlhhijo42vGw6qw6hh3BqxTPG2nb/EOnz2M7Wd3JbzF5I1BEu1ogokU/eA3EDoRk4IzWWNRvLIAatZkoOt1aAyR/Vk++ufYMB3avOqQ5JWR6FOfPG7NV0V12uoZfQjNRx2sCNuSJAfXFOt54bmBJraWOaFxuSSNgysPUEcGpKzNLsKKrahf22nwiS8lEasdqjBLO3oqjlj7AE1RM+p3wK2sA0+E/8ALe5w0n1WMcD6seD1U0xXLt3cSCWO0sY1n1GYHyYS2BgdXc/woMjJ+gGSQD2Ohaamk6VBZq5lZMtJKRgySMSzvjtliTjtnFcr4HsIdO8R6nsLyy3NpAzzytudyjy5yf8AgYwBgDHAFdzXdh4JRuupxV5tys+gUUUVuYEV3cw2drLc3UqQ28Sl5JHOAoHUmvO7u8n8QXKXt9E8VpG2+0tHBBQdpJB/z0Pofujgc5J0PibbXZTT74uH0i0YvdRMu5Y24KTsMjKoQc9cZDY+XI5260+O8k828tBdRsB+7Fyzxt6Hy2wlAE0+saejvCZxPIvyvDAjTuv+8qAkfiK811PwLqMl/wCb4WhNjaMWY22oOFjQnn5NhZgp/ukDb29K9Qhljt4liFrLboowqJFkAe2zIFTwzLNnYJBj+/Gy/wAxSavuVGbg7xPKz4D8SbOJtLDH5v8Aj4k+U/Xy+R7Y/GkfwV4iERWaKxc462902f8Ax5FxXrNQPeWyMVe4hVhwQXAIqeRGyxNTuePP4R16MOW0qffnmWGWHLD1K7+T26H2rT+HcC6PqdymtxzWEEeJbZbkNFAspBV2Td8u4rtGMnHzY+8SfVRyOKKagk7kzrynHlZRWfTdWjeFJbO+jGCyBllA+o596safNe6C4k0lnltB9/T5H+Qj/pkT/q29AMIe4GdwmoqjE7nStRttVsY7uyk3xPkcjDKw4KsDyGB4IPSrdebQyXemXxvtKZfMfHn2znEdyAMDJ/hcDow7cEEAY7nRNWttYsvtFrvRlOyWGQASQvjJRwCcHkdCQQQQSCCQDQooooA8d/aL/wCPbQv9+b+SV83Wn/HpD/uL/KvpH9ov/j20L/fm/klfN1p/x6Q/7i/yry8T/FfyPSw/8NfM3fBv/I6+Gv8AsLWf/o9K+1q+KfBv/I6+Gv8AsLWf/o9K+1q6cH8LOfFfEgooorrOUKKKKACiiigArnPFuvPYBNP00q2q3C7lJG5bePkea47jPAXqx9gxHR1w/iDwfKdUu9U0xvtTXTiS4s7mVsMQoUGMk4HCj5WGM9CnOQDnVhvbeR4NPgQb28ya9u33tK5HLbV5c8YOSuOMcDFZ+ueEo/EEcf8AbN47SJ91raFI9v0LBmxwMjdg46VpwLYNOLaexS0vAD/o1xAEkwOpA/iH+0pK+hq/Dbww5MMUceeuxQM0AnbY4tfhtpqEMmo6qGHGfMjJI9DlOfxqA/DnylK2msS7c/L9pgEhUemVK13k0SzLtcuBnPyOVP5giovscX9+4/7/AL/40uVGirTWzPM7n4d6siMlvc2E+GLRuzPCU+g2v798dulUW8H+Iop4bmGzaO9iORNbzxg5x1Ulv59sg5Br12GBIc7DIc8fPIzfzJpJIZHkLLczIMfdUJj9VJqeRF/WanUxtClvbLSrS3m0i8+0BAZn8yEhpTy7E+Zk5Yk5681v1WNkjcvLcM3c+cy5/BSB+lH2C1Jy8EcjZzukG9vzOTVmBZqCa33XEV1BLJbXkORHcREBgD1U54ZTgZUgjgHqAQ02FmRg2tv/AN+x/hR9htwcohi9onMYP1CkZoA6DR/FbLNFaa+kdvK5CR3cWRBKx4AOcmNieACSDwAxJxWPqNu+k65cWswPkXcslzaykcOWJd4yf7wYsQO6kdcNjHuJdOZpLQX7PIw2yWyOLh3HpsIYn6AV1PhGxu9T8N3Gm+IIZ5rKNgtpPcI0U7IAMFgfnDoRw5wTgHryQDm9U0Ky1GTznRobrGBcQna+OwPZh7MCKyLrwrctDLFb6rlXUrm5tw7dPVCg/Sum1K2u/Dx26o5nsAcJqO0AAdhMBwjf7XCk/wB0kLUo5HFXGpOOiYrHnOlSebplpJjG6FGx6fKKtVa1LRr2xvZpLK3a6sZnMgSMgPCzHLDBIyuckY5GcYxisae8mRykltNZgcebeROi59uMH/voV6lOvCSWpDQtpcRpGsEiS+ZCNhIiYjjjIIGORg/jUvnTSHEMBA/vynaMew5P4HFZ8eoW5JtrO7icg5klDh3Ynn5VHU8+mBxgHGBf8y8muFWHT9QCDklrSRS/sNwAH1JHT8ar2kVuwsOEMzf6y5YH0iQKP1yf1pfssf8Aem/7/P8A41ei0rWJxuWzgt19Li4w35IGGPxpjeH9fIyZLDPpHMyj9Y2qHiKS6jsyp9lj/vTf9/n/AMaPssf96b/v8/8AjV/SvD/iC7szdwWL3kRkeIeTcRYJRirEF/LOMgj86bcWeoW3FzpWpxkfeP2OR1X6soK/rVKtTezFZlE2cDY8yPzMdPNJfH0znFTaZb6hENSm0bSxc+Zss/NjceZbnAZikbYU53wjG4ZIXIOAKasodgkKSzTHgQwxs8hPpsAz+nFeq+DPDDWWgW66iGhvnuvt0qxsPlbgKhPIOFRAcdSuQelYYuceSyHFHJeC/F0d9O2k6oHttXjcoI5gVaQ4ZsBWAYEKuSCOAV5JNb13aLHBcWssLT6XcKVaNAS0W7rgDkqevHKnpxjbteNfCVj4osCsyCLUI1It7tCyumeqkqQTG3Rlzgg+uCMaHWbaK1m+3f6Hc2oCz20hy6HOBgdXDH7pA+bjHpXnFi+AbqWXUI2mdnlntHimZht3PbTeXvx23eYxx2wBXeVwnw2iluZru/lXEaeZGmCCFkkmeWVMjg7cxoSP4kYdq7ugAooooAKKKKAOW8V/8hzS/wDr2uP/AEKGqVWfEweXxHaERuI7a0fLkcMZXXAB9R5Rz/vCq1cGI+M76HwGbNo1s1w9xatNZXLnc8ls23efVlOUY+7Amj+zbr/oNah1/uQf/Gq0qKxua2KNlpdrZymZFeS5K7TPM5kkI9NzZwM87Rge1XqKKQD9Ffb4utARgPZXAz774SB+WT+Brs64qC3uG1bSrmCFpFguCZMDHyNG6Hn0BYH/AID612td+HfuHDXXvhRRRW5iBGRg9K5W58GwRszaPdy2Ck5FvsEkAPshwyj/AGVYKPSuqooA4tvC+sIcrqVhKD2No8ePx8xs0n/CN6z/AM/On/8AfD/412tFAHGL4V1fgvq9gPUCwc/r51SL4Uv2wJtXhA9YbMqf/HnYfpXX0UAcavgCz6vqN4WPXENsBn2/dZ/U1FL4CVBmz1EEn/n8s4pAPp5YjP5k129FAHCp4X1e0Vlt/wCypgecgvb5P0Cv/P8AOmy+HNamULNaaRIuc4a7cjP/AH5rvKKAOATwZfXAAl/smyHcxQm4Y/QkIAfcg/Sun8O+HrLQY5RaGWSabHmzSkbnxnAwAFAGTwoA5J6kmtiigAooooA5/wAbeFrLxbor2F7mORTvt7hVBeCTsw9uxHcEivGIf2fdSihSP/hIbQ7VC5+ytzgf71fQ9FZzpQnrJFxqShpFnhGhfA3UNN17S9Qk121kSzvIbootswLiORXwDu4ztxXu9FFOEIwVoilOU9ZBRRRVkhRRRQAUUUUAFFFFAFXUtOs9Ttjb6jaw3UOQdkqBgCOhGehHrWG/g2zB/wBEvdStV7hZ/Nz+Mocj8K6aigDkz4PdP9VrV83r50cLfltRf60DwhKxAk1m6C9/KhiDfmVI/SusooA5dPB0Q4k1fVJF7gmFc/isYP5GpP8AhD7D/n51D/wINdJRQBzLeEIBkRalqUa+geN/1ZCab/wh6Y/5DOqflB/8arqKKAOaTwdYN/x93Wo3Ppm5MWP+/Wz/ACfpViPwjoSf63TYbkjobsm4I+hkLYrdooAjt4IbaFYbaKOGJRhUjUKoHsBUlFFACEBgQQCDwQa52XwbpOc2a3FgR90Ws7LGvsIzmMD/AIDXR0UAcm3hCVObfWrtj/08wxOP/HFQ/rUbeFdT/h1azH1sGP8A7VrsKKAOQ/4RXUDwdWtgO5WyOfwzIR+lSL4OJ5l1rUAc9IkhUY/FGP611dFAHMr4PtTxcahqU49DKsf6xqpqUeDtGwQYrtlPVXv52B9iC/I9q6GigCO3gitreOC2ijhgjUIkcahVRQMAADgAelSUUUAFFFFABVPUNLsNSEY1GxtbsRnKCeFZNp9RkcVcooAZBFHBDHDBGkUSKFREUKqgdAAOgp9FFABRRRQAUUUUABAIwRkVA9nbOctBHn124qeik0nuNNrYpHS7M/8ALEfgx/xoGl2Y/wCWP/jx/wAau0VPs49ivaS7lVdPtF6QJ+IzUyQQp9yKNfooFSUU1FLZEuTe7CiiiqEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These positions allow nasal medications to penetrate into the sinuses, highlighted in green in the right hand column. To give the medications, get into the position shown and give the medication into the nose. Stay in the position for the amount of time specified by your healthcare provider. For the maxillary sinuses (first position), the medication must be given on each side separately. For the other two positions, medications can be given to both sides of the nose at the same time.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel Hamilos, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37526=[""].join("\n");
var outline_f36_41_37526=null;
var title_f36_41_37527="Invasive hemodynamic tracing HCM with variable LVOT obstruction";
var content_f36_41_37527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Invasive hemodynamic tracing in a patient with HCM showing variable left ventricular outflow tract obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are four surface ECG leads (I, II, III, and V6) and simultaneous pressure tracings from the left ventricle (LV, arrow) and aorta (Ao, arrow). Although no change in heart rate occurs during this tracing, a spontaneous increase in the LV outflow tract obstruction and LV pressure is observed with the gradient increasing from 10 to 80 mmHg. The increase in gradient is associated with a narrowing of the aortic pulse pressure and the development of a spike-and-dome arterial configuration (SD, arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lameh Fananapazir, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37527=[""].join("\n");
var outline_f36_41_37527=null;
var title_f36_41_37528="Dexamethasone suppression tests";
var content_f36_41_37528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dexamethasone suppression tests",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/41/37528/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/41/37528/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/41/37528/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/41/37528/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/41/37528/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/41/37528/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/41/37528/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    suppression tests are used to assess the status of the hypothalamic-pituitary-adrenal (HPA) axis and for the differential diagnosis of adrenal hyperfunction. The low-dose dexamethasone suppression tests are used to assess nonsuppressible cortisol production by adrenal incidentalomas and to differentiate patients with Cushing's syndrome of any cause from patients who do not have Cushing's syndrome. The high-dose dexamethasone suppression tests help to distinguish patients with Cushing's disease (Cushing's syndrome caused by pituitary hypersecretion of corticotropin [ACTH]) from most patients with the ectopic ACTH syndrome (Cushing's syndrome caused by nonpituitary ACTH-secreting tumors).",
"   </p>",
"   <p>",
"    This topic will review the basic principles of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression tests. Additional information on their role in determining the diagnosis and the cause of subclinical and clinical Cushing's syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=see_link\">",
"     \"The adrenal incidentaloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21913?source=see_link\">",
"     \"Establishing the diagnosis of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEXAMETHASONE SUPPRESSION TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression tests assess the pituitary corticotroph cell response to glucocorticoid negative feedback inhibition of ACTH secretion. Dexamethasone is a potent glucocorticoid, about 30 to 40 times more potent than cortisol. Thus, the average daily maintenance dose of dexamethasone for a patient with adrenal insufficiency is 0.5 mg, versus 20 mg for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dexamethasone and steroid measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurements of serum, salivary, and urinary cortisol by current assays are",
"    <strong>",
"     unaffected",
"    </strong>",
"    by the presence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . Antibodies used in current cortisol immunoassays are directed toward the D ring of the molecule and react very poorly with dexamethasone, which has a 16-alpha-methyl modification of the D ring. Structurally-based assays such as mass spectrometry or high pressure liquid chromatography fully discriminate the two steroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Low-dose dexamethasone suppression tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The binding of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    to glucocorticoid receptors in corticotroph cells inhibits pituitary ACTH secretion. Dexamethasone directly inhibits steroidogenesis in rat adrenals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/1\">",
"     1",
"    </a>",
"    ], but in humans, dexamethasone has no inhibitory effect on steroid production when exogenous ACTH is infused [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the HPA axis is normal, any supraphysiologic dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    is sufficient to suppress pituitary ACTH secretion. This should lead to reductions in cortisol secretion and its concentration in serum, saliva, as well as in the 24-hour urine excretion.",
"   </p>",
"   <p>",
"    Two main protocols are used. No special precautions are required, as side effects are virtually absent, and either test can be conducted on an outpatient basis by a compliant patient. Obviously, the test cannot be conducted if the patient is receiving exogenous ACTH or other glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Overnight screening test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overnight test is a quick screening test for nonsuppressible cortisol production and subclinical or clinical Cushing's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    (1 mg, ie, two tablets of 0.5 mg) is taken orally between 11 PM and midnight, and a single blood sample is drawn at 8 AM the next morning for assay of serum cortisol and, if available, serum dexamethasone. A dose of 0.3",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    surface area can be used in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose did not need to be adjusted in one study in obese adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/6\">",
"     6",
"    </a>",
"    ]. In a second series of 100 consecutive obese adults (BMI &gt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    a false positive rate of morning plasma cortisol &gt;1.8",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    was found in 8 percent of individuals receiving 1 mg overnight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , while it was only 2 percent in those receiving 2 mg overnight dexamethasone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/7\">",
"     7",
"    </a>",
"    ]. However, we do not suggest the routine use of the 2 mg overnight test.",
"   </p>",
"   <p>",
"    When initially studied in healthy individuals, the 8 AM normal serum cortisol concentration was less than 5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (140",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    and the serum",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    concentration 0.08 to 6.5",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (0.2 to 17",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The criterion for interpretation of the test has been revised based on the observation that, using current, more specific immunoassays, most normal individuals suppress their 8 AM cortisol value of less than 2",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (55",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2008 Endocrine Society Guidelines suggest a diagnostic cortisol criterion of 1.8",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    on the morning following an overnight 1 mg dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , recognizing that this choice will optimize sensitivity but decrease specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in some patients with Cushing's disease, 8 AM serum cortisol concentration has been reported to suppress to 1.8",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    after 1 mg overnight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/10\">",
"     10",
"    </a>",
"    ]. It is likely that this phenomenon is not as rare as previously thought:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of a single practitioner's experience in 103 patients with Cushing's syndrome showed that 14 of 80 (18 percent) with Cushing's disease suppressed to less than 5",
"      <span class=\"nowrap\">",
"       mcg/dL,",
"      </span>",
"      and 6 of 80 (8 percent) suppressed to less than 2",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (55",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of 97 patients with Cushing's syndrome using a slightly higher 1.5 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      dose, four suppressed to between 1.2 and 2.8",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (34 and 77",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Japanese individuals, who are leaner than individuals in Western populations, a 0.5 mg dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      was found to give higher sensitivity (99.1 percent) and specificity (98.4 percent) for ACTH-dependent Cushing&rsquo;s syndrome when using a cutoff of 3.05",
"      <span class=\"nowrap\">",
"       mcg/dL,",
"      </span>",
"      while in the same patients receiving 1 mg dexamethasone, the sensitivity (96.2 percent) and specificity (98.2 percent) were slightly lower when using a cut-off of 1.70",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/15\">",
"       15",
"      </a>",
"      ]. However, we do not suggest using this dose for routine testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the 1-mg low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    tests should not be used as the sole criterion for excluding the diagnosis of Cushing's syndrome.",
"   </p>",
"   <p>",
"    Conversely, the 1 mg low-dose test has a significant false-positive rate when sensitivity is maximized. Using a serum cortisol criterion of less than 3.6",
"    <span class=\"nowrap\">",
"     mcg/dL,",
"    </span>",
"    the test has a 12 to 15 percent false positive rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/3,4,16\">",
"     3,4,16",
"    </a>",
"    ]. If, however, the criterion for suppression of serum cortisol is increased to less than 7.2",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    the false positive rate falls to 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/4\">",
"     4",
"    </a>",
"    ]. This suggests that the use of multiple criteria may be useful in interpreting the test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 97 patients with Cushing's syndrome and 101 in whom the diagnosis was excluded, using a 1.5 mg test dose, 100 percent specificity was achieved only at a cut-off threshold of 14.3",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (395",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If the concentration is between 1.2 and 14.3",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (34 to 395",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      the test is equivocal. In the study mentioned above, the test sensitivity and specificity were 91 percent at a criterion of 6.3",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (175",
"      <span class=\"nowrap\">",
"       nmol/L).",
"      </span>",
"      The sensitivity increased to 100 percent, but the specificity decreased to 41 percent, at a criterion of 1.2",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (33",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/14\">",
"       14",
"      </a>",
"      ]. Patients with equivocal responses may be normal, or they may have Cushing's syndrome or pseudo-Cushing's syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/17\">",
"       17",
"      </a>",
"      ]. They require additional tests to exclude Cushing's syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21913?source=see_link&amp;anchor=H3#H3\">",
"       \"Establishing the diagnosis of Cushing's syndrome\", section on 'Physiologic hypercortisolism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the morning serum cortisol concentration is greater than 14.3",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      (395",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      the patient probably has Cushing's syndrome, and further diagnostic tests must be performed to confirm the diagnosis and determine its etiology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Salivary cortisol has been used as an endpoint for the test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/132?source=see_link\">",
"     \"Measurement of cortisol in serum and saliva\"",
"    </a>",
"    .) When measured by a radiocompetition assay, the salivary cortisol concentration at 8 AM after 1 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    given at midnight was 0.8 &plusmn; 0.4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (2.1 &plusmn; 1.1",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    (range, 0.6 to 1.1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [1.7 to 3",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    in 101 normal subjects, which gave a sensitivity and specificity of 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/18\">",
"     18",
"    </a>",
"    ]. A criterion of less than 1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (2.8",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    also achieved 100 percent diagnostic accuracy for distinguishing between 27 patients with Cushing's syndrome and 64 normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/16\">",
"     16",
"    </a>",
"    ]. Another study found a 91 percent sensitivity for Cushing's syndrome, but the criterion for interpretation was a percent of the obese range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available commercial assays for salivary cortisol require spitting into a cup or using a collection device, and use different assay techniques. Because results may vary among laboratories, it is important to use an assay that has been validated for this purpose and provides an appropriate criterion for its interpretation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/132?source=see_link\">",
"     \"Measurement of cortisol in serum and saliva\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Standard two-day, 2 mg test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two-day test is used to assess suppressibility in patients with an equivocal overnight test or in patients who have not had an overnight test.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    , 0.5 mg is taken orally every six hours, usually at 8 AM, 2 PM, 8 PM, and 2 AM, for a total of eight doses. The dose can be modified in children who weigh less than about 45 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/21\">",
"     21",
"    </a>",
"    ]. Blood is drawn two or six hours after the last dose for measurement of cortisol and dexamethasone (and ACTH, if desired). The response also has been evaluated using urine corticosteroid excretion during a baseline day and the second day of dexamethasone administration, but this is not currently recommended (see below).",
"   </p>",
"   <p>",
"    The normal response to the two-day test consists of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary cortisol excretion should fall to less than 10 mcg (27 nmol) per 24 hours on the second day of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      administration.",
"     </li>",
"     <li>",
"      Serum cortisol concentration is less than 5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (140",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      a plasma ACTH concentration is less than 5",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (1.1",
"      <span class=\"nowrap\">",
"       pmol/L),",
"      </span>",
"      and a serum",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      concentration is between 2.0 and 6.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (5 to 17",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When using more specific assays to measure serum cortisol, the criteria for suppression are lower. In one retrospective study of 245 patients with ACTH-dependent Cushing's, evaluation of serum cortisol concentrations at 24 and 48 hours during the two-day low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      suppression test correctly identified 98 percent of patients (a serum cortisol concentration &lt;1.8",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (50",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      at either time was considered to be indicative of complete suppression) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/132?source=see_link\">",
"       \"Measurement of cortisol in serum and saliva\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Smaller prospective studies examining patients suspected of having Cushing's syndrome reported 90 to 100 percent sensitivity and 97 to 100 percent specificity using a serum cortisol concentration of 1.4 or 2.2",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (38 or 60",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      as the exclusion criterion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]. Thus, use of the 2 mg, two-day test has greater specificity at high sensitivity than the 1 mg overnight test. As a result, this is the better screening test, with the caveat that it requires more patient effort than the 1-mg test to achieve excellent diagnostic results.",
"     </li>",
"     <li>",
"      Urinary 17-OHCS excretion should fall to 2.5 mg (6.9 &micro;mol) or less per 24 hours, irrespective of creatinine excretion (ie, lean body weight). Urinary 17-OHCS are now rarely utilized.",
"     </li>",
"     <li>",
"      Urinary corticosteroid endpoints provide less sensitivity and specificity; serum cortisol endpoints should be used instead. In one study of 39 patients with Cushing's syndrome and 19 with pseudo-Cushing's syndrome, using the criterion of suppressing 17-OHCS excretion to less than 4",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (11",
"      <span class=\"nowrap\">",
"       &micro;mol/day)",
"      </span>",
"      gave a sensitivity and specificity of 69 and 74 percent, respectively. Using urinary cortisol suppression to less than 3.6",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      (100",
"      <span class=\"nowrap\">",
"       nmol/day)",
"      </span>",
"      gave a sensitivity and specificity of 56 and 100 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/23\">",
"       23",
"      </a>",
"      ]. In another study, 9 of 54 patients with Cushing's syndrome suppressed urinary cortisol excretion to less than 10",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      (27",
"      <span class=\"nowrap\">",
"       nmol/day),",
"      </span>",
"      while 5 of 30 suppressed 17-OHCS excretion to less than 3",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (8",
"      <span class=\"nowrap\">",
"       &micro;mol/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/10\">",
"       10",
"      </a>",
"      ]. In a retrospective study, 7 percent of patients with Cushing's syndrome suppressed urinary cortisol to less than 20",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      (55",
"      <span class=\"nowrap\">",
"       nmol/day)",
"      </span>",
"      or 17-OHCS to less than 3.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (7",
"      <span class=\"nowrap\">",
"       &micro;mol/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measuring plasma ACTH, if either of the tests is positive, gives an indication of the etiology of the hypercortisolism: it will usually be high normal or high in patients with the ectopic ACTH syndrome, within the normal range in those with Cushing's disease, and undetectable in those with an adrenal tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Diagnostic accuracy of low-dose dexamethasone tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a recent meta-analysis, the 1 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    test and the two-day 2 mg test were both accurate diagnostic tests, but the 2 mg test had slightly less diagnostic accuracy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the 1 mg test, in 14 studies including 249 patients with Cushing's syndrome out of 5305 undergoing testing (using various diagnostic criteria), there was a likelihood ratio of 16.4 (CI 9.3-28.8) for an abnormal result and 0.06 (0.03-0.14) for a normal result.",
"     </li>",
"     <li>",
"      For the two-day 2 mg test, eight studies were identified, including 136 patients with Cushing's syndrome out of 323 who were tested. It found a likelihood ratio of 7.3 (CI 3.6-15.2) for an abnormal result and 0.18 (CI 0.06-0.52) for a normal result.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Serum dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measuring serum",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    is recommended for all dexamethasone suppression tests. It provides verification that the drug was taken and indicates whether the serum concentration is within the limits expected in an individual who metabolizes the drug normally. Nomograms are available that relate serum dexamethasone concentrations to serum cortisol concentrations in normal subjects and in patients with Cushing's disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/8,27\">",
"     8,27",
"    </a>",
"    ]. Commercial laboratories often provide a range of expected values for a specific dose and interval until the blood draw. Finding an abnormally high or low serum dexamethasone concentration allows one to interpret the cause of an unusual serum or urinary cortisol response and to repeat the test, if necessary, with the same or another dexamethasone dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     High-dose dexamethasone suppression tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basis for the high-dose suppression tests is the fact that ACTH secretion in Cushing's disease is only relatively resistant to glucocorticoid negative feedback inhibition and will not suppress normally with either the overnight 1 mg or the two-day low-dose test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. By increasing the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    four- to eightfold (ie, 12 to 16 times the usual daily maintenance dose), ACTH secretion can be suppressed in most patients with Cushing's disease. In contrast, most nonpituitary malignant tumors that produce ACTH ectopically (such as oat-cell lung carcinomas) are not responsive to glucocorticoid negative feedback; adrenal tumors that cause Cushing's syndrome are not dependent on ACTH secretion. In both of these disorders, pituitary ACTH secretion is already suppressed. As a result, dexamethasone cannot suppress ACTH secretion further and has no effect on cortisol secretion at any dose. However, this test need not be performed for primary adrenal disease, the diagnosis of which should have been established by the combination of simultaneous high serum cortisol and low plasma ACTH concentrations (versus the normal or high plasma ACTH concentrations with a pituitary or ectopic ACTH-secreting tumor).",
"   </p>",
"   <p>",
"    Several high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression tests are in use:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Overnight 8 mg test",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    (8 mg) is taken orally between 11 PM and midnight, and a single blood sample is drawn at 8 AM the next day for measurement of serum cortisol and, if one wishes, plasma ACTH and serum dexamethasone. With this protocol, the 8 AM serum cortisol concentration is less than 5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (140",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in most patients with Cushing's disease (ie, a pituitary tumor), and is usually undetectable in normals.",
"   </p>",
"   <p>",
"    An alternative test strategy involves calculation of the suppression of morning serum cortisol concentration on the day before and after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    administration, and considering a 50 (or 69) percent or more suppression to indicate Cushing's disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/30\">",
"     30",
"    </a>",
"    ]. This approach yielded a 77 to 92 percent sensitivity and 57 to 100 percent specificity in studies that used various time points for blood collection and included up to seven patients with ectopic ACTH secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Standard two-day, 8 mg test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient collects at least one baseline 24-hour urine specimen, usually beginning at 8 AM. After the baseline collection is completed, the patient begins taking 2 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    orally every six hours for a total of eight doses, usually at 8 AM, 2 PM, 8 PM, and 2 AM, and the urine collections are continued. In practice, this test is often performed immediately after completing the low-dose dexamethasone suppression test (if the test is positive) and no intervening baseline urine collection is obtained. The urine collections are assayed for urinary free cortisol, and creatinine. In addition, a blood specimen can be collected six hours after the last dose of dexamethasone for measurement of cortisol, dexamethasone, and ACTH.",
"   </p>",
"   <p>",
"    This protocol leads to the following values in normal subjects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary free cortisol excretion is less than 5 mcg (14 nmol) per 24 hours.",
"     </li>",
"     <li>",
"      Serum cortisol and plasma ACTH concentrations are low and usually undetectable.",
"     </li>",
"     <li>",
"      Serum",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      concentrations range from about 8 to 20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (20 to 51",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients with Cushing's disease demonstrate a significant (ie, greater than day-to-day baseline variation) reduction in urinary cortisol excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/28\">",
"     28",
"    </a>",
"    ]. About 70 percent suppress urinary cortisol excretion by more than 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/32\">",
"     32",
"    </a>",
"    ]. As in the low-dose tests, serum cortisol concentrations respond similarly and reinforce the urinary steroid results. Plasma ACTH concentrations are also significantly suppressed in patients with Cushing's disease, and serum",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    concentrations provide information about compliance and steroid metabolism.",
"   </p>",
"   <p>",
"    The vast majority of patients with the ectopic ACTH syndrome from malignant tumors fail to suppress with high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . The study mentioned above reported that two or three of six patients with ectopic ACTH secretion and 86 percent of patients with Cushing's disease showed suppression of urinary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum cortisol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An effectiveness analysis of 73 patients with ACTH-dependent Cushing's syndrome examined the results from the overnight or two-day 8 mg test and found 81 percent sensitivity and 67 percent specificity for differentiating Cushing's disease from ectopic ACTH secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/33\">",
"     33",
"    </a>",
"    ]. In this study, the diagnostic groups showed complete overlap in responses, with suppression ranging from 0 to 99 percent, suggesting that this test cannot be used alone for the differential diagnosis of ACTH-dependent Cushing's syndrome.",
"   </p>",
"   <p>",
"    Perhaps as many as one-half of patients with ACTH-secreting pulmonary carcinoid tumors and occasionally other tumors, such as thymic carcinoid tumors, hepatomas, and pheochromocytomas, respond with decreased tumor secretion of ACTH and reduced urinary steroid excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. While pulmonary carcinoid tumors represent only about 5 to 40 percent of patients with ectopic ACTH secretion in various series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/37\">",
"     37",
"    </a>",
"    ], they represent a difficult diagnostic problem because they are often occult and may mimic the clinical features of Cushing's disease without the short course, severe hypercortisolism and hypokalemia considered more typical of ectopic ACTH secretion from malignant tumors such as oat-cell lung carcinomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/55/9082?source=see_link\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One report suggested a mechanism by which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression might occur in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/36\">",
"     36",
"    </a>",
"    ]. Six of eight ACTH-producing bronchial carcinoids expressed both proopiomelanocortin (POMC) and the vasopressin V3 receptor on the cell surface, a phenotype similar to pituitary corticotrophs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/29\">",
"     29",
"    </a>",
"    ]. In contrast, POMC and V3 receptor expression were much lower in dexamethasone nonresponsive noncarcinoid ACTH-producing tumors.",
"   </p>",
"   <p>",
"    It is prudent to perform at least one test in addition to the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression test, even in patients who meet current criteria for suppression, as the specificity of this test is less than 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21913?source=see_link\">",
"     \"Establishing the diagnosis of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intravenous dexamethasone suppression tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several versions of an intravenous test have been utilized and serve both in the initial and differential diagnosis of Cushing's syndrome within one day, while avoiding the potential difficulties of drug compliance and absorption with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . Dexamethasone is infused at 1",
"    <span class=\"nowrap\">",
"     mg/hour",
"    </span>",
"    IV for four [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/40\">",
"     40",
"    </a>",
"    ], or seven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/41\">",
"     41",
"    </a>",
"    ] hours, or at 5",
"    <span class=\"nowrap\">",
"     mcg/kg/hour",
"    </span>",
"    for five hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/42\">",
"     42",
"    </a>",
"    ]. Plasma cortisol is suppressed to levels &lt; 1.4 to 3.0",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (&lt;38 to 83",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in the evening and the following morning in normal or obese individuals and is above these levels at 9 AM in patients with CS (&gt;20 percent of baseline value or &gt;4.7",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [130",
"    <span class=\"nowrap\">",
"     nmol/L]),",
"    </span>",
"    with a sensitivity and specificity of 100 and 90 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/39,41\">",
"     39,41",
"    </a>",
"    ]. Differentiation between Cushing's disease and ectopic ACTH or ACTH-independent Cushing's syndrome can be made on the basis of a 50 percent decrease in plasma cortisol that occurs following dexamethasone infusion in patients with Cushing's disease. However, similar to the oral high-dose dexamethasone suppression test, specificity is incomplete, as some patients with Cushing's disease fail to suppress cortisol in response to dexamethasone and some benign ectopic ACTH cases do suppress cortisol in response to dexamethasone. Less than 5 percent of patients with Cushing's disease fail to suppress cortisol with oral or IV high doses of dexamethasone (usually patients with large corticotroph tumors), whereas doses &gt;16",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    may cause suppression in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/28\">",
"     28",
"    </a>",
"    ]. Although all the dexamethasone suppression tests are useful, none of them correctly categorizes every patient with ACTH-dependent Cushing's syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SOURCES OF ERROR",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several common sources of error in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improper urine collection &mdash; This problem can be detected by measurement of creatinine excretion. The creatinine value provides reliable information about the reproducibility of a series of urine collections and some information about the completeness of an isolated collection. In adults under the age of 50 years, daily creatinine excretion should be 20 to 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (177 to 221",
"      <span class=\"nowrap\">",
"       &micro;mol/kg)",
"      </span>",
"      lean body weight in men and 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (133 to 177",
"      <span class=\"nowrap\">",
"       &micro;mol/kg)",
"      </span>",
"      lean body weight in women. From the ages of 50 to 90 years, there is a progressive 50 percent decline in creatinine excretion (to about 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in men), due primarily to a fall in muscle mass. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35190?source=see_link\">",
"       \"Calculation of the creatinine clearance\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=see_link\">",
"       \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"      </a>",
"      .) The use of serum rather than urinary endpoints obviates this source of error.",
"     </li>",
"     <li>",
"      Elevated corticosteroid-binding globulin &mdash; Women taking exogenous estrogens may have elevated corticosteroid-binding globulin (CBG) levels with concomitantly increased serum cortisol values. This may result in an apparent lack of suppression. Theoretically, in this setting, salivary cortisol values would show normal suppression. It may be prudent to measure CBG in women taking estrogens, and to repeat the test after their discontinuation in patients who have a high CBG value and do not suppress cortisol normally.",
"     </li>",
"     <li>",
"      Variation in hormone secretion &mdash; Day-to-day variation can occur in hormone secretion by tumors, particularly by malignant pituitary and nonpituitary ACTH-secreting and cortisol-secreting adrenocortical tumors. This problem can only be detected by serial baseline 24-hour urine steroid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/43-45\">",
"       43-45",
"      </a>",
"      ] or salivary cortisol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/46\">",
"       46",
"      </a>",
"      ] determinations. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/132?source=see_link\">",
"       \"Measurement of cortisol in serum and saliva\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Variation in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      intake or metabolism &mdash; Failure of the patient to take the dexamethasone or abnormal metabolism of the dexamethasone can interfere with interpretation of the test. Drugs that induce hepatic CYP3A4 enzymes, such as barbiturates,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , troglitazone,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      , and aminoglutethimide, increase the metabolism of dexamethasone and other steroids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. These errors can be detected by measuring serum dexamethasone at the appropriate interval after the last dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Unusual responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary steroid excretion of most patients with Cushing's disease is suppressed by high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . Resistance to suppression is more common in patients with higher baseline ACTH and cortisol secretion. In less than five percent of patients with Cushing's disease, for example, higher doses of dexamethasone (16 to 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    are required to produce significant suppression. These patients tend to have large tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    doses should be considered in patients with a pituitary macroadenoma and ACTH-dependent Cushing's syndrome whose response to standard high-dose dexamethasone suppression is substantial, but equivocal. Further suppression at higher doses of dexamethasone is convincing evidence of a pituitary ACTH source, in which case petrosal sinus sampling would not be indicated. In one study, only 3 of 19 patients with Cushing's disease failed to suppress serum cortisol after both 8 and 32 mg dexamethasone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Paradoxical responses to dexamethasone in primary pigmented nodular adrenocortical disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paradoxical increase in urinary free cortisol during the sequential low-dose (2 mg) and high-dose (8 mg) six-day",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression testing (the Liddle test) was found in 9 of 13 patients with PPNAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/53\">",
"     53",
"    </a>",
"    ]. In this study, no paradoxical increase in cortisol was seen in nine patients with macronodular adrenal disease, but it was observed in 3 of 15 patients with a unilateral adenoma. This delayed \"paradoxical\" response can be useful diagnostically to identify otherwise asymptomatic carriers in familial forms of PPNAD or Carney complex or to distinguish PPNAD from other adrenocortical tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/35/22072?source=see_link\">",
"     \"Cushing's syndrome due to primary pigmented nodular adrenocortical disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also rare reports of \"paradoxical\" responses to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in which cortisol secretion increased, rather than decreased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/54\">",
"     54",
"    </a>",
"    ]. However, most of these reports are poorly documented in terms of reproducibility of the response. In only one well-documented case was the cause (spontaneous variation in tumor ACTH secretion) defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37528/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    suppression tests are used to assess the status of hypothalamic-pituitary-adrenal (HPA) axis and for the differential diagnosis of adrenal cortex hyperfunction. The low-dose dexamethasone suppression tests are used to assess non-suppressible cortisol production by adrenal incidentalomas and to differentiate patients with Cushing's syndrome of any cause from patients who do not have Cushing's syndrome. The high-dose dexamethasone suppression tests help to distinguish patients with Cushing's disease (Cushing's syndrome caused by pituitary hypersecretion of corticotropin [ACTH]) from most patients with the ectopic ACTH syndrome originating from malignant tumors, but from a smaller proportion of those secondary to benign carcinoid tumors.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/1\">",
"      Loose DS, Do YS, Chen TL, Feldman D. Demonstration of glucocorticoid receptors in the adrenal cortex: evidence for a direct dexamethasone suppressive effect on the rat adrenal gland. Endocrinology 1980; 107:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/2\">",
"      Tuck ML, Sowers JR, Asp ND, et al. Mineralocorticoid response to low dose adrenocorticotropin infusion. J Clin Endocrinol Metab 1981; 52:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/3\">",
"      Cronin C, Igoe D, Duffy MJ, et al. The overnight dexamethasone test is a worthwhile screening procedure. Clin Endocrinol (Oxf) 1990; 33:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/4\">",
"      Montwill J, Igoe D, McKenna TJ. The overnight dexamethasone test is the procedure of choice in screening for Cushing's syndrome. Steroids 1994; 59:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/5\">",
"      Hindmarsh PC, Brook CG. Single dose dexamethasone suppression test in children: dose relationship to body size. Clin Endocrinol (Oxf) 1985; 23:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/6\">",
"      Pasquali R, Ambrosi B, Armanini D, et al. Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-response study. J Clin Endocrinol Metab 2002; 87:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/7\">",
"      Sahin M, Kebapcilar L, Taslipinar A, et al. Comparison of 1 mg and 2 mg overnight dexamethasone suppression tests for the screening of Cushing's syndrome in obese patients. Intern Med 2009; 48:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/8\">",
"      Meikle AW, Lagerquist LG, Tyler FH. Apparently normal pituitary-adrenal suppressibility in Cushing's syndrome: dexamethasone metabolism and plasma levels. J Lab Clin Med 1975; 86:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/9\">",
"      Blethen SL, Chasalow FI. Overnight dexamethasone suppression test: normal responses and the diagnosis of Cushing's syndrome. Steroids 1989; 54:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/10\">",
"      Wood PJ, Barth JH, Freedman DB, et al. Evidence for the low dose dexamethasone suppression test to screen for Cushing's syndrome--recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem 1997; 34 ( Pt 3):222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/11\">",
"      Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999; 84:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/12\">",
"      Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/13\">",
"      Findling JW, Raff H, Aron DC. The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome. J Clin Endocrinol Metab 2004; 89:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/14\">",
"      G&ouml;rges R, Knappe G, Gerl H, et al. Diagnosis of Cushing's syndrome: re-evaluation of midnight plasma cortisol vs urinary free cortisol and low-dose dexamethasone suppression test in a large patient group. J Endocrinol Invest 1999; 22:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/15\">",
"      Oki Y, Hashimoto K, Hirata Y, et al. Development and validation of a 0.5 mg dexamethasone suppression test as an initial screening test for the diagnosis of ACTH-dependent Cushing's syndrome. Endocr J 2009; 56:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/16\">",
"      Barrou Z, Guiban D, Maroufi A, et al. Overnight dexamethasone suppression test: comparison of plasma and salivary cortisol measurement for the screening of Cushing's syndrome. Eur J Endocrinol 1996; 134:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/17\">",
"      Moro M, Putignano P, Losa M, et al. The desmopressin test in the differential diagnosis between Cushing's disease and pseudo-Cushing states. J Clin Endocrinol Metab 2000; 85:3569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/18\">",
"      Laudat MH, Cerdas S, Fournier C, et al. Salivary cortisol measurement: a practical approach to assess pituitary-adrenal function. J Clin Endocrinol Metab 1988; 66:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/19\">",
"      Castro M, Elias PC, Quidute AR, et al. Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J Clin Endocrinol Metab 1999; 84:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/20\">",
"      Raff H, Homar PJ, Burns EA. Comparison of two methods for measuring salivary cortisol. Clin Chem 2002; 48:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/21\">",
"      Streeten DH, Stevenson CT, Dalakos TG, et al. The diagnosis of hypercortisolism. Biochemical criteria differentiating patients from lean and obese normal subjects and from females on oral contraceptives. J Clin Endocrinol Metab 1969; 29:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/22\">",
"      Isidori AM, Kaltsas GA, Mohammed S, et al. Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 2003; 88:5299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/23\">",
"      Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA 1993; 269:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/24\">",
"      Newell-Price J, Trainer P, Perry L, et al. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1995; 43:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/25\">",
"      Kennedy L, Atkinson AB, Johnston H, et al. Serum cortisol concentrations during low dose dexamethasone suppression test to screen for Cushing's syndrome. Br Med J (Clin Res Ed) 1984; 289:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/26\">",
"      Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab 2008; 93:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/27\">",
"      Meikle AW. Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone. Clin Endocrinol (Oxf) 1982; 16:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/28\">",
"      LIDDLE GW. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1960; 20:1539.",
"     </a>",
"    </li>",
"    <li>",
"     Liddle GW. The adrenals. In: Textbook of Endocrinology, Williams RW (Ed), WB Saunders, Philadelphia 1981. p.242.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/30\">",
"      Bruno OD, Rossi MA, Contreras LN, et al. Nocturnal high-dose dexamethasone suppression test in the aetiological diagnosis of Cushing's syndrome. Acta Endocrinol (Copenh) 1985; 109:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/31\">",
"      Dichek HL, Nieman LK, Oldfield EH, et al. A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1994; 78:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/32\">",
"      Tyrrell JB, Findling JW, Aron DC, et al. An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing's syndrome. Ann Intern Med 1986; 104:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/33\">",
"      Aron DC, Raff H, Findling JW. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1997; 82:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/34\">",
"      Flack MR, Oldfield EH, Cutler GB Jr, et al. Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome. Ann Intern Med 1992; 116:211.",
"     </a>",
"    </li>",
"    <li>",
"     Orth, DN. Ectopic hormone production. In: Endocrinology and Metabolism. Felig, P, Baxter, JD, Broadus, AE, Frohman, LA (Eds), McGraw-Hill, New York 1987, pp. 1692-1735.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/36\">",
"      de Keyzer Y, Lenne F, Auzan C, et al. The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. J Clin Invest 1996; 97:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/37\">",
"      Wajchenberg BL, Mendonca BB, Liberman B, et al. Ectopic adrenocorticotropic hormone syndrome. Endocr Rev 1994; 15:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/38\">",
"      Abou Samra AB, Dechaud H, Estour B, et al. Beta-lipotropin and cortisol responses to an intravenous infusion dexamethasone suppression test in Cushing's syndrome and obesity. J Clin Endocrinol Metab 1985; 61:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/39\">",
"      Jung C, Alford FP, Topliss DJ, et al. The 4-mg intravenous dexamethasone suppression test in the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 2010; 73:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/40\">",
"      Croughs RJ, Docter R, de Jong FH. Comparison of oral and intravenous dexamethasone suppression tests in the differential diagnosis of Cushing's syndrome. Acta Endocrinol (Copenh) 1973; 72:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/41\">",
"      Biemond P, de Jong FH, Lamberts SW. Continuous dexamethasone infusion for seven hours in patients with the Cushing syndrome. A superior differential diagnostic test. Ann Intern Med 1990; 112:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/42\">",
"      Atkinson AB, McAteer EJ, Hadden DR, et al. A weight-related intravenous dexamethasone suppression test distinguishes obese controls from patients with Cushing's syndrome. Acta Endocrinol (Copenh) 1989; 120:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/43\">",
"      Bailey RE. Periodic hormonogenesis--a new phenomenon. Periodicity in function of a hormone-producing tumor in man. J Clin Endocrinol Metab 1971; 32:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/44\">",
"      Brown RD, Van Loon GR, Orth DN, Liddle GW. Cushing's disease with periodic hormonogenesis: one explanation for paradoxical response to dexamethasone. J Clin Endocrinol Metab 1973; 36:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/45\">",
"      Scott RS, Espiner EA, Donald RA. Intermittent Cushing's disease with spontaneous remission. Clin Endocrinol (Oxf) 1979; 11:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/46\">",
"      Hermus AR, Pieters GF, Borm GF, et al. Unpredictable hypersecretion of cortisol in Cushing's disease: detection by daily salivary cortisol measurements. Acta Endocrinol (Copenh) 1993; 128:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/47\">",
"      Dimaraki EV, Jaffe CA. Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test. J Clin Endocrinol Metab 2003; 88:3113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/48\">",
"      Ma RC, Chan WB, So WY, et al. Carbamazepine and false positive dexamethasone suppression tests for Cushing's syndrome. BMJ 2005; 330:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/49\">",
"      Selvais P, Donckier J, Buysschaert M, Maiter D. Cushing's disease: a comparison of pituitary corticotroph microadenomas and macroadenomas. Eur J Endocrinol 1998; 138:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/50\">",
"      Woo YS, Isidori AM, Wat WZ, et al. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 2005; 90:4963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/51\">",
"      Katznelson L, Bogan JS, Trob JR, et al. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab 1998; 83:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/52\">",
"      al-Saadi N, Diederich S, Oelkers W. A very high dose dexamethasone suppression test for differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1998; 48:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/53\">",
"      Stratakis CA, Sarlis N, Kirschner LS, et al. Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. Ann Intern Med 1999; 131:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37528/abstract/54\">",
"      Fehm HL, Voight KH, Lang RE, et al. Paradoxical ACTH response to glucocorticoids in Cushing's disease. N Engl J Med 1977; 297:904.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 160 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37528=[""].join("\n");
var outline_f36_41_37528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEXAMETHASONE SUPPRESSION TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dexamethasone and steroid measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Low-dose dexamethasone suppression tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Overnight screening test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Standard two-day, 2 mg test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Diagnostic accuracy of low-dose dexamethasone tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Serum dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      High-dose dexamethasone suppression tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Overnight 8 mg test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Standard two-day, 8 mg test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intravenous dexamethasone suppression tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SOURCES OF ERROR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Unusual responses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Paradoxical responses to dexamethasone in primary pigmented nodular adrenocortical disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/55/9082?source=related_link\">",
"      Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35190?source=related_link\">",
"      Calculation of the creatinine clearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/35/22072?source=related_link\">",
"      Cushing's syndrome due to primary pigmented nodular adrenocortical disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/132?source=related_link\">",
"      Measurement of cortisol in serum and saliva",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=related_link\">",
"      The adrenal incidentaloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_41_37529="ECD lesion biopsy";
var content_f36_41_37529=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erdheim-Chester disease lesion biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The figure demonstrates a representative hematoxylin/eosin-stained ECD lesion biopsy sample from a retroperitoneal, perinephric infiltrate (400x magnification). It shows the bland histiocytic infiltrate with foamy (xanthomatous) cytoplasm and interspersed inflammatory cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Allen CE, McClain KL. Erdheim-Chester: beyond the lesion. Blood 2011; 117:2745. Copyright &copy; 2011 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37529=[""].join("\n");
var outline_f36_41_37529=null;
var title_f36_41_37530="Treatment of idiopathic membranous nephropathy";
var content_f36_41_37530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of idiopathic membranous nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/41/37530/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/41/37530/contributors\">",
"     Daniel C Cattran, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/41/37530/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/41/37530/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/41/37530/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/41/37530/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/41/37530/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranous nephropathy (MN) is among the most common causes of the nephrotic syndrome in nondiabetic adults, accounting for up to one-third of biopsy diagnoses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MN in adults is most often idiopathic (approximately 75 percent of cases) but can be caused by a variety of drugs, infections, and underlying diseases. These include gold,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , systemic lupus erythematosus, malignancy, and hepatitis B and C virus infection (",
"    <a class=\"graphic graphic_table graphicRef80418 \" href=\"mobipreview.htm?14/6/14443\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is often not possible to distinguish idiopathic from secondary MN on clinical grounds alone, even though serologic studies (eg, antinuclear antibodies, hepatitis B serology) and a history of drug exposure or cancer may be revealing of a potential cause. However there are certain findings on electron microscopy and immunofluorescence that suggest secondary disease. In patients with secondary MN, cessation of the offending drug or effective treatment of the underlying disease is usually associated with improvement in the nephrotic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link\">",
"     \"Causes and diagnosis of membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of idiopathic MN, beginning with a review of the natural history and risk factors for progressive disease, will be presented here. The clinical trials supporting the efficacy of initial immunosuppressive regimens and the effectiveness of alternative agents in unresponsive patients are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/39/12918?source=see_link\">",
"     \"Alternative agents in the treatment of idiopathic membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the potential toxicity of the drugs used to treat idiopathic membranous nephropathy (MN), with or without the nephrotic syndrome, the decision to initiate therapy is based, in part, upon an understanding of the natural history of untreated patients, with and without features of the nephrotic syndrome at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spontaneous complete remission of proteinuria occurs in 5 to 30 percent at five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/2-4\">",
"       2-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Spontaneous partial remission (&le;2 g of proteinuria per day) occurs in 25 to 40 percent at five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/2-4\">",
"       2-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The occurrence of end-stage renal disease in untreated patients is approximately 14 percent at five years, 35 percent at 10 years, and 41 percent at 15 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/1,4\">",
"       1,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relatively benign short-term course in many patients with idiopathic MN was illustrated in a report of 100 consecutive patients who received no immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence of spontaneous remission increased over time. Of the 37 patients followed for at least five years, 65 percent were in complete or partial remission, and 16 percent had progressed to end-stage renal disease (",
"    <a class=\"graphic graphic_figure graphicRef61059 \" href=\"mobipreview.htm?30/50/31533\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most of the patients in this study had only mild to moderate disease. At baseline, the mean serum creatinine was 1.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (97",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    only 41 percent had edema, 37 percent were nonnephrotic (protein excretion less than 3.5",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    and 56 percent excreted less than 5 g of protein per day. However, a high rate of spontaneous remission was also seen in the 34 patients who excreted 5 to 10 g of protein per day at baseline; mean protein excretion was 1.0",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    at the end of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors for progressive idiopathic MN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the often benign clinical course, immunosuppressive agents should be considered only in those with idiopathic MN who are most at risk for progressive disease or who have severe symptomatic nephrotic syndrome. Both histologic and clinical findings may be important in risk assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical findings associated with a higher risk of developing end-stage renal disease include older age at onset (particularly greater than 50 years), male sex, nephrotic range proteinuria (particularly if protein excretion exceeds 8 to 10",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    and an increased serum creatinine at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/2,5-10\">",
"     2,5-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to these adverse risk factors, women, children, and young adults, nonnephrotic range proteinuria, a progressive decline in protein excretion, and presentation with normal renal function have been associated with a relatively benign course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/1,3,11-13\">",
"     1,3,11-13",
"    </a>",
"    ]. In addition, patients of Asian ancestry seem to have a better long-term prognosis than other ancestries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following studies illustrate the prognostic importance of certain clinical features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/5,8-10,12-14\">",
"     5,8-10,12-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 184 patients with idiopathic MN from Toronto, Canada the overall likelihood of progressing to a creatinine clearance &le;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      was 26 percent at a mean follow-up of 5.8 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/8\">",
"       8",
"      </a>",
"      ]. In contrast, the risk was 66 percent in patients with proteinuria exceeding 8",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for more than six months.",
"     </li>",
"     <li>",
"      Among 949 nephrotic patients from Japan with idiopathic MN, the overall rates of renal survival (defined as serum creatinine less than 3.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [265",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      were 96, 90, 81, and 61 percent at 5, 10, 15, and 20 years after diagnosis, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/5\">",
"       5",
"      </a>",
"      ]. On multivariate analysis, significant predictors at presentation of progression to end-stage renal disease were male gender, age greater than 60 years, serum creatinine concentration &ge;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&le;133",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      and tubulointerstitial lesions &ge;20 percent of the renal biopsy area.",
"     </li>",
"     <li>",
"      Among 108 patients from Toronto who presented with subnephrotic proteinuria (defined as less than 3.5",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      mean 2.2",
"      <span class=\"nowrap\">",
"       g/day),",
"      </span>",
"      40 percent remained subnephrotic and 60 percent developed nephrotic range proteinuria. The median follow-up time was 55 months in the former group and 82 months in the latter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/13\">",
"       13",
"      </a>",
"      ]. The patients who did develop nephrotic range proteinuria had a modestly but statistically significant higher rate of proteinuria at baseline (2.4 versus 2.0",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      and a significantly higher rate of loss of estimated glomerular filtration rate (following development of nephrotic range proteinuria) during follow-up (3.5 versus 0.9",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year).",
"      <br/>",
"      <br/>",
"      Approximately 70 percent of patients who developed nephrotic range proteinuria did so within the first year. This probably explains why the rate of loss of renal function in these patients was similar to that in 287 patients who had nephrotic range proteinuria at presentation.",
"     </li>",
"     <li>",
"      In one study, among 328 patients with nephrotic range proteinuria, a greater than 50 percent reduction in protein excretion at one year predicted eventual spontaneous remission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review of the literature analyzed the evidence concerning the clinical significance of the above risk factors for progressive deterioration of renal function among patients with idiopathic MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/11\">",
"     11",
"    </a>",
"    ]. The following conclusions were drawn:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with persistent normal renal function at three years have a favorable prognosis and are unlikely to benefit from therapy. However, it is unclear if treatment should be withheld until patients display evidence of deteriorating renal function.",
"     </li>",
"     <li>",
"      A good prognosis is also associated with female sex, younger age at onset, the absence of glomerular scarring (segmental sclerosis) and tubulointerstitial disease on renal biopsy, and nonnephrotic range proteinuria.",
"     </li>",
"     <li>",
"      An extended duration (eg, six months) of heavy proteinuria has a poor prognosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Probability of progression'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Histologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic findings are frequently regarded as important predictors of outcome, as the risk of progression is increased in patients with glomerular scarring (segmental sclerosis) and correlates more closely with the severity of the tubulointerstitial disease than with the degree of glomerular injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/5,15,16\">",
"     5,15,16",
"    </a>",
"    ]. This observation is typical of most glomerular diseases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Tubulointerstitial fibrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More marked tubulointerstitial disease is often associated with older age, higher mean arterial pressure, and lower creatinine clearance at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, although tubulointerstitial disease severity is associated with reduced renal survival, it may not predict this outcome independent of baseline clinical variables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Importance of attaining remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attainment of a complete remission (whether spontaneous or not) is associated with good long-term outcomes. In contrast, little is known about the prognosis in patients with a partial remission.",
"   </p>",
"   <p>",
"    The prognostic importance of attaining remission was best evaluated in a study cohort of 348 patients with nephrotic syndrome due to idiopathic MN from Toronto: 39 percent received no immunosuppressive therapy, 45 percent received one immunosuppressive drug, and 16 percent received combined immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A complete remission was defined as protein excretion below 0.3",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    while a partial remission was defined as protein excretion below 3.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    plus a 50 percent or greater reduction in protein excretion from the peak value (for example, a patient with a peak value of 8.0",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    who experiences a decline to a value of 4.0",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    has not experienced a remission). Renal failure was defined as a creatinine clearance &le;15",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    initiation of dialysis, or renal transplantation. Five patients had renal failure at initial assessment and were excluded from the analysis.",
"   </p>",
"   <p>",
"    Over the five-year mean observation period, a complete, partial, or no remission was realized in 102, 136, and 110 patients (29, 39, and 32 percent), respectively. The mean time to complete remission was 30 months, and the mean time to partial remission was 23 months.",
"   </p>",
"   <p>",
"    At a median follow-up of five years, the following findings were associated with a better renal survival on multivariate analysis that took into account clinical and laboratory data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher initial creatinine clearance and lower proteinuria at presentation.",
"     </li>",
"     <li>",
"      Lower mean arterial blood pressure over the observation period.",
"     </li>",
"     <li>",
"      Attainment of complete or partial remission in proteinuria. None of the 32 patients who attained complete remission developed renal failure during follow-up, while a partial remission was independently associated with a slower decrease in renal function over time (-0.17 versus -0.86",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per month with no remission) and a lower incidence of renal failure (9 versus 29 percent, adjusted hazard ratio 0.17).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the heterogeneity of regimens and the high frequency of spontaneous remission, conclusions could not be reached regarding specific treatment groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Probability of progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon a study of 184 patients identified through the Toronto Glomerulonephritis Registry, a semiquantitative algorithm has been developed to predict the probability of progression to chronic kidney disease, which was defined as a creatinine clearance &le;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/8\">",
"     8",
"    </a>",
"    ]. The probability of progression was assessed for those with 4, 6, and 8",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of proteinuria that persisted for 6, 9, 12, or 24 months.",
"   </p>",
"   <p>",
"    Multiple additional variables (including age, sex, serum creatinine, and creatinine clearance on presentation, serum albumin, presence of hypertension, rate of change of creatinine clearance, and therapy) were also tested to determine whether the predictive value provided by proteinuria could be improved. Of these variables, the initial creatinine clearance and the rate of change of clearance were the most useful predictors.",
"   </p>",
"   <p>",
"    Based upon this approach, the best fitting logistic model utilized the following clinical characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent proteinuria for over six months",
"     </li>",
"     <li>",
"      Creatinine clearance upon presentation",
"     </li>",
"     <li>",
"      Slope of the decline in creatinine clearance over the assessed proteinuria period",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The addition of renal pathology as a variable had no effect on the performance of the model.",
"   </p>",
"   <p>",
"    This model was tested in two additional populations of patients identified through the Italian Idiopathic Membranous Nephropathy Study group (110 patients) and a database obtained from Helsinki University (84 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/9\">",
"     9",
"    </a>",
"    ]. The accuracy in predicting the development of chronic renal insufficiency was 85, 87, and 79 percent in populations from Toronto, Finland, and Italy, respectively. This was higher than the predictive value of proteinuria &gt;3.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    at the time of biopsy, which was only 52, 43, and 34 percent, respectively, in the same populations.",
"   </p>",
"   <p>",
"    Based upon the best fitting logistic model, the following are examples of the risk of progression to a creatinine clearance &le;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    for patients with specific clinical characteristics over a follow-up period of more than five years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk is only 6 percent for the patient with proteinuria &lt;3.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      and stable normal renal function over six months.",
"     </li>",
"     <li>",
"      The risk increases to 72 percent in the patient with proteinuria of 12",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      and a creatinine clearance on presentation of 96",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      which declines to 78",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      by six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon this model, we define low-, moderate-, and high-risk patient subsets with varying degrees of risk for progression to more advanced kidney insufficiency (defined as a creatinine clearance &le;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ) over five years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk &ndash; Proteinuria remains less than 4",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      and creatinine clearance remains normal for a six-month follow-up period. Such patients have a less than 8 percent risk of developing chronic renal insufficiency over five years.",
"     </li>",
"     <li>",
"      Moderate risk &ndash; Proteinuria is between 4 and 8",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      and persists for more than six months. Creatinine clearance is normal or near normal and remains stable over six months of observation. Chronic renal insufficiency develops over five years in approximately 50 percent of these patients.",
"     </li>",
"     <li>",
"      High risk &ndash; Proteinuria is greater than 8",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      and persists for three months",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal function that is either below normal (and considered due to MN) or decreases during the observation period. Approximately 75 percent of such patients are at risk of progression to chronic renal insufficiency over five years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This risk stratification applies only to the likelihood of progressive renal failure. It does not take into account the risks that may be associated with other complications of the nephrotic syndrome, such as worsening atherosclerosis due to hypercholesterolemia and thromboemboli due to the associated hypercoagulable state. Thus, in addition to preservation of renal function, immunosuppressive therapy may be beneficial by shortening the overall exposure to the nephrotic state, thereby minimizing the risk of other complications. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Lipid-lowering'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Anticoagulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acute decline in renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive MN typically occurs gradually. Some patients develop an acute decline in renal function and at least three disorders should be excluded in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute bilateral renal vein thrombosis which may be associated with flank pain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"       \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-induced acute interstitial nephritis, in which white cell, white cell casts, and possibly eosinophils are typically seen in the urine sediment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27209?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute interstitial nephritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Superimposed crescentic glomerulonephritis, in which red cells and cellular casts are found in the urine sediment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link\">",
"       \"Causes and diagnosis of membranous nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Secondary MN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with secondary MN, cessation of the offending drug (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , gold, or nonsteroidal anti-inflammatory drug) or effective treatment of the underlying disease is usually associated with improvement in the nephrotic syndrome. With penicillamine or gold associated disease, protein excretion may continue to rise for the first 1 to 12 months (mean 2 months) after the offending drug has been discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The mean time to resolution of proteinuria is 9 to 12 months, although two to three years is required in some cases. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link\">",
"     \"Causes and diagnosis of membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     NONIMMUNOSUPPRESSIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high rate of gradual spontaneous improvement in patients with idiopathic membranous nephropathy (MN) (",
"    <a class=\"graphic graphic_figure graphicRef61059 \" href=\"mobipreview.htm?30/50/31533\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], only selected patients with more severe or progressive disease should receive immunosuppressive therapy. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Immunosuppressive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast, almost all patients are candidates for more general therapies for nephrotic syndrome, such as angiotensin inhibition, lipid-lowering, and, in selected patients, anticoagulation. Other aspects of therapy include diuretics to control edema and maintenance of adequate nutrition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of an ACE inhibitor or an angiotensin II receptor blocker (ARB) is recommended in virtually all patients with proteinuric chronic kidney disease since such therapy may significantly reduce the rate of disease progression, acting at least in part by lowering the intraglomerular pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evidence for a renal protective effect with an ACE inhibitor or an ARB is relatively weak among patients with MN. Possible benefits with use of an ACE inhibitor or ARB were noted in a study from the Spanish Group for the Study of Glomerular Disease (GLOSEN), which retrospectively examined the outcomes of 328 patients with MN and nephrotic range proteinuria (&gt;3.5",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/12\">",
"     12",
"    </a>",
"    ]. Although none were treated with immunosuppressive medication, 67 percent of patients received either an ACE inhibitor or ARB and 32 percent developed complete or partial remission, defined as reduction of protein excretion to &lt;0.3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in at least three consecutive visits, or to &lt;3.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    with normal serum albumin, respectively. The mean time to achieve partial or complete remission was approximately 15 and 39 months. However, because this was not a randomized controlled trial, it is not possible to draw definitive conclusions about the benefit of ACE inhibitors or ARBs on the frequency of spontaneous remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/20\">",
"     20",
"    </a>",
"    ]. Furthermore there was a significant rise in the serum creatinine among patients who did not remit in this study, suggesting that there is a significant hazard associated with withholding immunosuppressive therapy in all patients while waiting for spontaneous remission.",
"   </p>",
"   <p>",
"    Other observations from this study were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remission was more frequent with lower baseline proteinuria: 37, 26, and 22 percent among those with baseline protein excretion &lt;8, 8 to 12, and &gt;12",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      The chances of achieving remission were higher among patients treated with ACE inhibitor or an ARB compared to those who were not: 22, 33 and 36 percent compared to 11, 14, and 19 percent at 1, 2, and 3 years, respectively. These differences were only significant among patients who had protein excretion &lt;8",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      but were not observed among those with more severe proteinuria.",
"     </li>",
"     <li>",
"      Independent predictors for remission included baseline serum creatinine, baseline protein excretion, and &gt;50 percent reduction in protein excretion at one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, limited data from other trials in small numbers of patients with idiopathic MN suggest that the antiproteinuric response and slowing of disease progression is less in MN than in other glomerular diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/17,21,22\">",
"     17,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10654384\">",
"    <span class=\"h2\">",
"     Proteinuria goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal proteinuria goal in patients with chronic kidney disease is less than 1000",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H149378842#H149378842\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Proteinuria goal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, this goal is often not attainable in patients with idiopathic MN. As noted above, the renal prognosis in idiopathic MN is markedly improved in patients who attain at least partial remission of proteinuria, defined as protein excretion below 3.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    <strong>",
"     plus",
"    </strong>",
"    a 50 percent or greater reduction in protein excretion from the peak value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/17\">",
"     17",
"    </a>",
"    ]. Partial remission was independently associated with a slower decrease in renal function over time (-0.17 versus -0.86",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per month with no remission) and a lower incidence of renal failure (9 versus 29 percent, adjusted hazard ratio 0.17). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Importance of attaining remission'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Attainment of partial remission can result from one or more of the following: angiotensin inhibition, immunosuppressive therapy, and spontaneous remission, which is not uncommon in idiopathic MN (",
"    <a class=\"graphic graphic_figure graphicRef61059 \" href=\"mobipreview.htm?30/50/31533\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Natural history'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Goal blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal blood pressure in patients with any form of proteinuric chronic kidney disease is less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg, or perhaps lower. Attainment of this goal can slow the progression of proteinuric chronic kidney disease and can provide cardiovascular protection since chronic kidney disease is associated with a marked increase in cardiovascular risk. The data supporting these recommendations are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link&amp;anchor=H13#H13\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Blood pressure control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Attainment of the blood pressure goal in patients with MN usually requires more than angiotensin inhibition alone. Correction of volume overload is of particular importance and usually requires loop diuretics. Diuretics should be pushed until the blood pressure goal is reached or the patient has attained \"dry weight\" which, in the presence of persistent hypertension, is defined as the weight at which further fluid removal leads to symptoms (fatigue, orthostatic hypotension) or to decreased tissue perfusion as evidenced by an otherwise unexplained elevation in the blood urea nitrogen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum creatinine concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of hypertension in acute and chronic kidney disease\", section on 'Choice of antihypertensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A low-salt diet is an important component of antihypertensive therapy (especially when using angiotensin inhibitors) and edema control in patients with MN. In addition, a high salt diet can increase proteinuria, and in some individuals, a high salt diet rather than increased immunologic activity should be considered as an underlying cause of worsening proteinuria. (See",
"    <a class=\"local\" href=\"#H441807498\">",
"     'Exclusion of high salt intake'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H10#H10\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Importance of salt intake'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Lipid-lowering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperlipidemia, with often dramatic elevations in the serum cholesterol concentration, is commonly present in patients with nephrotic syndrome. The mainstay of therapy for such hypercholesterolemia is statins. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=see_link\">",
"     \"Statins and chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nephrotic syndrome, particularly those with MN, are at increased risk for thrombotic events, such as deep vein and renal vein thrombosis or pulmonary embolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk in MN was illustrated in a series of 898 patients in the Glomerular Disease Collaborative Network and the Toronto Glomerulonephritis Registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/23\">",
"     23",
"    </a>",
"    ]. Clinically evident and radiologically confirmed venous thromboembolic events occurred in 7.2 percent of patients. The median time to the first thromboembolic event was 3.8 months; 74 percent occurred within the first two years of diagnosis and 86 percent occurred within three years. A low serum albumin concentration at the time of diagnosis, but not the degree of proteinuria, independently predicted a venous thromboembolic event. Compared with patients who had a serum albumin concentration greater than 2.8",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    the risk of an event was 2.5-fold greater in patients with a serum albumin concentration below 2.8",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p>",
"    All patients who have a thromboembolic event should be treated initially with low molecular weight or unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , followed by oral anticoagulation (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ), the same regimen used for patients without nephrotic syndrome who have deep vein thrombosis or a pulmonary embolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H42#H42\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue is the possible role of prophylactic anticoagulation in patients at high risk for thromboembolism. This issue, including the definition of high risk, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link&amp;anchor=H14#H14\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\", section on 'Prophylactic anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     IMMUNOSUPPRESSIVE THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Indications for and choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since many patients with mild to moderate disease undergo spontaneous remission (",
"    <a class=\"graphic graphic_figure graphicRef61059 \" href=\"mobipreview.htm?30/50/31533\">",
"     figure 1",
"    </a>",
"    ) and immunosuppressive agents have appreciable toxicity, the decision to treat must be based upon the probability that the patient will have progressive disease (defined as an otherwise unexplained elevation in serum creatinine or persistent high-grade or increasing proteinuria in patients at moderate to high risk for progression) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We tailor our treatment regimen based upon the risk of progressive disease, using the algorithm described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/8,9,25\">",
"     8,9,25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Probability of progression'",
"    </a>",
"    above.) First-line immunosuppressive therapy consists of cytotoxic drugs (usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) plus glucocorticoids or a calcineurin inhibitor with low-dose or no glucocorticoids (a regimen based upon cytotoxic drugs is preferred in some high-risk patients with declining glomerular filtration rate due to MN and an estimated glomerular filtration rate above 30",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    ). Patients who do not respond to one regimen are usually treated with the other, and those with resistant disease may be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . These recommendations are broadly similar to those made by the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence supporting the efficacy of this approach will be presented below. Alternative immunosuppressive for which there is less evidence of benefit, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/39/12918?source=see_link\">",
"     \"Alternative agents in the treatment of idiopathic membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Measurement of protein excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the following sections, risk stratification into low, moderate, and high risk for progression is based upon the degree of proteinuria obtained on a 24-hour collection and on the glomerular filtration rate as estimated from the creatinine clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. A random urine protein-to-creatinine ratio should",
"    <strong>",
"     not",
"    </strong>",
"    be used for initial risk stratification since the relationship between the ratio and 24-hour protein excretion varies widely among patients (",
"    <a class=\"graphic graphic_figure graphicRef63722 \" href=\"mobipreview.htm?33/38/34413\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, the urine protein-to-creatinine ratio may be performed serially to detect changes in protein excretion (either spontaneously or after therapy) over time. We determine the ratio from an overnight collection, not a random specimen. However, when therapeutic decisions will be made from the degree of proteinuria, we perform a 24-hour collection for protein excretion and creatinine clearance since the criteria to treat or not to treat are based upon studies using 24-hour collections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Low risk for progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a low risk for progressive disease among asymptomatic patients with normal renal function and protein excretion that remains less than 4.0",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    on a 24-hour urine collection for a six-month observation period. Such patients should",
"    <strong>",
"     not",
"    </strong>",
"    be treated with immunosuppressive therapy as long they have subnephrotic proteinuria since they have an excellent long-term prognosis and often undergo spontaneous partial or complete remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/2-4,13,27\">",
"     2-4,13,27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Probability of progression'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Such patients should be treated with appropriate nonimmunosuppressive therapy (as described above) and monitored periodically for disease progression. We suggest clinical assessment and measurement of urinary protein excretion and serum creatinine every three months for two years and twice yearly thereafter since the risk of developing progressive disease falls significantly after two years. The rationale for prolonged monitoring for disease progression was provided by a review of 395 patients with membranous nephropathy (MN), 108 of whom (27 percent) presented with subnephrotic proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/13\">",
"     13",
"    </a>",
"    ]. Among these patients, 66 (61 percent) progressed to nephrotic syndrome; of these, 46 patients (70 percent) progressed within the first year, 11 (18 percent) progressed between years 1 to 4, and 9 patients (13 percent) progressed after year 4 (19 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Moderate risk for progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at moderate risk for progression have the following clinical features that persist for over six months: protein excretion between 4.0 and 8.0",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    on a 24-hour urine collection, normal or near normal renal function (defined as creatinine clearance &ge;80",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    and asymptomatic disease or edema controlled by diuretics.",
"   </p>",
"   <p>",
"    As previously mentioned, up to 45 percent of such patients undergo spontaneous complete or partial remission over a period of three to six years (",
"    <a class=\"graphic graphic_figure graphicRef61059 \" href=\"mobipreview.htm?30/50/31533\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Spontaneous remission is most likely in women, children, those with lesser amounts of proteinuria, and adults under age 50 with a normal serum creatinine concentration and benign histologic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/1-3,8\">",
"     1-3,8",
"    </a>",
"    ]. Although unproven, the rate of partial remission may be higher with the use of ACE inhibitors or ARBs. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Angiotensin inhibition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several trials have assessed the effect of immunosuppressive agents in patients with idiopathic MN. The efficacy of combination regimens using glucocorticoids plus either cytotoxic therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ) or a calcineurin inhibitor therapy is summarized below. In contrast, glucocorticoids alone are",
"    <strong>",
"     not",
"    </strong>",
"    effective, with the possible exception of Japanese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of other drugs have been tried in the treatment of patients at moderate risk of progression but are not considered first-line agents. These include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, intravenous immunoglobulin and synthetic adrenocorticotropic hormone (ACTH).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    may be of benefit in patients with resistant MN. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Resistant disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/39/12918?source=see_link\">",
"     \"Alternative agents in the treatment of idiopathic membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Cytotoxic therapy plus glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three randomized prospective trials that primarily enrolled patients who would be categorized as having moderate risk for progression found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , both given with glucocorticoids, are effective in inducing remission of proteinuria and preventing progression to end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/3,4,28\">",
"     3,4,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two of the trials, mostly of patients with moderate disease (mean protein excretion 6",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in one), reported 10-year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The patients receiving immunosuppressive therapy had significantly higher rates of complete or partial remission (88 versus 47 percent and 72 versus 34 percent with symptomatic therapy alone) and a higher rate of surviving without end-stage renal disease (92 versus 60 percent and 89 versus 65 percent). Partial remission was defined as a normal serum creatinine plus protein excretion less than 2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    or, in one trial, more than 50 percent less than baseline, whichever was lower. In one of the trials, 15 of the 46 patients assigned to supportive therapy alone chose to have immunosuppressive therapy at 2 to 4.5 years after initial randomization; seven of these patients attained complete or partial remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, the true rate of remission with symptomatic therapy alone was 20 percent, not 34 percent.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    -based regimens are equally effective, as noted in a randomized head-to-head comparative trial that primarily enrolled moderate-risk patients (mean protein excretion 7 to 8",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and mean serum creatinine 1.05",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [93",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/28\">",
"     28",
"    </a>",
"    ]. However, since chlorambucil has more side effects, we prefer administering the cyclophosphamide-based regimen. Most studies evaluating cytotoxic therapy have included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and it is the clinical impression of many clinicians that cyclophosphamide alone is likely to be less beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/3,25,29\">",
"     3,25,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the lower rate of toxicity with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , the preferred regimen is oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (0.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) given for months 1, 3, and 5 plus oral cyclophosphamide (2.0 to 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) given for months 2, 4, and 6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/4,28\">",
"     4,28",
"    </a>",
"    ]. The glucocorticoid months begin with pulse methylprednisolone, 1 g intravenously daily for three days, without oral prednisone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    have proven efficacy in patients with idiopathic MN. Cyclosporine plus low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (maximum of 10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is effective in inducing remission of proteinuria and in preventing progression to end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. The best data are from a randomized trial of 51 patients (mean protein excretion 9.3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and mean serum creatinine 1.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [106",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    who were unresponsive to at least an eight-week course of daily glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/30\">",
"     30",
"    </a>",
"    ]. The patients were assigned to prednisone (0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    up to a maximum dose of 15",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus either placebo or cyclosporine (dose adjusted to maintain a trough blood level of 125 to 225",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    for 26 weeks.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -treated group had a significantly higher rate of complete (&le;300",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or partial remission of proteinuria, which was defined as less than 3.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    plus at least a 50 percent reduction from baseline (75 versus 22 percent with placebo). Renal function was the same in both groups. One year after the cessation of therapy, relapse of proteinuria was common, but 39 percent of treated patients were still in remission, compared to 13 percent with placebo. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Relapsing disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    is an alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    since outcomes appear to be similar. Tacrolimus is less commonly associated with some of the side effects observed with cyclosporine, such as hirsutism or gingival hypertrophy. On the other hand, there is more clinical experience with cyclosporine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (without glucocorticoids) was demonstrated in a randomized trial of 48 patients with MN who were treated with tacrolimus (0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 12 months with a six-month taper) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/33\">",
"     33",
"    </a>",
"    ]. The rate of complete or partial remission was significantly higher with tacrolimus at both 12 months (82 versus 24 percent) and 18 months (94 versus 35 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Summary of moderate risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at moderate risk for progression have protein excretion between 4.0 and 8.0",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    obtained on a 24-hour collection, which persists for six months, normal or near normal renal function (defined as creatinine clearance &ge;80",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    and asymptomatic disease or edema controlled by diuretics.",
"   </p>",
"   <p>",
"    As mentioned above, up to 45 percent of such patients will undergo spontaneous partial or complete remission over three to four years (",
"    <a class=\"graphic graphic_figure graphicRef61059 \" href=\"mobipreview.htm?30/50/31533\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Since immunosuppressive therapy has potentially serious side effects and is associated with an appreciable relapse rate, we suggest close monitoring without the administration of immunosuppressive medications for six months in patients at moderate risk for progression, providing renal function remains stable and edema is controlled with diuretics. Subsequent therapy varies with the course of the disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We do not initiate immunosuppressive therapy if protein excretion spontaneously or as a consequence of angiotensin inhibition falls to less than 4",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"     </li>",
"     <li>",
"      Among patients who do not have a decline in 24-hour protein excretion to less than 4 g by six months, we suggest continuation of nonimmunosuppressive therapies and initiation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      plus glucocorticoids, or either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      plus glucocorticoids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, other experts would continue to withhold immunosuppressive therapy beyond six months in patients who continue to show a progressive reduction in proteinuria, even though protein excretion remains above 4",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    This strategy is based upon the observation that an appreciable number of these patients eventually undergo spontaneous remission (",
"    <a class=\"graphic graphic_figure graphicRef61059 \" href=\"mobipreview.htm?30/50/31533\">",
"     figure 1",
"    </a>",
"    ) and will therefore avoid the potential adverse effects of immunosuppressive therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    -glucocorticoid and calcineurin inhibitor-glucocorticoid regimens appear to have similar efficacy, although relapses seem to be more common with calcineurin inhibitors. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Relapsing disease'",
"    </a>",
"    below.) The choice between these regimens can depend upon a variety of factors, including patient preference. As an example, a woman of child-bearing age may want to avoid cyclophosphamide because of its fertility risk, while an older patient with hypertension may prefer to avoid the vascular side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link&amp;anchor=H9#H9\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Female gonadal toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If cytotoxic therapy is chosen, there is a lower rate of toxicity with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      . The preferred regimen is oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (0.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) given for months 1, 3, and 5 plus oral cyclophosphamide (2.0 to 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) given for months 2, 4, and 6 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/4,28\">",
"       4,28",
"      </a>",
"      ]. The glucocorticoid months begin with pulse methylprednisolone, 1 g intravenously daily for three days, without oral prednisone.",
"     </li>",
"     <li>",
"      Either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      are options if a calcineurin inhibitor-based approach is chosen. The preferred regimen for cyclosporine is treatment for at least six months at a dose of 3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in two divided doses to maintain whole blood trough levels of 120 to 200",
"      <span class=\"nowrap\">",
"       mcg/L;",
"      </span>",
"      some investigators would also initiate therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      given every other day (maximum 10 mg every other day). More prolonged cyclosporine use may be associated with nephrotoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/34\">",
"       34",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Subsequent therapy is based upon the initial response:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among those with a complete remission (protein excretion &le;300",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      we gradually taper the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      dose with therapy being discontinued after at least two to four months.",
"     </li>",
"     <li>",
"      Among those with a partial remission (protein excretion less than 3.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      plus at least a 50 percent reduction from baseline), we start to reduce the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      dose to the minimally nephrotoxic range of 1.5 to 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, which is given for at least one to two years. The duration of therapy is based upon an ongoing assessment of the benefits and risks. Relapse of proteinuria can occur after cyclosporine is discontinued. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Relapsing disease'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      -based approach is chosen for initial therapy, the preferred regimen is 0.05",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in two divided doses to maintain whole blood trough levels between 3 and 5",
"      <span class=\"nowrap\">",
"       mcg/L.",
"      </span>",
"      The dose may be increased to achieve a higher trough level between 5 and 8",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      if there is no reduction in proteinuria by two months, providing the renal function has not worsened.",
"      <br/>",
"      <br/>",
"      Among patients who attain a complete or partial remission, tacrolimus should be continued for 12 months and then tapered over 6 months (reducing the dose by 25 percent every 2 months to zero). Monitoring is the same as with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    should be discontinued if no response occurs by four to six months. In addition, patients who do not respond to one of these drugs are unlikely to respond to the other.",
"   </p>",
"   <p>",
"    Patients treated with either a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or a calcineurin inhibitor-based regimen are considered unresponsive if a substantial reduction in proteinuria (30 to 50 percent from peak levels) is not observed after six months of therapy. In such patients, we consider the other regimen, such as cyclophosphamide and glucocorticoids in those initially treated with a calcineurin inhibitor. There are no published studies that have assessed the effectiveness of this strategy, although it appears to be successful in our personal experience. Among patients who do not respond to initial cyclophosphamide plus glucocorticoid therapy, we usually wait three to six months after the cessation of cytotoxic therapy before initiating a calcineurin inhibitor, unless the patient has severe symptoms or a rise in serum creatinine.",
"   </p>",
"   <p>",
"    Some patients fail treatment with both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and calcineurin inhibitor-based regimens. The treatment of such patients is discussed below. (See",
"    <a class=\"local\" href=\"#H41\">",
"     'Resistant patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     High risk for progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-risk patients with idiopathic MN are defined as those with protein excretion exceeding 8",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    that persists for more than three months",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal function that is either below normal (and considered due to MN) or decreases during the observation period, despite maximum nonimmunosuppressive therapy. These patients are also likely to have prominent nephrotic symptoms or signs, such as marked hypoalbuminemia and edema. Approximately 75 percent of such patients progress to worsened renal insufficiency over five years.",
"   </p>",
"   <p>",
"    One problem with estimating the glomerular filtration rate by creatinine clearance or an estimation equation is that creatinine secretion is often markedly increased in patients with nephrotic syndrome compared with normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/35\">",
"     35",
"    </a>",
"    ]. As a result, the serum creatinine will be lower than expected from the glomerular filtration rate in a given patient, and the creatinine clearance will overestimate the glomerular filtration rate by a greater degree than in nonnephrotic subjects. In one study, the overestimate was 36",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    in nephrotic patients with a serum albumin level less than 2.6",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    compared with 11",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    in normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1567303628\">",
"    <span class=\"h3\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-risk patients are usually treated with immunosuppressive therapy, as described below. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Summary of high risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Our treatment preferences for high-risk patients differ according to the course of renal function during the observation period:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are classified as high risk because of deterioration of glomerular filtration rate (GFR) due to membranous nephropathy, combination therapy with glucocorticoids and a cytotoxic drug (ie,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      , preferably cyclophosphamide) appears to provide the best protection against progressive renal disease.",
"     </li>",
"     <li>",
"      For all other patients who are classified as high risk, including those with protein excretion exceeding 8",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      that persists for more than three months, combination therapy consisting of either glucocorticoids plus a cytotoxic drug or glucocorticoids plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      are equally acceptable treatment options.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The preference of cytotoxic therapy in those patients who are high risk because of deterioration of GFR due to idiopathic MN is based upon the United Kingdom (UK) Membranous Trial, an open-label randomized trial of 108 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/36\">",
"     36",
"    </a>",
"    ]. Smaller trials and observational studies have also suggested that therapy combining glucocorticoids with a cytotoxic drug may be beneficial in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/28,29,37-41\">",
"     28,29,37-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The UK Membranous Trial only enrolled patients who had a progressive decline in estimated glomerular filtration rate (eGFR, calculated using the Cockcroft-Gault equation) of at least 20 percent during the preceding two years and a baseline serum creatinine less than 3.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (300",
"    <span class=\"nowrap\">",
"     micromol/L);",
"    </span>",
"    enrolled patients had a mean eGFR of 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    and a mean protein excretion of 8.5",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    In addition, no patient was receiving anti-inflammatory or immunosuppressive therapy at baseline.",
"   </p>",
"   <p>",
"    Patients were randomly assigned to one of the following three therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supportive treatment plus glucocorticoids and cytotoxic therapy for six months &ndash; During months 1, 3, and 5, patients received intravenous methylprednisone (1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for three days), followed by oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (0.5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      for 28 days); during months 2, 4, and 6, patients received oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      (0.15",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      throughout the month).",
"     </li>",
"     <li>",
"      Supportive treatment plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      for twelve months &ndash; The initial dose of cyclosporine was 5",
"      <span class=\"nowrap\">",
"       mg/kg/day,",
"      </span>",
"      and the dose was adjusted to achieve a plasma concentration of 100 to 200",
"      <span class=\"nowrap\">",
"       mcg/L.",
"      </span>",
"     </li>",
"     <li>",
"      Supportive treatment alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary endpoint (an additional decline in eGFR of at least 20 percent) occurred significantly less frequently with glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    as compared with supportive treatment alone (58",
"    <span class=\"nowrap\">",
"     [19/33]",
"    </span>",
"    versus 84",
"    <span class=\"nowrap\">",
"     [31/37]",
"    </span>",
"    percent). However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy did not reduce the incidence of renal function loss as compared with supportive treatment (81",
"    <span class=\"nowrap\">",
"     [29/36]",
"    </span>",
"    versus 84 percent). In addition, fewer patients who received glucocorticoids and chlorambucil developed end-stage renal disease (1 patient compared with 4 patients receiving supportive treatment and 6 patients receiving cyclosporine).",
"   </p>",
"   <p>",
"    There was no difference in mortality among the three groups. Nearly all patients received angiotensin-converting enzyme (ACE) inhibitors. The frequency of adverse events were similar in the",
"    <span class=\"nowrap\">",
"     glucocorticoid/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"      chlorambucil",
"     </a>",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    groups, although patients receiving glucocorticoids and chlorambucil had significantly more serious adverse events than those receiving supportive treatment only (primarily hematological events such as leukopenia and anemia).",
"   </p>",
"   <p>",
"    Limitations of the UK Membranous Trial include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with declining GFR due to MN comprise a small fraction of all patients with idiopathic MN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/17\">",
"       17",
"      </a>",
"      ]. It is not known whether the results of this trial apply to other patients with MN.",
"     </li>",
"     <li>",
"      In addition, the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      dose escalation in this trial was faster than common practice. Since calcineurin inhibitors such as cyclosporine can produce an acute reversible reduction in GFR, it is possible that this could have produced some of the adverse renal events. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"       \"Cyclosporine and tacrolimus nephrotoxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The majority of patients were followed for less than one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the UK Membranous Trial used",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -based regimen is thought to be equally effective, as noted in a randomized head-to-head comparative trial that primarily enrolled moderate-risk patients (mean protein excretion 7 to 8",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and mean serum creatinine 1.05",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [93",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, observational data showed greater benefit with daily oral cyclophosphamide (1.5 to 2.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for one year compared with daily oral chlorambucil in months 2, 4, and 6; both groups received the same glucocorticoid regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/37\">",
"     37",
"    </a>",
"    ]. Chlorambucil also has more side effects; therefore, we prefer administering a cyclophosphamide-based regimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results of the UK Membranous Trial (which found no benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) contrast with two smaller randomized trials that showed benefit from cyclosporine in patients defined as high risk based upon, respectively, reduced GFR and high-grade persistent proteinuria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial randomly assigned 17 patients with progressive disease (baseline creatinine clearance about 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      ) to placebo or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      monotherapy (3.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, with dose adjustment to maintain a 12-hour trough cyclosporine concentration of 110 to 170",
"      <span class=\"nowrap\">",
"       mcg/L)",
"      </span>",
"      for 12 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/42\">",
"       42",
"      </a>",
"      ]. Cyclosporine produced a greater decline in proteinuria and a slowing of renal function decline as compared with placebo.",
"     </li>",
"     <li>",
"      A second trial randomly assigned 51 patients with heavy proteinuria (mean 9.3",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      but intact renal function to combination therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (dose adjusted to maintain a trough blood level of 125 to 225",
"      <span class=\"nowrap\">",
"       mcg/L)",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      up to a maximum dose of 15",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or to prednisone alone and followed them for 26 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/30\">",
"       30",
"      </a>",
"      ]. The cyclosporine-treated group had a significantly higher rate of complete or partial remission of proteinuria (75 versus 22 percent with placebo).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Summary of high risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-risk patients with idiopathic MN are defined as those with 24-hour protein excretion exceeding 8",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    that persists for more than three months",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal function (estimated from the serum creatinine) that is either below normal or decreases during the observation period, despite maximum conservative therapy. These patients have an approximately 75 percent chance of progression to end-stage renal disease without effective therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/8,32\">",
"     8,32",
"    </a>",
"    ]. Patients who present with severe symptoms, marked hypoalbuminemia (&lt;2.0",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    or an elevated serum creatinine that does not represent preexisting disease may be treated with immunosuppressive therapy without delay. Patients with advanced and chronic renal impairment (estimated glomerular filtration rate less than 30",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    for &gt;3 months) are a possible exception since it is not clear that immunosuppressive therapy is beneficial in this subgroup.",
"   </p>",
"   <p>",
"    The decision to treat high-risk patients with more than 8",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of proteinuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progressive disease must be individualized. Many of these patients respond to therapy, particularly those with normal or near normal renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. The likelihood of benefit probably decreases with more advanced disease, but it is not possible to predict in advance which patients will have a clinically significant response.",
"   </p>",
"   <p>",
"    Patients considered to be at high risk because of deteriorating renal function should be carefully assessed for other causes that may be additional to or independent of MN. As an example, older patients or those with long-standing hypertension may have a reduced glomerular filtration rate independent of MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients who have no other apparent reasons for reduced renal function or who have progressive deterioration while under observation should be treated without delay.",
"   </p>",
"   <p>",
"    In general, our approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients classified as high risk because of deteriorating renal function due to idiopathic MN and for whom immunosuppressive therapy is felt appropriate, we suggest combination therapy with glucocorticoids and a cytotoxic agent (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      ). For reasons presented above, we prefer cyclophosphamide rather than chlorambucil. (See",
"      <a class=\"local\" href=\"#H1567303628\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients selected for cytotoxic therapy, we suggest daily oral therapy rather than pulse intravenous therapy with the cytotoxic agent. This preference is based upon a randomized trial of 18 patients assigned to either oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      or intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ; both groups received glucocorticoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/38\">",
"       38",
"      </a>",
"      ]. The patients assigned to daily oral chlorambucil had a significant reduction of serum creatinine at six months from 2.9 to 2.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (260 to 186",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      In contrast, the patients treated with monthly intravenous cyclophosphamide pulses had an increase in serum creatinine from 2.5 to 3.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (218 to 297",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      Both groups had a similar reduction in proteinuria.",
"     </li>",
"     <li>",
"      If cytotoxic therapy is chosen, an acceptable regimen is the one used in the UK Membranous Trial, substituting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      : during months 1, 3, and 5, treat with intravenous methylprednisone (1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for three days), followed by oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (0.5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      for 28 days); during months 2, 4, and 6, treat with oral cyclophosphamide (1.5 to 2.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day).",
"     </li>",
"     <li>",
"      In high-risk patients who decline or who cannot receive cytotoxic therapy, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      in combination with glucocorticoids. As an example, a woman of child-bearing age may want to avoid",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      therapy because of its fertility risk. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link&amp;anchor=H9#H9\">",
"       \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Female gonadal toxicity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In all other patients classified as high risk (eg, those with protein excretion exceeding 8",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      that persists for more than three months but with normal eGFR), we suggest",
"      <strong>",
"       either",
"      </strong>",
"      combination therapy with glucocorticoids and a cytotoxic agent",
"      <strong>",
"       or",
"      </strong>",
"      combination therapy with glucocorticoids and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      . If cyclosporine therapy is chosen, an acceptable regimen is 3.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for 12 months, starting at a lower dose and gradually increasing to achieve a 12-hour trough cyclosporine concentration of 110 to 170",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/42\">",
"       42",
"      </a>",
"      ]. Given the risk of nephrotoxicity with cyclosporine, we attempt to maintain trough concentrations at the lower end of the target range and monitor the serum creatinine concentration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"       \"Cyclosporine and tacrolimus nephrotoxicity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once therapy is discontinued, there is an appreciable relapse rate (25 to 30 percent) that may require a second course with attendant side effects. The relapse rate may be somewhat lower and more delayed with cytotoxic as compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Relapsing disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Relapsing disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse to nephrotic range proteinuria, after an initial response to immunosuppressive therapy, may require repeat treatment. The approach to retreatment is partially dependent upon the initial regimen. However, before immunosuppressive therapy is considered, a change in diet to a high salt",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high protein intake should be excluded as a cause of the increasing proteinuria. Salt restriction is also important for control of both blood pressure and edema. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Goal blood pressure'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441807498\">",
"    <span class=\"h3\">",
"     Exclusion of high salt intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with proteinuric chronic kidney disease, the antiproteinuric effect of angiotensin inhibitors and non-dihydropyridine calcium channel blockers is enhanced with salt restriction and impaired by a high salt intake even when blood pressure control is appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Presumed mechanisms are that high salt intakes increase intraglomerular pressure and flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H10#H10\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Importance of salt intake'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential importance of a high salt intake as a cause of relapsing proteinuria in idiopathic MN was illustrated in a series of seven patients who underwent repeat renal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/45\">",
"     45",
"    </a>",
"    ]. Four patients had recurrent active disease and were treated with immunosuppressive therapy. The other three patients did not have active MN as evidenced by the absence of subepithelial immune deposits on electron microscopy, although there were chronic changes such as thickening and vacuolization of the glomerular basement membrane. These patients, compared with those with active disease, had on 24-hour urine collection much higher rates of excretion of both sodium (353 versus 141",
"    <span class=\"nowrap\">",
"     meq/day)",
"    </span>",
"    and urea nitrogen (15.7 versus 9.6",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    Furthermore, lowering sodium intake in two of these patients from approximately 300 to less than 100 to 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was associated with marked reductions in the 24-hour urine protein-to-creatinine ratio from 4.5 to less than 1.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and from 2.4 to approximately 1.0",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    The effect of dietary protein restriction was not evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Cytotoxic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -based therapy, relapse of proteinuria has been described in 25 to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/4,28,39,46,47\">",
"     4,28,39,46,47",
"    </a>",
"    ]. Such patients may be treated with a calcineurin inhibitor or with a second course of cytotoxic therapy using the same regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/28,39,47\">",
"     28,39,47",
"    </a>",
"    ]. We do not give more than two courses of cytotoxic therapy in patients who repeatedly relapse.",
"   </p>",
"   <p>",
"    The apparent benefits of cytotoxic therapy in this setting must be weighed against the adverse effects of a second course, as treatment-related complications (primarily bone marrow depression and infection) are common, occurring in as many as two-thirds of high-risk patients treated with daily oral cytotoxic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, the risk of gonadal toxicity is high in patients who receive more than one course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . Thus, for patients in whom gonadal toxicity is a factor, we suggest treatment with calcineurin inhibitors rather than cyclophosphamide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients treated with calcineurin inhibitor-based therapy, a higher rate of relapse has been reported than with cytotoxic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/30,31,33,34\">",
"     30,31,33,34",
"    </a>",
"    ]. Similar findings have been noted in patients with membranous lupus nephritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44233?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features and therapy of membranous lupus nephritis\", section on 'NIH trial of cyclophosphamide versus cyclosporine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a trial cited above, relapse occurred in 9 of the 21 (43 percent)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -treated patients who attained remission at 52 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/30\">",
"     30",
"    </a>",
"    ]. No further relapses occurred in the ensuing 26 weeks, which was the end of follow-up. Relapses may occur more frequently when lower doses of cyclosporine (1.0 to 1.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) are used, when the trough levels are less than 100",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    or perhaps when cyclosporine is given without glucocorticoids, which we do not recommend [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relapses can occur during tapering or after cessation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy. In either case, we treat with cyclosporine at a dose of 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and continue to monitor renal function and whole blood trough levels. An alternative, particularly in patients who did not tolerate the initial cyclosporine regimen, is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -based therapy.",
"   </p>",
"   <p>",
"    Limited data suggest similar results with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . In one trial, relapse occurred in 9 of 19 (47 percent) patients who attained complete or partial remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/33\">",
"     33",
"    </a>",
"    ]. All of the relapses occurred at a mean of 4.2 months after the cessation of tacrolimus therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Resistant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to moderate- or high-risk patients with stable renal function who fail treatment with both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and calcineurin inhibitor-based regimens is not known. We prefer a trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in such patients, although only limited data are available suggesting efficacy.",
"   </p>",
"   <p>",
"    Three observational (nonrandomized) studies in patients with idiopathic resistant MN have reported outcomes following the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large single-center study, 100 patients with idiopathic MN and persistent proteinuria greater than 3.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      despite six months of angiotensin inhibition were treated with one to four weekly infusions of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/48\">",
"       48",
"      </a>",
"      ]. At baseline, 32 patients had previously failed immunosuppressive therapy with other agents; the mean age was 52 years, mean serum creatinine was 1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (106",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      and mean proteinuria was 9.1",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"      Patients were followed for a minimum of six months (mean follow-up, 29 months). Complete remission, defined as a reduction in proteinuria to below 0.3",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      was achieved in 27 patients; partial remission, defined as a reduction in proteinuria by more than 50 percent to a level below 3",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      was achieved in 38 patients. The remaining 35 patients did not achieve remission. The proportion of patients having a complete or partial remission did not differ according to prior therapy with other immunosuppressive agents. Rituximab therapy was generally well tolerated: 28 patients had infusion reactions that were considered minor, and 11 patients had serious adverse events, none of which were considered related to therapy.",
"     </li>",
"     <li>",
"      In another study,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (1 g given two weeks apart) was given to 15 severely nephrotic patients (6.1 to 23",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      with MN; seven had failed previous immunosuppressive therapy and eight had a creatinine clearance below 80",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/49\">",
"       49",
"      </a>",
"      ]. At 12 months, two and six patients had achieved complete or partial remission, respectively; seven of these eight patients had a baseline creatinine clearance above 80",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      . In contrast, five of the six patients who did not attain remission at 12 months had a baseline creatinine clearance below 75",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      . The likelihood of remission was not related to previous treatment. Adverse effects were minor and primarily consisted of infusion reactions.",
"     </li>",
"     <li>",
"      The same group reported a second observational study in which 20 patients with MN, protein excretion greater than 5.0",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      and creatinine clearance greater than 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73, were treated with a different",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      regimen: four weekly doses of rituximab 375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      with retreatment at six months independent of the initial response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/50\">",
"       50",
"      </a>",
"      ]. Eleven patients (55 percent) had failed prior immunosuppressive therapy. At 12 months, complete or partial remission had occurred in 10 patients, and, at 24 months, among 18 patients who completed the study, 16 achieved either a complete (4) or partial (12) remission. These data suggest that rituximab may provide benefit to patients who failed prior immunosuppressive therapy, especially those with relatively preserved renal function. In the two studies cited above, four weekly doses of rituximab (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      appear to have the same effect on proteinuria reduction as a regimen of 1 g every two weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest therefore the somewhat simpler and cheaper regimen of a dose of 1 g given intravenously and repeated in two weeks. Patients who continue to have significant proteinuria may have this dose repeated at six months.",
"   </p>",
"   <p>",
"    A decline in anti-phospholipase A2 receptor (PLA2R) antibodies may predict the clinical response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/51\">",
"     51",
"    </a>",
"    ]. PLA2R is a transmembrane receptor that is highly expressed in glomerular podocytes and has been identified as a major antigen in human idiopathic MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link&amp;anchor=H7#H7\">",
"     \"Causes and diagnosis of membranous nephropathy\", section on 'Phospholipase A2 receptor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-PLA2R antibodies were measured in serum samples from 35 patients with MN who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    as part of the two studies cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/51\">",
"     51",
"    </a>",
"    ]. Serum samples were collected prior to treatment with rituximab and at 1, 3, 6, 9, and 12 months after treatment. Twenty-five patients (71 percent) had PLA2R antibodies at baseline. Of these, PLA2R antibodies declined or disappeared in 17 (68 percent) weeks or months prior to any observed change in proteinuria. Patients who had a decline in anti-PLA2R were more likely to achieve remission compared with those in whom the level of anti-PLA2 antibodies did not change (59 versus 0 percent, respectively at 12 months and 88 versus 33 percent, respectively at 24 months). One patient who relapsed had a return of anti-PLA2R antibodies prior to the onset of proteinuria. The lag-time between disappearance of circulating anti-PLA2R antibodies and a remission of proteinuria may help to explain why only about 75 to 80 percent of patients with idiopathic MN are positive for anti-PLA2R antibody in cross-sectional studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. The anti-PLA2R autoantibody-negative patients may be in the midst of a spontaneous or treatment induced remission. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link&amp;anchor=H7#H7\">",
"     \"Causes and diagnosis of membranous nephropathy\", section on 'Phospholipase A2 receptor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although this study needs to be validated in prospective clinical trials, it suggests that monitoring serum anti-PLA2R antibodies may allow a more accurate assessment of the immunological response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (and possibly other therapies) than is provided by measurement of proteinuria alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Immunosuppressive agents in older patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients above age 65 appear to progress at the same rate as younger subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/57\">",
"     57",
"    </a>",
"    ]. However, most of the above randomized trials had few, if any, patients over age 65 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/3,4,28,30,42\">",
"     3,4,28,30,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two retrospective studies of 115 patients older than 60 to 65 years found little evidence of benefit from glucocorticoids alone with a higher incidence of side effects, such as infection, peptic ulcer disease, and gastrointestinal disturbances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. However, there may be a response to cytotoxic or to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy, as discussed above. This was illustrated in a retrospective study of 41 patients over age 65 who were treated with either steroids, steroids plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , or supportive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/59\">",
"     59",
"    </a>",
"    ]. At a mean follow-up of 92 months, a greater percentage of patients who received chlorambucil were in remission compared to patients who did not.",
"   </p>",
"   <p>",
"    In older patients, immunosuppressive therapy should be considered only for those who are at high risk for progression and after maximum conservative therapy has failed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. A careful examination to rule out an underlying malignancy is mandatory before considering immunosuppressive therapy in older patients with apparently idiopathic MN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo spontaneous or drug-induced remission generally have a good long-term prognosis. Thirty to 40 percent of patients who receive cytotoxic therapy plus glucocorticoids undergo complete remission of proteinuria, 30 to 50 percent undergo partial remission, and the incidence of progressive renal insufficiency is only about 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/3,4,27,28\">",
"     3,4,27,28",
"    </a>",
"    ]. Relapse of proteinuria occurs in up to 20 to 30 percent of cases, and such patients should be considered for retreatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/4,28,39,46\">",
"     4,28,39,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis after complete remission (whether treatment-associated or spontaneous) was reported in 82 adults with biopsy-confirmed idiopathic membranous nephropathy (MN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/46\">",
"     46",
"    </a>",
"    ]. The mean total observation time was 101 months, 69 months of which was in the post-remission period. Three distinct groups of patients were identified:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Those who remained in remission (67 percent)",
"     </li>",
"     <li>",
"      Those with a remitting, relapsing course but without renal insufficiency (20 percent)",
"     </li>",
"     <li>",
"      Those who developed renal insufficiency (13 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No patient subsequently developed end-stage renal disease. Multivariate analysis revealed that female sex and persistently low levels of proteinuria were associated with a durable remission. These parameters are also associated with a better long-term prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, progressive disease is characterized by persistent heavy proteinuria and a gradual elevation in the serum creatinine concentration over a period of years. As noted above, however, effective therapy can improve outcomes in such patients. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Summary of high risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who attain partial remission have a much better outcome than those with stable or progressive disease. This was illustrated in an observational study that included 136 patients with idiopathic MN who had partial remission and 110 who had no remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/41/37530/abstract/17\">",
"     17",
"    </a>",
"    ]. At a median follow-up of five years, partial remission was independently associated with a slower decrease in renal function over time (-0.17 versus -0.86",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per month with no remission) and a lower incidence of renal failure (9 versus 29 percent, adjusted hazard ratio 0.17). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Importance of attaining remission'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranous nephropathy (MN) is among the most common causes of the nephrotic syndrome in nondiabetic adults. MN is often idiopathic but may also be caused by drugs and underlying diseases. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important predictors of risk for a progressive decline in renal function are persistent severe proteinuria for at least three months, a reduced creatinine clearance at presentation, and a decline in creatinine clearance over the assessed proteinuria period. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors for progressive idiopathic MN'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following categories of risk for progression, which are used for therapeutic decisions, are based upon the degree of proteinuria and the creatinine clearance as measured in a 24-hour collection. A random urine protein-to-creatinine ratio should NOT be used for risk stratification, but can be used for serial monitoring. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Measurement of protein excretion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk of progression &ndash; Protein excretion remains less than 4",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      and creatinine clearance remains normal for a six-month follow-up period.",
"     </li>",
"     <li>",
"      Moderate risk of progression &ndash; Protein excretion is between 4 and 8",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      and persists for more than six months, and creatinine clearance is normal or near normal and remains stable over 6 to 12 months of observation.",
"     </li>",
"     <li>",
"      High risk of progression &ndash; Protein excretion is greater than 8",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      and persists for three months",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      creatinine clearance is reduced (and considered due to MN) or declines over three months of observation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Probability of progression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other significant adverse risk factors include age greater than 50 years and male gender. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Nonimmunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonimmunosuppressive therapy is given to almost all patients with idiopathic MN, even those who require treatment with immunosuppressive drugs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with persistent proteinuria, we recommend angiotensin inhibition with an ACE inhibitor or an ARB (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Angiotensin inhibition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The proteinuria goal is less than 1000",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      For the many patients who cannot attain this goal, we suggest a goal of at least partial remission, which has been defined as protein excretion below 3.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      plus a 50 percent or greater reduction in protein excretion from the peak value (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In addition to angiotensin inhibition, other factors that can contribute to these goals are spontaneous remission and immunosuppressive therapy. (See",
"      <a class=\"local\" href=\"#H10654384\">",
"       'Proteinuria goal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Importance of attaining remission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal blood pressure is less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg. This is discussed separately. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Goal blood pressure'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The management of dyslipidemia and hypercoagulability in patients with the nephrotic syndrome are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"       \"Lipid abnormalities in nephrotic syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"       \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Immunosuppressive therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Low risk",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who remain at low risk of progression over a six-month period, we recommend continued observation rather than administering immunosuppressive therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Such patients should be periodically monitored every three months for two years and twice yearly thereafter to assess for disease progression that might warrant therapy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Low risk for progression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Moderate risk",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who remain at moderate risk for progression and do",
"      <strong>",
"       not",
"      </strong>",
"      continue to show a progressive decline in proteinuria at six months, we recommend the initiation of immunosuppressive therapy rather than continued observation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For moderate-risk patients with a progressive decline in protein excretion over this period that remains above 4",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      we suggest immunosuppressive therapy rather than continued observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, some clinicians would continue to withhold immunosuppressive therapy beyond six months in such patients who are doing well and are at high risk of having an adverse event with immunosuppressive therapy.",
"     </li>",
"     <li>",
"      If immunosuppressive therapy is administered, we recommend either a cytotoxic-based or calcineurin inhibitor-based regimen, each combined with glucocorticoids, rather than other therapies or glucocorticoid monotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The choice between a cytotoxic-based or calcineurin inhibitor-based regimen depends primarily upon clinician and patient preference, after a thorough discussion of the potential benefits and risks. As an example, calcineurin inhibitor-based therapy may be preferred among those who elect to avoid toxicity of cytotoxic agents, such as the risk of decreased fertility. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Summary of moderate risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a cytotoxic-based therapy is chosen, we recommend a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -based regimen rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      because of a lower rate of side effects (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Our preferred regimen is presented above. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Summary of moderate risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a calcineurin-based therapy is chosen, the administration of either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      is largely based upon patient preference. As an example, tacrolimus may be preferred among those who wish to avoid some of the side effects commonly observed with cyclosporine, such as hirsutism or gingival hypertrophy. Our preferred cyclosporine and tacrolimus-based regimens are presented above. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Summary of moderate risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients treated with either a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or a calcineurin inhibitor-based regimen are considered unresponsive if a substantial reduction in proteinuria (30 to 50 percent from peak levels) is not observed after four to six months of therapy.",
"     </li>",
"     <li>",
"      Among those who do not respond to initial treatment with a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or a calcineurin inhibitor-based regimen, we suggest treatment with the other regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The dosing regimens are the same as those described for initial therapy, as tolerated. For patients initially treated with cytotoxic therapy, we usually wait three to six months after the cessation of cytotoxic therapy before initiating a calcineurin inhibitor, unless the patient has severe symptoms or a rise in serum creatinine secondary to active MN. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Summary of moderate risk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     High risk",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are at high risk of progression, we recommend the initiation of immunosuppressive therapy rather than continued observation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'High risk for progression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Summary of high risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients classified as high risk because of declining renal function, we suggest combination therapy with glucocorticoids and a daily oral cytotoxic agent (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      ) rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or other therapies (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For reasons presented above, we prefer cyclophosphamide rather than chlorambucil. An acceptable dosing strategy is discussed above. Patients who wish to avoid cytotoxic therapy (eg, a woman of child-bearing age) can reasonably choose treatment with cyclosporine and glucocorticoids. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Summary of high risk'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1567303628\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In other high-risk patients selected for immunosuppressive therapy (based on persistent high-grade proteinuria but preserved renal function), we recommend either a cytotoxic-based or a calcineurin inhibitor-based regimen, each in combination with glucocorticoids, rather than other therapies (",
"      <a class=\"external\" href=\"file:__www.uptodate.com_contents_grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). An acceptable calcineurin-based dosing strategy is presented above. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Summary of high risk'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1567303628\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Relapsing patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse of proteinuria occurs in 25 to 30 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and a higher percentage of those treated with a calcineurin inhibitor. The choice of therapy varies with the initial regimen that was used and with concerns about toxicity. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Relapsing disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients initially treated with a calcineurin inhibitor, we suggest a repeat course of therapy at the same dose used in the initial regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An alternative, particularly in patients who did not tolerate the initial regimen, is using a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -based regimen.",
"     </li>",
"     <li>",
"      Among patients initially treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -based therapy, the options are repeating the original regimen, which must be weighed against the adverse effects, or switching to calcineurin inhibitor-based therapy. If gonadal toxicity is an issue, we recommend use of a calcineurin inhibitor (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Resistant patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistant patients are defined as those with moderate or high risk disease who fail an adequate trial of treatment with both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -based and calcineurin inhibitor-based regimens. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Resistant disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    can be considered after a careful evaluation of the potential risks and benefits of further immunosuppression. Weak evidence suggests that a clinically relevant response to rituximab may be less likely in patients with a creatinine clearance below 75",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    .",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/1\">",
"      Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 1995; 25:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/2\">",
"      Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/3\">",
"      Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 48:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/4\">",
"      Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007; 18:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/5\">",
"      Shiiki H, Saito T, Nishitani Y, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int 2004; 65:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/6\">",
"      Glassock RJ. Diagnosis and natural course of membranous nephropathy. Semin Nephrol 2003; 23:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/7\">",
"      Bazzi C, Petrini C, Rizza V, et al. A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Kidney Int 2000; 58:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/8\">",
"      Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 1992; 42:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/9\">",
"      Cattran DC, Pei Y, Greenwood CM, et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997; 51:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/10\">",
"      Troyanov S, Roasio L, Pandes M, et al. Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int 2006; 69:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/11\">",
"      Reichert LJ, Koene RA, Wetzels JF. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis 1998; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/12\">",
"      Polanco N, Guti&eacute;rrez E, Covars&iacute; A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010; 21:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/13\">",
"      Hladunewich MA, Troyanov S, Calafati J, et al. The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 2009; 4:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/14\">",
"      Branten AJ, du Buf-Vereijken PW, Klasen IS, et al. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 2005; 16:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/15\">",
"      Wakai S, Magil AB. Focal glomerulosclerosis in idiopathic membranous glomerulonephritis. Kidney Int 1992; 41:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/16\">",
"      Wu Q, Jinde K, Nishina M, et al. Analysis of prognostic predictors in idiopathic membranous nephropathy. Am J Kidney Dis 2001; 37:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/17\">",
"      Troyanov S, Wall CA, Miller JA, et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004; 66:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/18\">",
"      Hall CL, Jawad S, Harrison PR, et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. Br Med J (Clin Res Ed) 1988; 296:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/19\">",
"      Hall CL, Fothergill NJ, Blackwell MM, et al. The natural course of gold nephropathy: long term study of 21 patients. Br Med J (Clin Res Ed) 1987; 295:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/20\">",
"      Glassock RJ. Idiopathic membranous nephropathy: getting better by itself. J Am Soc Nephrol 2010; 21:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/21\">",
"      du Buf-Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am J Kidney Dis 2005; 46:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/22\">",
"      Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 2008; 3:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/23\">",
"      Lionaki S, Derebail VK, Hogan SL, et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol 2012; 7:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/24\">",
"      Philibert D, Cattran D. Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? Nat Clin Pract Nephrol 2008; 4:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/25\">",
"      Ponticelli C, Zucchelli P, Passerini P, Cesana B. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N Engl J Med 1992; 327:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/26\">",
"      KDIGO. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/27\">",
"      Cattran DC. Idiopathic membranous glomerulonephritis. Kidney Int 2001; 59:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/28\">",
"      Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/29\">",
"      Jindal K, West M, Bear R, Goldstein M. Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. Am J Kidney Dis 1992; 19:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/30\">",
"      Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001; 59:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/31\">",
"      Alexopoulos E, Papagianni A, Tsamelashvili M, et al. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant 2006; 21:3127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/32\">",
"      Cattran D. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 2005; 16:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/33\">",
"      Praga M, Barrio V, Ju&aacute;rez GF, et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 2007; 71:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/34\">",
"      Goumenos DS, Kalliakmani P, Tsakas S, et al. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin Nephrol 2004; 61:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/35\">",
"      Branten AJ, Vervoort G, Wetzels JF. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant 2005; 20:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/36\">",
"      Howman A, Chapman TL, Langdon MM, et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013; 381:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/37\">",
"      Branten AJ, Reichert LJ, Koene RA, Wetzels JF. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. QJM 1998; 91:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/38\">",
"      Reichert LJ, Huysmans FT, Assmann K, et al. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann Intern Med 1994; 121:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/39\">",
"      du Buf-Vereijken PW, Branten AJ, Wetzels JF, Membranous Nephropathy Study Group. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol Dial Transplant 2004; 19:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/40\">",
"      Bruns FJ, Adler S, Fraley DS, Segel DP. Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone. Ann Intern Med 1991; 114:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/41\">",
"      Torres A, Dom&iacute;nguez-Gil B, Carre&ntilde;o A, et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int 2002; 61:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/42\">",
"      Cattran DC, Greenwood C, Ritchie S, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 1995; 47:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/43\">",
"      Krikken JA, Laverman GD, Navis G. Benefits of dietary sodium restriction in the management of chronic kidney disease. Curr Opin Nephrol Hypertens 2009; 18:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/44\">",
"      Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011; 343:d4366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/45\">",
"      Barnes CE, Wilmer WA, Hernandez RA Jr, et al. Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated. Nephron Clin Pract 2011; 119:c145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/46\">",
"      Laluck BJ Jr, Cattran DC. Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis 1999; 33:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/47\">",
"      du Buf-Vereijken PW, Wetzels JF. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity. Nephrol Dial Transplant 2004; 19:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/48\">",
"      Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/49\">",
"      Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008; 73:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/50\">",
"      Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010; 5:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/51\">",
"      Beck LH Jr, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011; 22:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/52\">",
"      Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/53\">",
"      Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 2011; 364:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/54\">",
"      Qin W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011; 22:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/55\">",
"      Hofstra JM, Beck LH Jr, Beck DM, et al. Anti-phospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011; 6:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/56\">",
"      Cravedi P, Ruggenenti P, Remuzzi G. Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy. J Am Soc Nephrol 2011; 22:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/57\">",
"      Hebert LA. Therapy of membranous nephropathy: what to do after the after (meta) analyses. J Am Soc Nephrol 1995; 5:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/58\">",
"      Zent R, Nagai R, Cattran DC. Idiopathic membranous nephropathy in the elderly: a comparative study. Am J Kidney Dis 1997; 29:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/59\">",
"      Passerini P, Como G, Vigan&ograve; E, et al. Idiopathic membranous nephropathy in the elderly. Nephrol Dial Transplant 1993; 8:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/41/37530/abstract/60\">",
"      Cattran DC, Reich HN, Beanlands HJ, et al. The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 2008; 23:2247.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3051 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37530=[""].join("\n");
var outline_f36_41_37530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors for progressive idiopathic MN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Histologic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Importance of attaining remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Probability of progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute decline in renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Secondary MN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NONIMMUNOSUPPRESSIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10654384\">",
"      Proteinuria goal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Goal blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Lipid-lowering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      IMMUNOSUPPRESSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Indications for and choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Measurement of protein excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Low risk for progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Moderate risk for progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Cytotoxic therapy plus glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Summary of moderate risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      High risk for progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1567303628\">",
"      - Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Summary of high risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Relapsing disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H441807498\">",
"      - Exclusion of high salt intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Cytotoxic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Resistant disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Immunosuppressive agents in older patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Nonimmunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Low risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Moderate risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - High risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Relapsing patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Resistant patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3051\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3051|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/50/31533\" title=\"figure 1\">",
"      Natural history of MN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/38/34413\" title=\"figure 2\">",
"      Urine protein creat ratio",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3051|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/6/14443\" title=\"table 1\">",
"      Causes membranous nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/39/12918?source=related_link\">",
"      Alternative agents in the treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44233?source=related_link\">",
"      Clinical features and therapy of membranous lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=related_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_41_37531="Plasma sodium and volume";
var content_f36_41_37531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F73306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F73306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lack of relation between plasma sodium concentration and volume",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Substance added",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plasma osmolality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plasma sodium",
"       </td>",
"       <td class=\"subtitle1\">",
"        Extracellular volume",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intracelluar volume",
"       </td>",
"       <td class=\"subtitle1\">",
"        Urine sodium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NaCl",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Water",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isotonic NaCl",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Osmotic and volume effects of addition of NaCl, water, and isotonic saline. Each of the interventions increased the extracellular volume and therefore urine sodium excretion even though the plasma sodium was increased, decreased, and unchanged, respectively. Thus, there is no predictable relationship between the plasma sodium concentration and volume. When occurring acutely, the decrease in intracellular volume with hypernatremia and increase in intracellular volume with hyponatremia occurring in the brain are primarily responsible for the symptoms associated with these disturbances.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37531=[""].join("\n");
var outline_f36_41_37531=null;
var title_f36_41_37532="Diagnostic criteria for functional dyspepsia";
var content_f36_41_37532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F87623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F87623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for functional dyspepsia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic criteria for functional dyspepsia*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         One or more",
"        </strong>",
"        of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Bothersome postprandial fullness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Early satiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Epigastric pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Epigastric burning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         AND",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        No evidence of structural disease (including at upper endoscopy) that is likely to explain the symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic criteria for postprandial distress syndrome*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Must include",
"        <strong>",
"         one or both",
"        </strong>",
"        of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Bothersome postprandial fullness, occurring after ordinary sized meals, at least several times per week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Early satiation that prevents finishing a regular meal, at least several times a week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Supportive criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Upper abdominal bloating or postprandial nausea or excessive belching can be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Epigastric pain syndrome may coexist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic criteria for epigastric pain syndrome*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Must include",
"        <strong>",
"         all",
"        </strong>",
"        of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Pain or burning localized to other abdominal or chest regions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. The pain is intermittent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Not generalized or localized to other abdominal or chest regions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Not relieved by defecation or passage of flatus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5. Not fulfilling criteria for gallbladder and sphincter of Oddi disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Supportive criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. The pain may be of a burning quality but without a retrosternal component",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. The pain is commonly induced or relieved by ingestion of a meal but may occur while fasting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Postprandial distress syndrome may coexist",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Criteria must be&nbsp;fulfilled for the last three months with symptom onset at least six months before diagnosis.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130:1466. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37532=[""].join("\n");
var outline_f36_41_37532=null;
var title_f36_41_37533="Lung cancer TMN staging 7th edition";
var content_f36_41_37533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for lung cancer (7th edition)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Primary tumor (T)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T1",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Tumor &le;3 cm diameter, surrounded by lung or visceral pleura, without invasion more proximal than lobar bronchus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor &le;2 cm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor &gt;2 cm but &le;3 cm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        T2",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Tumor &gt;3 cm but &le;7 cm, or tumor with any of the following features:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Involves main bronchus, &ge;2 cm distal to carina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Invades visceral pleura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T2a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor &gt;3 cm but &le;5 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T2b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor &gt;5 cm but &le;7 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        T3",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Tumor &gt;7 cm or any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Directly invades any of the following: chest wall, diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium, main bronchus &lt;2 cm from carina (without involvement of carina)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Atelectasis or obstructive pneumonitis of the entire lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        Separate tumor nodules in the same lobe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor of any size that invades the mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, or with separate tumor nodules in a different ipsilateral lobe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Regional lymph nodes (N)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N0",
"       </td>",
"       <td colspan=\"3\">",
"        No regional lymph node metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N1",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N2",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N3",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Distant metastasis (M)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0",
"       </td>",
"       <td colspan=\"3\">",
"        No distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        M1",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        M1a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural or pericardial effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        M1b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Distant metastasis (in extrathoracic organs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Stage groupings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IA",
"       </td>",
"       <td>",
"        T1a-T1b",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IB",
"       </td>",
"       <td>",
"        T2a",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Stage IIA",
"       </td>",
"       <td>",
"        T1a,T1b,T2a",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2b",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Stage IIB",
"       </td>",
"       <td>",
"        T2b",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Stage IIIA",
"       </td>",
"       <td>",
"        T1a,T1b,T2a,T2b",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N1,N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4",
"       </td>",
"       <td>",
"        N0,N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Stage IIIB",
"       </td>",
"       <td>",
"        T4",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N3",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IV",
"       </td>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M1a or M1b",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groups in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2:706.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37533=[""].join("\n");
var outline_f36_41_37533=null;
var title_f36_41_37534="Single lumen catheter";
var content_f36_41_37534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Single lumen catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hologic.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37534=[""].join("\n");
var outline_f36_41_37534=null;
var title_f36_41_37535="Acute diaphyseal fracture";
var content_f36_41_37535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute diaphyseal fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This fracture demonstrates typical extension of the fracture line towards the intermetatarsal joint. Note the characteristics of an acute fracture: narrow fracture line, normal thin cortex adjacent to the fracture, and normal intramedullary canal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_41_37535=[""].join("\n");
var outline_f36_41_37535=null;
